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Abstract
Dietary fats have been implicated in the progression of coronary heart disease and 
clear differences have been shown for the effects of saturated, monounsaturated and 
polyunsaturated fatty acids on the different stages of disease. In part, these effects can be 
explained by the regulation of gene transcription. In this study, a novel cardiac cell-line 
was targeted for the investigation of fatty acid effects on gene transcription. The aims of 
this study were to (i) characterise the P19CL6 cell-line at the transcriptional level, (ii) 
investigate the effects of long-chain fatty acids and clofibrate on mRNA levels of specific 
lipid metabolism-related genes, such as heart-type fatty acid-binding protein and 
peroxisome proliferator-activated receptor-a, -|3, and -y in the P19CL6 cell-line, and (iii) 
determine the effects of long chain fatty acids and clofibrate on global transcriptome 
levels in P19CL6 cells, using cDNA microarray analysis.
P19CL6 cells displayed characteristics indicative of a cardiomyocyte phenotype 
including: the expression of cardiac-specific markers (a-MHC, P-MHC and CaCh-h), an 
increase in pulse rate with increasing adrenaline concentration and the display of 
mononuclear cardiomyocyte morphology. However, spontaneous contraction was 
inconsistent between cultures of P19CL6 cells and pulse rate decreased significantly with 
increasing passage number until no “beating” was eventually recorded. These 
observations led us to conclude that P19CL6 cells may display a heterogeneous 
phenotype, which was investigated further.
Analysis of microarray data indicated that global transcriptome profiles observed in 
the P19CL6 cell-line are not indicative of a pure adult cardiac or skeletal muscle 
phenotype, and more closely related to mouse embryonic heart tissue. However, the 
H9C2(2-1) cell-line was more closely related to adult and embryonic heart tissue than the 
P19CL6 cell-line. Therefore it was concluded that the H9C2(2-1) cell-line represents a 
better cardiomyocyte model system than the P19CL6 cell-line.
The results of this study also showed that in P19CL6 cells long-chain fatty acids (but 
not clofibrate) significantly increased the abundance of peroxisome proliferator-activated 
receptor-a and -y, whereas no changes were observed in the expression levels of 
heart-type fatty acid-binding protein and peroxisome proliferator-activated receptor-P, 
under the conditions used. The non-response of the latter genes can probably be 
explained by the relatively short time of exposure of cells in culture. Microarray analysis
IV
showed that linoleic and a-linolenic acids and clofibrate had similar effects, and that 
these differed fi’om those of palmitic and oleic acids. These results are in agreement with 
other studies showing that cellular responses to polyunsaturated fatty acids differ fi*om 
those observed with saturated and monounsaturated fatty acids.
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Chapter 1
Introduction
Chapter 1:
1.1 Introduction
Coronary heart disease (CHD) is the leading cause of death in developed 
countries (Mata and Ortega, 2003; Talmud and Stephens, 2004; Chilton, 2004) and the 
prevention and treatment of CHD continues to be a significant challenge (Bartlett and 
Eaton, 2004). The link between dietary fat, blood lipid profile and heart disease has been 
clearly established (Szapary and Rader, 2004; Calder, 2004b; Wijendran and Hayes,
2004), with saturated fatty acids and cholesterol being considered as atherogenic fat, 
whereas polyunsaturated fatty acids are cardioprotective (Ascherio, 2002; Mori and 
Beilin, 2001; Wijendran and Hayes, 2004; Dyerberg et al., 2004; Calder, 2004a; Mesa et 
al., 2004; Calder, 2004b). Many of the potentially beneficial effects of dietary 
polyunsaturated fatty acids in preventing or inhibiting the progression of CHD are 
mediated through the control of gene transcription (Calder, 2004a; Calder, 2004b; 
Wijendran and Hayes, 2004). These fatty acids elicit their effects by co-ordinately 
suppressing lipid synthesis in the liver and up-regulating fatty acid up-take and oxidation 
in the liver, heart, and skeletal muscle, therefore improving the plasma lipid 
profile (Jump, 2004; Mesa et ah, 2004; Clarke, 2000; Pegorier et al., 2004).
Investigating the effect of different dietary fatty acids on the cardiovascular system 
has increased over the past two decades (Ascherio, 2002; Mori and Beilin, 2001; 
Wijendran and Hayes, 2004; Dyerberg et al., 2004; Calder, 2004a; Mesa et al., 2004; 
Calder, 2004b). However, there are a limited number of cardiovascular model systems 
available for the in vfrm investigation of fatty acid effects on cardiomyocytes (White et 
al., 2004; Mitcheson et al., 1998). Isolated embryonic and neonatal rat primary 
cardiomyocytes have been the most widely used models to study cardiac biology in vitro, 
but their use is somewhat limited because they lack many adult cardiomyocyte 
characteristics and become overgrown by non-myocytes after a few days in 
culture (White et al., 2004; Claycomb et al., 1998; Mitcheson et al., 1998). Different 
types of stem cells can differentiate into cardiac muscle cells in vitro, and the P19 mouse 
embryonal carcinoma (EC) cell-line was one of the first examples described and has been 
the most extensively characterized (van der Heyden and Defize, 2003). P19 embryonal 
carcinoma cells are multipotent and can differentiate into different cell types such as 
cardiac, skeletal muscle and neural cells (van der Heyden et al., 2003; van der Heyden
and Defize, 2003; McBumey et al., 1982; Skeijanc, 1999; McBumey, 1993). Application 
of dimethyl sulphoxide (DMSO) to P19 cells, triggers signaling events that results in the 
differentiation into a cardiac-muscle phenotype (Skeijanc, 1999; McBumey, 1993). 
Therefore, as result of their capacity to form cardiomyocytes in vitro  ^P19 cells have been 
widely used to study cardiac cell physiology (van der Heyden et al., 2003; Anisimov et 
al., 2002; van der Heyden and Defize, 2003).
The P19C16 cell-line is a suh-clone of PI 9 cells that has been reported to efficiently 
differentiate into cardiomyocytes upon exposure to DMSO under adherent culture 
conditions (Habara-Ohkubo, 1996). The P19CL6 cell-line has been widely used as an in 
vitro model of cardiovascular cells (Young et al., 2004; van der Heyden and Defize, 
2003; van der Heyden et al., 2003; Peng et al., 2002; Anisimov et al., 2002; Paquin et al., 
2002; Ridgeway et al., 2000; Monzen et al., 2001) and was used in this study to 
investigate the effect of long-chain fatty acids (LCFA) and fibrates on the expression of 
genes related to lipid metabolism.
1.2 Coronary Heart Disease (CHD)
1.2.1 Definition
Coronary heart disease (CHD) has been the single most important cause of premature 
death in modem and industrialised countries over the last two decades (Lindsay and Gaw, 
2001; Mata and Ortega, 2003; Talmud and Stephens, 2004; Chilton, 2004; Renaud and 
Lanzmann-Petithory, 2001). The World Health Organisation (WHO) has predicted that 
cardiovascular diseases will represent the major cause of morbidity and mortality 
worldwide before 2010 (Chapman, 2003). This will be accompanied by a marked 
increase in the prevalence of Diabetes Mellitus, obesity and the Metabolic 
Syndrome (Chapman, 2003). .
1.2.2 Risk factors
The importance of underlying risk factors in the diagnosis, treatment, and 
management of CHD is well known, with almost 300 variables being statistically 
associated with CHD (Poulter, 1999). However, evidence suggests that the vast majority 
of coronary events depend on genetic constitution, gene-environment interactions, 
lifestyle and factors such as age and gender (Assmann et al., 1999; Talmud, 2004; 
Mathers, 2004). Major CHD risk factors routinely assessed in clinical practice and 
epidemiological studies are classified in Table 1.1 into two main groups, namely those 
that are modifiable and unmodifiable (Lindsay and Gaw, 2001; Assmann et al., 1999; 
Fonarow and Horwich, 2003; Poulter, 2003):
Table 1.1: Major risk factors for CHD (Lindsay and Gaw, 2001)
CHD risk factors
Modifiable Unmodifiable
.Smoking
Elevated plasma cholesterol 
Obesity
Physical inactivity 
Excess alcohol 
Stress
Family history of CHD 
Personal history of CHD 
Diabetes Mellitus 
Age 
Gender
Epidemiological and clinical studies indicate that three main CHD risk factors should 
be considered in monitoring and management processes, namely abnormal plasma lipid 
concentrations or dyslipidaemia, hypertension and smoking (Talmud and Stephens, 2004; 
Poulter, 2003; Ascherio, 2002). High plasma lipid levels, particularly cholesterol, play an 
important role in the development of CHD and atherosclerosis (Chilton, 2004) and 
lowering cholesterol levels, particularly low-density lipoprotein-cholesterol (LDL-C), has 
been the focus of the prevention of CHD for the last 25 years (Poulter, 1999; Chilton, 
2004; Spratt, 2004). Recently, the importance of postprandial lipaemia and moderately 
raised serum triacylglycerol levels in the development of coronary heart disease has been 
recognised to generate pro-atherogenic changes in serum lipoproteins, including the 
formation of small dense LDL and the reduction of cardioprotective high-density
lipoproteins (HDL) (Griffin and Fielding, 2001; Tulenko and Sumner, 2002; Wang and 
Briggs, 2004; Bemeis and Rizzo, 2004).
1.2.3 Atherosclerosis
Atherosclerosis is a pathological process that ultimately leads to a localized 
obstruction of an artery due to the progressive build-up of lipids in the arterial 
wall (Plutzky, 2003; Stocker and Keaney, 2004; Ross, 1999; Cullen, 2003). Several 
pathological processes participate in atherosclerotic plaque formation including: (1) 
Lipoprotein particles, and especially LDL, enter the arterial wall and undergo oxidation. 
(2) Oxidised LDL (ox-LDL) particles can incite a cascade of cellular responses that 
includes production of inflammatory mediators. (3) Vascular adhesion molecules 
(VCAM-1) are induced on the endothelial cell surface. (4) Monocytes attach to VCAM-1 
and enter the arterial wall. (5) Migrated monocytes take-up the ox-LDL and differentiate 
into foam cells. (6) Vascular smooth muscle cells respond to these stimuli and migrate 
into the intima, where they proliferate and form early atherosclerotic lesions, leading to 
the formation of a fibrous cap and complicated atherosclerotic plaque in the later 
stages (Plutzky, 2003; Ross, 1993; Barish and Evans, 2004; Li and Glass, 2004; Cullen, 
2003).
1.3 Properties of fatty acids
Dietary fat is an important macronutrient for the growth and development of all 
organisms (Wijendran and Hayes, 2004; Manco et al., 2004; Calder, 2004a). Changes in 
the quantity or composition of ingested dietary fat influences cellular processes and 
physiological systems (Jump, 2004). Many of these effects can be linked to changes in 
membrane lipid composition affecting membrane fluidity or eicosanoid signalling (Jump, 
2002b; Clarke, 2000; Jump, 2004). The properties of dietary fats are primarily 
determined by the composition of their fatty acids, which may be saturated (no double 
bonds), monounsaturated (one double bond) or polyunsaturated (with greater than one 
double bond) (Calder and Grimble, 2002). Unsaturated fatty acids can adopt two distinct 
geometric configurations, denoted as the cis and trans configurations (Fig. 1.1), where cis
fatty acids have a bend in the chain, and trans fatty acids adopt a straight configuration 
and function like saturated fatty acids (Yaqoob, 2003). There are four families of 
unsaturated fatty acids, denoted as n-9, n-7, n-6 and n-3 series (Calder and Grimble,
2002). This nomenclature indicates the position of the first double bond fi*om the methyl 
terminus of the hydrocarbon chain (Fig. 1.1) (Calder and Grimble, 2002). Humans are 
unable to synthesise linoleic acid (LA; 18:2 n-6) and a-linolenic acid (ALA; 18:3 n-3), 
and therefore these fatty acids are classified as essential fatty acids (EFA), and must be 
supplied in the diet (Yaqooh, 2003; Wijendran and Hayes, 2004). It is estimated that a 
minimum human requirement for LA and ALA is 1% and 2% of daily energy intake, 
respectively (Calder, 2004b). These two fatty acids can be converted into other 
polyunsaturated fatty acids (PUFA) of the n-3 and n-6 series hy further elongation and 
desaturation (Calder, 2003; Jump, 2002b; Jump, 2004; Nakamura and Nara, 2004).
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Figure 1.1: Diagrammatic representation different long-chain fatty acids (Calder 
and Grimble, 2002).
1.3.1 Fatty acids function as an energy source in the 
cardiomyocytes
The heart is able to use a number of different substrates for aerobic energy 
production including fatty acids, glucose, pyruvate, lactate, acetate, ketone bodies and, to 
a minor extent, amino acids (Belke et ah, 1999; Soltys et al., 2002; van der Vusse et al., 
2000). In the foetal heart, lactate oxidation and glycolysis are the preferred route of 
energy production, but following birth fatty acid oxidation becomes the predominant 
energy source providing over 70% of the energy needs for cardiac function under normal 
physiological conditions (Hauton et al., 2001; van Bilsen et ah, 2004; Lewin and 
Coleman, 2003; Makinde et al., 1998).
The heart relies heavily on the continuous supply of fatty acids, as endogenous 
synthesis is limited (Brinkmann et al., 2002; Stavinoha et al., 2004; Lewin and Coleman,
2003). However, the cardiac muscle may shift continuously from one source of energy to 
another, according to nutrient availability, which is controlled by diet, exercise, or 
pathophysiological state (Grynberg and Demaison, 1996; Ventura-Clapier et al., 2004; 
van Bilsen et al., 2004; van der Vusse et al., 2000). For example, under high glucose and 
low fatty acid availability, carbohydrates (and lactate) become the major energy substrate 
for the heart (Grynberg and Demaison, 1996; Belke et al., 1999), and the ability to 
metabolise FA by p-oxidation is reduced (Belke et al., 2002). In contrast, under fasting 
conditions fatty acids become the major source of energy and are preferentially oxidised 
in the heart, and carbohydrate utilization is decreased (Grynberg and Demaison, 1996; 
Frayn, 2003).
1.3.2 P-Oxidation of fatty acids
The oxidation of fatty acids is a central metabolic process for the provision of energy 
in the cell (Ghisla, 2004; Kim and Battaile, 2002). Fatty acid oxidation is achieved in a 
series of reactions that occur in mitochondria, peroxisomes and endoplasmic 
reticulum (Reddy and Hashimoto, 2001; Bartlett and Eaton, 2004; Ghisla, 2004; Kim and 
Battaile, 2002). The p-oxidation of fatty acids is confined to mitochondria and 
peroxisomes, whereas co-oxidation is a specialised pathway and occurs in the
microsomes (Reddy and Hashimoto, 2001; Bartlett and Eaton, 2004). Mitochondria 
catalyse the complete p-oxidation of the bulk of dietary short- (<Cg), medium- (Cg-Cn) 
and long-chain (C14-C20) fatty acids to acetyl groups that can either enter the Citric Acid 
Cycle for further oxidation or condense to form ketone bodies (acetoacetate, acetone, and 
p-hydroxybutyrate) in the liver (Reddy and Hashimoto, 2001; Kim and Battaile, 2002; 
Bartlett and Eaton, 2004; Ghisla, 2004). The liver exports ketone bodies to serve as fuels 
for extra-hepatic tissues such as heart, skeletal muscle and brain (Reddy and Hashimoto, 
2001 ; Kim and Battaile, 2002; Bartlett and Eaton, 2004).
In contrast to mitochondria, peroxisomes are involved in the p-oxidation and chain 
shortening of long-chain, very-long-chain and branched-chain fatty acids, and 
prostaglandins (Reddy and Hashimoto, 2001; Kim and Battaile, 2002). Although 
long-chain fatty acids are predominantly p-oxidised in mitochondria, the P-oxidation of 
very-long-chain fatty acids (>C2o) almost exclusively occurs in peroxisomes (Reddy and 
Hashimoto, 2001; Kim and Battaile, 2002). Unlike the mitochondrial pathway, 
peroxisomal p-oxidation system is carnitine-independent, and normally stops after a few 
cycles with the products exported to the mitochondria for complete oxidation (Reddy and 
Hashimoto, 2001; Kim and Battaile, 2002).
1.3.3 Lipoprotein metabolism
Chylomicrons (CM) containing apolipoprotein (apo) B-48 and large amounts of 
triacylglycerol (TAG) are synthesised in the intestine from dietary fats (Fig. 1.2) (Tulenko 
and Sumner, 2002; Wang and Briggs, 2004; Williams et al., 2004). In the circulation, 
CMs acquire apo-E and apo C-II and are reduced in size by the action of lipoprotein 
lipase (LPL), which catalyses removal of fatty acids from TAG pool. After its activation 
by apo C-II on CM, LPL hydrolyses most of the TAG to free fatty acids, the latter then 
bind to albumin and are deposited in tissues, mainly adipocytes and muscle (Wang and 
Briggs, 2004; Packard, 2003). VLDL, the other TAG-rich particle containing apo E, C-II 
and B-lOO, is synthesised in hepatocytes and secreted into the circulation for the delivery 
of lipids to the periphery (Tulenko and Sumner, 2002; Packard, 2003). In the circulation, 
LPL, is again activated by apo C-II, and hydrolyses and reduces VLDL triacylglycerol 
content, leaving the particle smaller, denser and cholesterol-enriched, termed
intermediate-density lipoprotein (IDL) that with further hydrolysis can generate LDL 
(Fig. 1.2) (Tulenko and Sumner, 2002; Packard, 2003).
Cholesterol homeostasis involves the reverse transport of cholesterol from tissues 
back to the liver (Rader, 2003; Fredenrieh and Bayer, 2003; Linsel-Nitschke and Tall,
2005). Nascent HDL (pre-pHDL) containing apo A-I, which is synthesised in the liver 
and intestine binds to peripheral cell surface receptors, e.g. ATP-binding cassette 
transporter 1 (ABCAl) that facilitates the efflux of free cholesterol from the cells onto the 
surface of pre-pHDL (Duval et al., 2004; Tulenko and Sumner, 2002; Wang and Briggs, 
2004; Fredenrieh and Bayer, 2003; Linsel-Nitschke and Tall, 2005). Absorbed
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Figure 1.2: Diagrammatic representation of lipoprotein metabolism. CM is synthesised by 
intestine from dietary fat, whereas VLDL and HDL are synthesised by liver from the endogenous 
sources. LPL in the circulation hydrolyses TAG core of CM and VLDL particles and releases 
free fatty acids. CETP: cholesterol ester transport protein; CM: chylomicron; FFA: free fatty 
acid; LDL: low-density lipoprotein; HDL: high-density lipoprotein; VLDL: very low-density 
lipoprotein; A, B48, BlOO, C and E are the major apolipoproteins associated with the 
particles (Tulenko and Sumner, 2002; Wang and Briggs, 2004).
cholesterol is then esterified by lecithin-cholesterol acyltransferase (LCAT), which is 
activated by apo A-I, and internalised into the hydrophobic core of the pre-pHDL particle, 
the process that promotes further cholesterol efflux, mainly facilitated by scavenger 
receptor B1 (SR-Bl) and gradually matures pre-pHDL to HDL] and HDL] (Tulenko and 
Sumner, 2002; Wang and Briggs, 2004; Linsel-Nitschke and Tall, 2005; Fredenrieh and 
Bayer, 2003; Spady, 1999). HDL] and HDL] exchange cholesterol, TAG and 
phospholipid with VLDL/LDL particles, mediated by cholesterol ester transfer protein 
(CETP), TAG transfer protein and phospholipid transfer protein (PLTP), respectively or 
are taken-up by the liver for degradation and disposal of cholesterol in the form of bile 
acids (Fig. 1.2) (Duval et al., 2004; Tulenko and Sumner, 2002; Wang and Briggs, 2004; 
Linsel-Nitschke and Tall, 2005).
1.3.4 Effect of fatty acids on PUFA metabolism
As discussed earlier, dietary LA and ALA are essential fatty acids and must be 
supplied in the diet (Yaqoob, 2003), and are then converted into other n-3 and n-6 
polyunsaturated fatty acids (Calder, 2003; Jump, 2002b). The major end-product of LA 
(18:2 n-6) metabolism is arachidonic acid (AA; 20:4 n-6), whereas ALA (18:3 n-3) is 
mainly metabolised to eicosapentaenoic acid (EPA; 20:5 n-3) and, to a much lesser 
extent, docosahexaenoic acid (DHA; 22:6 n-3) (Calder, 2003). The metabolism of n-3 
and n-6 fatty acids is competitive and both pathways use the same set of desaturation and 
elongation enzymes, most importantly A6-desaturase (Fig. 1.3) (Belury, 2002; Calder, 
2004b; Nakamura and Nara, 2004; Jump, 2004). Although ALA is the preferred substrate 
for the latter enzyme, LA is by far the most abundant substrate (Calder, 2004b). Due to 
this competitive effect, the composition of cellular lipid pools reflects, to some degree, 
alterations in dietary intakes of those two essential fatty acids (Yaqoob, 2003). Since LA 
is much more prevalent than ALA in human diets, the metabolism of n-6 fatty acids is 
quantitively the more important (Calder, 2004b), however dietary supplementation with 
LC n-3 PUFA is able to competitively suppress the n-6 pathway and vice versa (Calder 
and Grimble, 2002).
Both n-3 and n-6 polyunsaturated fatty acids are important components of membrane 
phospholipids, regulating membrane fluidity (Yaqoob, 2003). Although several
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20-carbon PUF As are able to serve as eicosanoid precursors, arachidonic acid 
(n-6 PUFA) is usually the principal substrate for their synthesis (Calder, 2003). 
Arachidonic acid in cell membranes can be mobilized by phospholipase A% 
(PLA2) (Calder, 2001) and subsequently acts as a substrate for cyclooxygenase (COX) 
and lipooxygenase (LOX) enzymes that give rise to the production of the inflammatory 
mediators such as prostaglandins (PG), thromboxanes (TX), and leukotrienes 
(LT) (Fig. 1.3) (Calder, 2001; Calder and Grimble, 2002; Calder and Miles, 2000; Calder, 
2003; Yaqoob, 2003; Calder, 2004b). On the other hand, n-3 fatty acids, especially 
eicosapentaenoic and docosahexaenoic acids, are known to exert anti -inflammatory 
effects and act as arachidonic acid antagonists by decreasing the availability of AA for 
eicosanoid production, reducing oxygenation of AA by COX and producing derivatives 
that are considered to promote a less thrombotice inflammatory environment 
(Fig. 1.3) (Calder and Grimble, 2002; Calder, 2004a; Calder, 2001; Plutzky, 2003;
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Figure 1.3: Outline of the biosynthesis and metabolism of PUFA. Linoleic (n-6) and 
a-Linolenic (n-3) acids are competitively converted into their highly unsaturated 
metabolites by the action of desaturase and elongase enzymes (Calder and Grimble, 2002; 
Calder, 2004a). COX: cyclooxygenase; LOX: lipooxygenase; PG: prostaglandin; LT: 
Leukotriene; TX: thromboxanes.
Calder, 2004b; Calder, 2003). The effects of n-3 and n-6 PUF As on inflammation and 
immunity has attracted much attention since atherosclerosis has, in part, an inflammatory 
basis (Ross, 1993; Chilton, 2004; Plutzky, 2003; Ross, 1999). Therefore, the ratio of 
n-6:n-3 fatty acids in both membranes and the diet may have important physiological 
implications (Wijendran and Hayes, 2004).
1.3.5 The link between dietary lipids and CHD
In the early 1950s it was known that populations with a high intake of saturated fat 
showed increased levels of atherosclerosis and CHD (Renaud and Lanzmann-Petithory,
2001). However, it was the Seven Countries Study (Keys, 1997), which clearly 
demonstrated that dietary saturated fatty acids (SFA) were a major environmental risk 
factor for CHD. Follow-up reports of the Seven Countries Study indicate that CHD 
mortality is closely and directly related to the intake of SFA and 
cholesterol (Panagiotakos et al., 2003; Ascherio, 2002; Kromhout et al., 1995). Over the 
last 50 years several large epidemiological studies have shown a strong relationship 
between high dietary saturated fat intake, increased plasma cholesterol, and CHD that has 
become known as diet-heart hypothesis (Chahoud et al., 2004; Panagiotakos et al., 2003; 
Ascherio, 2002; Kromhout et al., 1995; Sacks and Katan, 2002; Burr et al., 1989; 
GISSI-Trial, 1999; Cagÿula and Mustad, 1997; Kato et al., 1973; Keys, 1997). Since the 
establishment of the diet-heart hypothesis, many studies have been conducted to test the 
effects of different diets on CHD mortality (Chahoud et al., 2004; Panagiotakos et al., 
2003; Ascherio, 2002; Kromhout et al., 1995; Sacks and Katan, 2002; Burr et al., 1989; 
GISSI-Trial, 1999).
Dietary interventional trials have confirmed that the type of fatty acid consumed is 
more important than the amount of total fat in determining the rate of CHD 
events (Chahoud et al., 2004). Dietary fat, and in particular saturated fatty acids, increase 
blood cholesterol and lipid levels (Ascherio, 2002; Wolfram, 2003; Stender and 
Dyerberg, 2004; Eckel et al., 2001b; Eckel et al., 2001a; Sacks and Katan, 2002; Chahoud 
et al., 2004). Unlike long-chain SFA and cholesterol, which markedly increase LDL-C 
production and concentration in plasma (Eckel et al., 2001a), the effect of shorter chain 
fatty acids (Cô-Cn) on plasma LDL-C levels is poorly documented (Kromhout et al.,
1995; Tholstrup et al., 2004). Medium-chain fatty acids are absorbed into the portal vein 
and are rapidly oxidised by the liver, since the mitochondrial membrane is permeable to 
short- and medium-chain fatty acids (Olpin, 2004; Ramirez et al., 2001; St-Onge and 
Jones, 2002; Kromhout, 1999), whereas dietary LCFAs are packed into chylomicrons and 
bypass the liver via the lymphatic system, favouring uptake of fatty acids into adipose and 
muscle tissues (St-Onge and Jones, 2002; Leonhardt and Langhans, 2004).
In contrast to the atherogenic effect of saturated fatty acids, PUFAs display 
cardioprotective effects and reduce plasma total cholesterol and LDL-C (Ascherio, 2002; 
Mori and Beilin, 2001; Kris-Etherton et al., 2003), thereby correcting blood lipid profiles 
and reduce the risk of CHD mortality (Calder, 2004b; Wijendran and Hayes, 2004; Sacks 
and Katan, 2002; Chahoud et al., 2004; Calder, 2004b). Replacement of saturated fat 
with monounsaturated fat in the diet has been shown to yield a 30% reduction in 
CHD (Sacks and Katan, 2002). Similarly, the consumption of polyunsaturated fatty acids 
(PUFA) has been associated with a reduced risk of CHD and lower mortality (Oomen et 
al., 2000; Angerer and von Schacky, 2000; Hu et al., 2002). The beneficial effects of 
dietary PUFAs on cardiovascular diseases are now well established (Hu et al., 2002; Das, 
2000; Wijendran and Hayes, 2004; Jump, 2004) and are discussed below in more detail.
Unlike cis unsaturated fatty acids, dietary trans fatty acids {trans-VA) are regarded as 
atherogenic fat (2-to 10-fold greater than saturated fatty acids) (Stender and Dyerberg, 
2004; Wolfi-am, 2003) since they lower serum high-density lipoprotein-cholesterol 
(HDL-C), increase LDL-C, decrease LDL particle size, and impair vascular endothelial 
function (De Roos et al., 2001; Mauger et al., 2003). Thus, high trans-VA intake is 
associated with increase risk of CHD and mortality (Dyerberg et al., 2004), but up to 1% 
of daily dietary energy intake as trans-¥A has been proposed to have no obvious 
damaging effects (De Roos et al., 2001).
1.3.6 Cardioprotective effects of PUFA
Linoleic acid (n-6 PUFA) is probably the most potent dietary PUFA in lowering 
serum cholesterol (Renaud and Lanzmann-Petithory, 2001; Calder, 2004a; Calder, 2004b; 
Wijendran and Hayes, 2004). By contrast, long-chain n-3 PUFA (a major component of 
fish oils) supplementation reduces circulating triacylglycerol (TAG) levels and influences
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the susceptibility of LDL to oxidation (Leigh-Firbank et al., 2002). It has been proposed 
that eicosapentaenoic and docosahexaenoic n-3 fatty acids may be responsible for the low 
rates of CHD in populations with high fish consumption, such as the Greenland Inuits and 
Japanese (Das, 2000), as confirmed by the DART and GISSI dietary intervention trials 
and this is often referred to as the “fish oil effect” (GISSI-Trial, 1999; Burr et al., 1989). 
It has been suggested that three mechanisms contribute to the strong protective effect of 
long-chain n-3 fatty acids (Calder, 2004a; Calder, 2004b), particularly EPA and fish oil, 
towards cardiovascular events:
(i) An anti-thrombotic effect mediated through eicosanoid generation. When fish oil 
is consumed, EPA is incorporated into cell membrane phospholipids leading to a 
decrease in the amounts of AA in the cell membrane and therefore eicosanoid
- synthesis (Calder, 2001; Calder, 2004a; Calder, 2004b). Furthermore, EPA, is 
released by phospholipase A] hydrolysis of phospholipids competitively inhibits 
the oxygenation of AA by cyclooxygenases (Calder and Grimble, 2002), reducing 
the likelihood of a thrombotic effect (Calder and Grimble, 2002; Calder, 2004b).
(ii) An anti-arrhythmic action by decreasing cardiomyocyte membrane electrical 
excitability. The presence of n-3 PUFAs in cardiomyocyte membranes decreases 
electrical excitability and modulates the activity of ion channels. This promotes 
electrical stability and prevents often fatal cardiac arrhythmias (Calder, 2004b).
(iii) An anti-inflammatory effect on the inflammatory progression of atherosclerosis. 
Long-chain n-3 PUFAs stabilise atherosclerotic plaques by decreasing infiltration 
of inflammatory and immune cells into the plaques and/or the function of those 
cells once in the plaque (Calder, 2004a; Calder, 2004b).
PUFAs are not only potentially strong cardioprotectants (Calder, 2004a), but also 
play a key role in the prevention of obesity, diabetes, and cancer (De Lorgeril et al., 1998; 
Ntambi and Bene, 2001; Wolfram, 2003; Norman et al., 2004). Though both n-6 and n-3 
PUFAs have distinct biological effects that contribute to their cardioprotective action, the 
absolute levels of intake (g/day) and n-6:n-3 ratio required to achieve optimal CHD health 
are somewhat controversial (Wijendran and Hayes, 2004; Renaud and Lanzmann- 
Petithory, 2001). The International Society for the Study of Fatty Acids and Lipids 
(ISSFAL) statement on the recommended dietary supplementation for n-6 and n-3 fatty 
acids (based on a daily dietary energy intake of 2000 kcal) proposed 2%-3% from LA,
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1% from ALA, and 0.3% from EPA+DHA, providing a n-6:n-3 ratio of 2:1 (Simopoulos 
et al., 2000). While some investigators propose that dietary supplementation of n-6 and 
n-3 fatty acids should not be higher than 5% of energy intake with a ratio of 
n-6:n-3 PUFA in the range of 3-5:1 (Renaud and Lanzmann-Petithory, 2001), the latest 
recommendation is an intake of about 6% LA, 0.75% ALA, and 0.5% from EPA+DHA 
corresponding to a n-6:n-3 ratio of ~6:1 (Wijendran and Hayes, 2004).
1.3.7 Delivery of fatty acids to the cardiomyocytes
Fatty acids are delivered to cardiac myocytes in three ways (Augustus et al., 2003; 
Glatz et al., 2003; Glatz and Storch, 2001). First, fatty acids are generated in the local 
capillary by lipoprotein lipase-mediated hydrolysis of TAG in circulating chylomicrons 
(CM) and very low-density lipoprotein (VLDL) (Hauton et al., 2001; Augustus et al., 
2003; Mardy et al., 2001; Niu et al., 2004). Second, fatty acids are produced from 
intracellular hydrolysis of TAG in the core of internalised lipoproteins. Finally, fatty 
acids are obtained from circulating plasma albumin, and this represents the primary 
source of FA for the heart (Augustus et al., 2003; Niu et al., 2004). Cardiac fatty acid 
uptake and transport are mediated by a family of specific proteins that includes 
membrane-associated and cytoplasmic fatty acid-binding proteins (Glatz and Storch, 
2001; Glatz et al., 2003).
1.4 Membrane-associated fatty acid transporters
It was originally believed that the uptake of long-chain fatty acids into cardiac 
myocytes was purely mediated by diffiision across the membrane (DeGrella and Light, 
1985), as demonstrated by studies using model membrane systems (Kamp et al., 1993; 
Hamilton and Kamp, 1999; Kamp et al., 1995). However, this diffusional mechanism has 
been challenged by the identification of a number of membrane-associated fatty acid 
transporters (Abumrad et al., 1999) and it is now thought that membrane fatty acid 
transport is predominantly protein-mediated (Frohnert and Bemlohr, 2000; Pohl et al., 
2004a; Pohl et al., 2004c; Bonen et al., 2004). These findings suggest that the 
mechanisms of passive and facilitated diffiision of fatty acids coexist, and their relative
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contribution to overall fatty acid transport may depend on the cell type, hormonal states 
and the availability of fatty acids (Glatz and Storch, 2001). The tissue content of fatty 
acid transporters is responsive to various dietary, hormonal and pharmacological 
manipulations, as well as pathological states (Abumrad et al., 1999).
Cellular studies demonstrated a high-affinity protein-facilitated component in the 
transport of fatty acids across the cellular membrane (Gimeno et al., 2003; Glatz et al.,
2003). This led to the identification of three major membrane fatty acid transporting 
proteins (Brinkmann et al., 2002): fatty acid translocase (FAT/CD36), plasma membrane 
fatty acid-binding protein (FABPpm), and fatty acid transport protein (FATP). All three 
proteins are present in the heart and are found to be associated with the cardiomyocyte 
plasmalemmal (van Nieuwenhoven et al., 1999). Several other membrane-bound 
proteins, such as fatty acid receptor (FAR) (Fujii et al., 1987), adipocyte differentiation 
related protein (ADRP) (Gao and Serrero, 1999) and caveolin (Trigatti et al., 1999), have 
also been implicated in fatty acid transport (Table 1.2).
Table 1.2: Membrane-associated proteins involved in fatty acid uptake and 
transport (Abumrad et al., 1999; Gimeno et al., 2003; Hajri and Abumrad, 2002).
Protein MW^  (kDa) Tissue locaiisation
FAT/CD36 88
liver, heart, muscle, brain, epidermis, kidney, intestine, testis, 
adipose tissue, spleen
FABPpm 40 liver, heart, muscle, intestine, adipose tissue
FATP1 63 heart, muscle, brain, kidney, epidermis, lung, adipose tissue
FATP2 62 liver, kidney, intestine
FATP3 64 lung, liver, testis
FATP4 65 intestine, heart, muscle, lung, brain, testis, kidney, spleen
FATP5 63 liver
F ATP6 70 heart
Caveolin 22 lung, adipose tissue, endothelium
ADRP 53 adipose tissue, liver
FAR 56-60 heart
+
MW: molecular weight
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Following dissociation of fatty acids from plasma albumin, the transmembrane 
translocation of fatty acids most likely takes place either by passive diffusion through the 
lipid bilayer, and/or active transport facilitated by membrane-associated proteins 
(Fig. 1.4). The chain length of fatty acids and degree of unsaturation influenee their rate 
of uptake by the cell (van der Vusse et al., 2000). Fatty aeids that enter the cell by the 
membrane-associated transporters FABPpm and FAT/CD36, are delivered to intracellular 
acyl-eoenzyme A synthetase (ACS) for activation and estérification to acyl-CoA 
(Fig. 1.4) (Hertzel and Bemlohr, 2000). Non-esterified fatty acids bound to intracellular 
fatty acid-binding proteins (FABP), such as heart-type fatty acid-binding protein 
(H-FABP) that shuttle LCFAs to metabolic pathways. In addition to FABPpm and 
FAT/CD36 mediated transport, fatty acids also are taken-up by the cells through 
interaction with FATP, and are immediately activated to their acyl-CoA esters by 
sarcolemmal acyl-CoA synthetase (Glatz et al., 2003; Pohl et al., 2004c; Hertzel and 
Bemlohr, 2000). Aeyl-coenzyme A then binds to aeyl-CoA binding protein (ACBP), and 
translocates to different sites in intracellular metabolic pathways (Fig. 1.4) (Glatz and 
Storch, 2001; Glatz et al., 2003; Brinkmann et al., 2002).
interstftmi space Aibumm
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Figure 1.4: Molecular mechanism of uptake and utilization of long-chain fatty 
acids (Glatz et al., 2003). Fatty acids enter the cells through simple diffusion across the cell 
membrane or facilitated by membrane proteins such as FATP, FAT/CD36, and FABPpm. 
FATP functions as both fatty acid transporter and acyl-CoA synthetase. Fatty acid or acyl-CoA 
bound to a binding protein is transported to intracellular metabolic pathways. ACS: acyl-CoA 
synthetase; ACBP: acyl-CoA binding protein; FA: fatty acid; FAT: fatty acid translocase 
(FAT/CD36); FATP: fatty acid transport protein; FABPpm: plasmalemmal fatty acid-binding 
protein; H-FABP: heart-type fatty acid-binding protein.
The first putative membrane-bound fatty acid transporter to be identified was a 
40 kDa protein termed plasmalemmal fatty acid-binding protein (FABPpm) (Stremmel et 
al., 1985). Glatz et al. (1994) reported that FABPpm is an abundant component of the 
plasma membrane and it is estimated to constitute 2% of plasmalemmal protein and may 
co-operate with fatty acid translocase (FAT/CD36) to translocate fatty acids across the 
membrane (van der Vusse et al., 2000; Roepstorff et al., 2004).
Harmon and Abumrad (1993) identified an 88 kDa membrane protein involved in the 
rat adipose uptake and transport of fatty acids, that they referred to as FAT (fatty acid 
translocase), but this protein is homologous to human CD36 (Tandon et al., 1989). 
FAT/CD36 recognizes a broad range of ligands including oxidized LDL, anionic 
phospholipids, apoptotic cells, collagen, and fatty acids and is responsible for a large 
fi-action of fatty acid uptake by the heart (Hajri and Abumrad, 2002). FAT/CD36 is 
located in the plasma membrane, as well as intracellular pools of heart and skeletal 
muscle cells (Campbell et al., 2004; Bonen et al., 2004; Luiken et al., 2004). 
Translocation of FAT/CD36 fi*om the intracellular pools to the plasma membrane is 
induced by insulin and contraction (Chabowski et al., 2004; Luiken et al., 2004; Bonen et 
al., 2004). It is possible that FAT/CD36 acts as an acceptor or docking protein, either 
handing fatty acids to the other proteins or simply assisting their movement through 
hydrophobic environments (Campbell et al., 2004; Abumrad et al., 1999). It has recently 
been shown that FAT/CD36 is associated with lipid rafl;s in the plasma membrane that are 
used as platforms to bind or transport LCFA (Pohl et al., 2004a; Pohl et al., 2004b; Pohl 
et al., 2004c). Since disruption of lipid rafts decreases binding of LCFAs to FAT/CD36 it 
is likely that plasma membrane lipid rafts regulate the cell surface availability of 
FAT/CD36 and therefore control LCFA uptake and transport (Pohl et al., 2004a; Pohl et 
al., 2004b; Pohl et al., 2004c; Pohl et al., 2005).
Schaffer and Lodish (1994) identified a 63 kDa membrane-associated protein, named 
fatty acid transport protein (FATP), which increases the uptake of LCFA. Recently, a 
large family of FATPs has been reported (Table 1.2) (Gimeno et al., 2003). FATPs have 
sequence similarity to very-long-chain fatty-acyl CoA synthetase and possibly function 
both as a LCFA transporter and as an acyl-CoA synthetase (Frohnert and Bemlohr, 2000; 
Abumrad et al., 1998; Pohl et al., 2004a). An AMP-binding sequence that mediates 
acyl-CoA synthetase activity is found in all known FATPs (Coe et al., 1999; Pohl et al., 
2004a; Pohl et al., 2004c). The different members of the FATP family show
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characteristic expression patterns in different fatty acid metabolising tissues (Gimeno et 
al., 2003; Hajri and Abumrad, 2002). FATP4 is mainly expressed in the intestine. 
Likewise, FATPS and FATP6 are predominantly expressed in the liver and heart tissue, 
respectively, whereas FATPl is the major FATP in adipose tissue, but is also found in 
heart and skeletal muscle cells (Gimeno et al., 2003; Pohl et al., 2004c).
1.5 Intracellular Fatty Acid-Binding Proteins (FABPs)
1.5.1 Classification of intracellular FABPs
Intracellular fatty acid-binding proteins (FABP) are members of a conserved 
multi-gene family of the intracellular lipid-binding proteins (iLBPs) encoding 14-15 kDa 
proteins (Table 1.3) (Hertzel and Bemlohr, 2000; Haunerland and Spener, 2004; 
Veerkamp and Maatman, 1995). FABPs were discovered in the early 1970s as abundant 
cytoplasmic proteins that bind long-chain fatty acids in a non-covalent and reversible 
manner (Coe and Bemlohr, 1998; Ockner et al., 1972), and show a characteristic pattem 
of tissue distribution (Hertzel and Bemlohr, 2000; Zimmerman et al., 2001). At least 16 
members of this protein family have been identified with 22%-73% amino acid identity 
(Table 1.3) (van der Vusse et al., 2000; Adida and Spener, 2002; Haunerland and Spener,
2004). Some FABPs, such as I-FABP and T-FABP, are found exclusively in one tissue, 
whereas others, such as L-FABP and H-FABP, are expressed in more than one tissue 
(Table 1.3), suggesting that these proteins have evolved separately in order to fulfil 
different physiological functions (Massolini and Calleri, 2003). FABPs are classified into 
four subfamilies, namely subfamily I, which comprises proteins specific for vitamin A 
derivatives; subfamily II, containing proteins with larger binding sites that allow binding 
of bulkier ligands, such as bile acids and heme; subfamily III with only one member 
(I-FABP), which is only expressed in intestine; and subfamily IV that includes the 
remaining FABPs (Haunerland and Spener, 2004).
Several functions have been proposed for the FABPs, and these include: (i) 
modulation of enzyme activity related to lipid metabolism; (ii) maintaining the fatty acid 
composition of cell membranes; and (iii) regulation of gene expression by interacting 
with LCFA-activated nuclear receptors, such as the peroxisome proliferators-activated
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receptors (PPAR) (Storch and Thumser, 2000). Consistent with these general concepts, 
the FABP content of the most cells is generally proportional to the rate of fatty acid 
metabolism, the latter being highest in hepatocytes, cardiomyocytes, and 
adipocytes (Haunerland arid Spener, 2004).
In summary, membrane-associated and cytoplasmic LCFA transporters could 
co-operate to facilitate efficient LCFA uptake and utilization (Stahl et al., 2001). 
However, the fate of cellular LCFA depends on the cellular energy demand, 
pathophysiological states and the physiochemical properties of the FA (Brinkmann et al., 
2002; Ferdinandusse et al., 2003).
Table 1.3: The FABP protein family.
ILBP-type Gene Expression Ligands
Subfamily 1 
CRBP l-IV 
CRABP 1, II
RBP1-4
RBP5, CRABP2
Ubiquitous mainly in liver, kidney, lung 
Ubiquitous mainly in epidermis and brain
Retinol 
Retinoic acid
Subfamily II 
L-FABP
I-FABP
FABP1
FABP6
Liver, intestine, kidney, lung, and pancreas 
Ileum
LCFA, acyl-CoA, 
and heme 
bile acids
Subfamily III 
I-FABP FABP2 Intestine, liver LCFA
Subfamily IV 
H-FABP
A-FABP
E-FABP
B-FABP
M-FABP
T-FABP
FABPS
FABP4
FABPS
FABP7
FABPS
FABP9
Heart, skeletal muscle, brain, kidney, lung, 
mammary, placenta, testis, ovary, and 
stomach
Adipose tissue, macrophages 
Skin, adipose tissue, lung, brain, heart, 
skeletal muscle, testis, retina, and kidney 
Brain, retina, and Central Nervous System 
Brain and Peripheral Nervous System 
Testis
LCFA
LCFA
LCFA
LCFA and DHA
LCFA
LCFA
Table was compiled from data in reviews (Hertzel and Bemlohr, 2000; Haunerland and Spener, 2004; Storch 
and Thumser, 2000) as well as utilizing the SwissPort Database (http://ca.expasy.org/sprot/sprot-top.html).
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1.5.2 Ligand-binding characteristics of FABPs
All FABPs contain 127-132 amino acids (Massolini and Calleri, 2003) and are 
composed of two a-helices and 10 anti-parallel p-strands organised into two p-sheets 
(Fig. 1.5) (Storch and Thumser, 2000). The p-sheets create an internal cavity lined with a 
large number of hydrophobic amino acid side chains, although the cavity also contains 
several polar amino acids (Massolini and Calleri, 2003; Zanotti, 1999). The fatty acid 
ligand binds in the hydrophobic cavity, with the carboxylate group oriented inwards, 
coordinated by tyrosine and arginine residues within the binding pocket (Zanotti, 1999; 
Hertzel and Bemlohr, 2000). The binding pocket of L-FABP (subfamily II) is 
considerably larger than that of other FABPs, allowing the binding of two fatty acid 
molecules (Haunerland and Spener, 2004; Pohl et al., 2005). Despite the overall 
similarity of FABPs, the ligand-binding configuration is specific for each FABP, though 
only slightly dependent on the type of fatty acid itself (Zanotti, 1999). For instance, 
I-FABP binds fatty acids in an almost linear conformation (Adida and Spener, 2002), 
whereas the members of subfamily IV bind fatty acids in a highly bent U-shaped 
conformation (Zanotti, 1999; Adida and Spener, 2002; Haunerland and Spener, 2004).
%
Figure 1.5: Structure of I-FABP showing the configuration of bound palmitic acid. The
a-helical portal domain (a-I and a-II) is shown in red, whereas the ten anti-parallel P-strands 
are labelled A through J and represented in blue. Palmitic acid is shown bound to the interior 
of the P-sheet domain demonstrating linear conformation with the carboxylate end oriented 
inwards and the acyl chain extending towards the a-helical portal domain (Storch and 
Thumser, 2000).
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FABPs bind long-chain fatty acids (C16-C20) with high affinity (Kd <500 nM) and a 
molar stoichiometry of 1:1, with the exception of L-FABP, which can bind two LCFA 
simultaneously (Thompson et ah, 1997; Storch and Thumser, 2000; Richieri et al., 2000; 
Adida and Spener, 2002; Massolini and Calleri, 2003). Ligand affinity is dependent on 
FABP-type, the length of acyl chain, and degree of fatty acid unsaturation (Massolini and 
Calleri, 2003). In general, affinities decrease with decreasing chain length, i.e. reduction 
in hydrophobicity, and increasing saturation (Richieri et al., 2000; Massolini and 
Calleri, 2003). LCFA binding affinity varies according to FABP type, with 
brain = myelin = heart > liver >intestine >adipocyte (Richieri et al., 2000; Zimmennan et 
al., 2001; Massolini and Calleri, 2003).
FABPs shuttle LCFA to metabolic pathways and LCFA-activated nuclear receptors 
in the nucleus, acting as a “cytosolic gateway”. Fatty acids and several of their 
metabolites function as messengers in cell signalling pathways and cell differentiation 
(Fig. 1.6) (Hertzel and Bemlohr, 1998; Calder, 2001; Jones-Villeneuve et al., 1983). 
They may also affect the abundance of transcription factors and regulate the activity of
FA
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Figure 1.6: Intracellular transport of fatty acids. Fatty acids entered the cell may influence on 
the membrane composition and intracellular transduction or may oxidised in the mitochondria. 
FAs also affect the abundance of transcription factors and regulate the activity of nuclear 
receptors that control gene expression. FA: fatty acid (Jump, 2004; Storch and Thumser, 2000).
nuclear receptors that control gene expression related to cell growth, differentiation, and 
metabolism (Jump, 2004; Khan and Vanden Heuvel, 2003; Clarke, 2001; Jump, 2002a; 
Jump, 2002b; Ntambi and Bene, 2001). The activation of nuclear receptors allows them 
to exert their biological function on gene expression (Yaqoob, 2004; Tan et al., 2002). 
LCFAs modulate gene transcription by interacting with transcription factors such as 
peroxisome proliferator-activated receptors (PPARs), liver X receptor (LXR), hepatic 
nuclear factor (HNF4-a) and sterol regulatory element-binding protein 
(SREBP) (Sampath and Ntambi, 2004). In cardiac and skeletal muscle cells, the 
expression of lipid-related genes is mainly under control of PPARs (Gilde and van Bilsen, 
2003; Guan et al., 2002).
Thus, fatty acids and other lipids present in our diets are not only nutritionally 
important but also serve as ligands, or precursors for ligands, that bind to receptors in the 
nucleus (Chawla et al., 2001) and positively or negatively regulate the expression of 
lipid-related genes and the synthesis of proteins involved in lipid metabolism (Jump, 
2002a; Jump, 2004; Jump and Clarke, 1999). Many of these genes encode for proteins 
that play a role in fatty acid transport or metabolism (Table 1.4) (Duplus et al., 2000; 
Jump, 2004; Clarke, 2000; Pegorier et al., 2004; Lee et al., 2003b; Ntambi and Bene,
2001). Changes in the amounts of these proteins is an adaptive response by cells to the 
variation in fatty acid concentration and availability (Duplus and Forest, 2002).
Table 1.4: Examples of fatty acid-regulated genes involved in lipid metabolism and
their corresponding function.
R egulation G ene F unction
Glucose-6-phosphatase (G6Pase) Glycogenolysis
Glucokinase (GK) Glycolysis
Liver-pyruvate kinase (L-PK) Glycolysis
Giucose-6-phosphate dehydrogenase (GePD) Glycolysis
ATP citrate-lyase (ACL) Lipogenesis
D o w n -re g u la tio n
Fatty acid synthase (FAS) Lipogenesis
Acetyl-CoA carboxylase (ACC) Lipogenesis
814 protein (814) Lipogenesis
8tearoyl-CoA desaturase-1 (8CD-1 ) Desaturation of FA
A5-desaturase A5-desaturation
A6-desaturase A6-desaturation
Apolipoprotein-CIII (apo-CIII) Lipoprotein metabolism
Fatty acid translocase (FAT/CD36) Membrane FA transport
Liver-fatty acid-binding protein (L-FABP) Intracellular FA transport
Heart-fatty acid-binding protein (H-FABP) Intracellular FA transport
Adipocyte-fatty acid-binding protein (A-FABP) Intracellular FA transport
Lipoprotein lipase (LPL) Lipoprotein metabolism
Apolipoprotein-AI (apo-AI) Lipoprotein metabolism
U p -re g u la tio n
Apolipoprotein-AII (apo-AI 1) Lipoprotein metabolism
Acyl-CoA synthetase (ACS) Fatty acid activation
Acyl-CoA oxidase (AOX) Peroxisomal FA p-oxidation
Cytochrom P450A2 (CYP4À2) Microsomal FA m-oxidation
Carnitine palmitoyltransferase-1 (CPT-1 ) Acyl-chain transporter
Uncoupling protein 2 and 3 (UCP2, UCP3) Controlling energy production
Phosphoenolpyruvate carboxykinase (PEPCK) Glyceroneogenesis
Glucose transporter (GLUT4) Glucose transport
FA: fatty acid. Table was compiled from data in reviews (Jump and Clarke, 1999; Duplus et al., 2000; Duplus and Forest, 
2002; Jump et al., 1994; Fruchart et al., 2001; Pegorier et al., 2004)
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1.6 Nuclear Receptors
1.6.1 Classification of nuclear receptors
Nuclear receptors function as ligand-activated transcription factors that regulate the 
expression of target genes to affect processes as diverse as reproduction, development, 
differentiation and general metabolism (Chawla et al., 2001; Francis et al., 2003; 
Schulman and Heyman, 2004). To date, more than 70 gene products have been identified 
as members of the steroid receptor superfamily, primarily based on their similarity to 
known hormone receptors. However, the latest estimate of the number in the human 
genome sequence, based on sequence alignment, is 48 nuclear receptor genes 
(Fig 1.7) (Zhang et al., 2004; Sladek and Giguere, 2000; Francis et ah, 2003; Maglich et 
al., 2001; Robinson-Rechavi et al., 2001). Nuclear receptors were first recognized as 
mediators of steroid hormone signalling (Nagy and Schwabe, 2004) and now include a 
large superfamily of ligand-modulated transcription factors (Nagy and Schwabe, 2004; 
Benoit et al., 2004). Nuclear receptors can be categorized into distinct functional classes 
according to their ligand binding properties (Benoit et al., 2004), including the hormone 
receptors, nutritional sensors, receptors with structural ligands, and a large number of 
so-called orphan nuclear receptors, whose ligands, target genes, and physiological 
functions were initially unknown (Fig 1.7) (Sladek and Giguere, 2000; Giguere, 1999; 
Escher and Wahli, 2000). The majority of nuclear receptors are constitutively localised in 
nuclei, although most steroid hormone receptors shuttle between the cytoplasm and the 
nucleus (Benoit et ah, 2004; Handschin and Meyer, 2005).
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Figure 1.7: Classification of nuclear receptors superfamily. 48 distinct members of the 
nuclear receptor superfamily were identified in the human genome. Nuclear receptors are 
categorised into subgroups, depending on type of their ligand and/or ligand-binding 
properties (Francis et al., 2003; Zhang et al., 2004; Maglich et al., 2001; Robinson-Rechavi 
et al., 2001; Chawla et al., 2001; Rangwala and Lazar, 2004; Benoit et al., 2004). AR: 
androgen receptor; CAR; constitutive androstane receptor; COUP-TF: chicken ovalbumin 
upstream promoter transcription factor; DAX: dosage-sensitive sex receptor; ER: estrogen 
receptor; ERR: ER-related receptor; FXR: famesoid X receptor; GCNF: germ cell nuclear 
factor; GR: glucocorticoid receptor; HNF4: hepatic nuclear factor-4; LRH-1: liver receptor 
homolog-1; LXR: liver X receptor; MR mineralocorticoid receptor; NGFI-B: nerve growth 
factor induced B; Nor 1: neuron-derived orphan receptor; Nurr 1: Nur-related factor 1; PNR: 
photoreceptor-specific nuclear receptor; PPAR: peroxisome proliferator-activated receptors; 
PR: progesterone receptor; PXR: pregnane X receptor; RAR: retinoic acid receptor; ROR: 
RAR-related orphan receptor; Rev-Erb: reverse-Erb; RXR: retinoid X receptor; SF-1: 
steroidogenic factor-1; SHP: short heterodimer partner; TEL: tailless; TR: thyroid hormone 
receptor; TR2,4: testicular receptor 2 and 4; VDR: vitamin D hormone receptor; LBP: 
ligand-binding pocket.
1.6.2 Structure of nuclear receptors
The structural organization of nuclear receptors is similar despite a wide variation in 
ligand sensitivity (Aranda and Pascual, 2001; Xu et al., 2001) and is composed of five 
different domains (Fig. 1.8) (Sladek and Giguere, 2000; Blanquart et al., 2003). The 
NH2-terminal region, termed domain A/B, varies in both sequence and length and 
harbours a ligand-independent transcriptional activation function (AF-1). The
26
DNA-binding domain (DBD), or C domain, contains two highly conserved zinc-fmger 
motifs that target the receptor to DNA. The hinge region (domain D) pennits protein 
flexibility and allows simultaneous protein dimerization and binding to DNA. All nuclear 
receptors also have a large COOH-terminal region (Domain E) that encompasses the 
ligand-binding domain (LBD), dimerization interface, and ligand-dependent activation 
factor-2 (AF-2) (Khan and Vanden Heuvel, 2003; Gilde and van Bilsen, 2003; Willson et 
al., 2001). The function of domain F has not been identified (Blanquart et al., 2003).
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Figure 1.8: Schematic representation of the structure of nuclear receptors. The domain 
A/B contains the ligand-independent Activation Function-1. Domain C is the DNA-binding 
domain, the hinge region (domain D) allows the receptor to change conformation, and domain 
E contains the Ligand-Dependent Activation Function-2. The function of domain F is 
unknown (Gilde and van Bilsen, 2003; Blanquart et al., 2003; Sladek and Giguere, 2000).
Nuclear receptors are switched between active and inactive states by binding 
hydrophobic ligands (Nagy and Schwabe, 2004). The ligand-binding domain of nuclear 
receptors is formed by 10-13 a-helices, 2-5 P-strands and connecting loops (Schulman 
and Heyman, 2004; Nagy and Schwabe, 2004), creating a deep ligand-binding pocket 
(LBP) that accommodates the lipophilic ligands (Benoit et al., 2004). The size, shape, 
and flexibility of the LBP, together with its composition of hydrophobic amino acid 
residues, detenuines the specificity and efficiency of ligand binding (Benoit et al., 2004; 
Nagy and Schwabe, 2004). For example, steroid and thyroid hormones bind to their 
respective nuclear receptors at low nanomolar concentrations, whereas PPARs and LXRs 
are activated by dietary fatty acids, cholesterol, and their metabolites at micromolar 
levels (Nagy and Schwabe, 2004; Benoit et al., 2004; Schulman and Heyman, 2004; 
Handschin and Meyer, 2005). In addition, the LBP of some nuclear receptors, e.g. PXR, 
is flexible and can expand when the nuclear receptor interacts with a large ligand (Benoit
et al., 2004). Some nuclear receptors, e.g. LHR-1 and ERRy, are in an active 
conformation even in the absence of exogenously added ligands (Benoit et al., 2004).
1.7 Peroxisome Proliferator-Activated Receptors
(PPARs)
Issemann and Green (1990) reported the discovery of a ligand-activated transcription 
factor that specifically interacted with drugs that were known to cause peroxisomal 
proliferation in the liver. Accordingly, this transcription factor was referred to as the 
Peroxisome Proliferator-Activated Receptor (PPAR) (Gilde and van Bilsen, 2003; Smith,
2002). Since the discovery of this PPAR, latter named PPARa, two other PPAR isoforms 
have been cloned (Lemberger et al., 1996). Although the PPARs were originally cloned 
as orphan receptors (Xu et al., 2001) this subfamily of nuclear receptors can be activated 
by both fatty acids and their metabolic derivatives, and thus serve as lipid sensors (Evans 
et al., 2004). Numerous studies performed during the last decade have revealed that 
PPARs are implicated in several physiological processes, such as the regulation of 
lipoprotein and lipid metabolism, inflammatory responses, glucose homeostasis and 
cellular differentiation (Khan and Vanden Heuvel, 2003; Smith, 2002; Blanquart et al., 
2003; Wahli, 2002; Manco et al., 2004).
1.7.1 Distribution of PPAR isoforms
To date, three isoforms of PPARs have been identified and these are PPARa, 
PPARp (also referred to as PPARS), and PPARy (Khan and Vanden Heuvel, 2003; 
Mandard et al., 2004). The tissue expression pattern of these PPAR isoforms (a, P, y) 
varies (Gilde and van Bilsen, 2003). PPARa is relatively abundant in tissues with a high 
capacity for fatty acid oxidation, such as liver, kidney, skeletal muscle, heart, brown 
adipose tissue and intestine (Escher and Wahli, 2000; Finck and Kelly, 2002; Kersten, 
2002; Ferre, 2004; Mandard et al., 2004). PPARp is expressed ubiquitously and plays 
key functions in the regulation of lipid metabolism and energy homeostasis (Khan and 
Vanden Heuvel, 2003; Ferre, 2004; Evans et al., 2004; Dressel et al., 2003; Grimaldi,
2005). PPARy on the other hand, displays a tissue-selective pattern of expression (Smith,
2002). Three different PPARy transcripts, termed PPARyl, PPARy2 and PPARy3, are 
derived from the PPARy gene (Willson et al., 2001; Francis et al., 2003). However, 
PPARyl and PPARy3 mRNA give rise to the same protein product having 28 amino acids 
less than PPARy2 in NH2-terminal (Willson et al., 2001; Francis et al., 2003; Ferre,
2004). PPARyl is broadly expressed, albeit at low levels (Willson et al., 2001), 
predominantly in adipocytes (Smith, 2002) whereas both PPARy2 and PPARy3 are highly 
expressed in adipose tissue (Willson et al., 2001; Smith, 2002). However, the functional 
significance of the multiple isoforms of PPARy is currently unclear (Willson et al., 2000).
1.7.2 Transcriptional activity of PPARs
All members of the nuclear receptor superfamily regulate transcription by binding to 
specific DNA sequences, known as hormone response elements, located in the 5'-flanking 
region of the target gene (Aranda and Pascual, 2001). In contrast to steroid nuclear 
receptors, which usually bind to these DNA response elements as homodimers (Khan and 
Vanden Heuvel, 2003), PPARs bind as a heterodimer with retinoid X receptor (RXR) 
(Fig. 1.9), the latter being activated by 9-cis retinoic acid (Escher and Wahli, 2000; 
Willson et al., 2001). The PPARiRXR heterodimer complex binds to a PPAR response 
element (PPRE), which consists of two direct repeat sequences of six nucleotides 
(consensus sequence: AGGTCA) separated by a single nucleotide spacer (Fig. 1.9) (Khan 
and Vanden Heuvel, 2003; Wahli, 2002; Willson et al., 2001 ; Frohnert et al., 1999).
PPARiRXR heterodimer-mediated transcription depends critically on the balance 
between co-activator and co-repressor complexes (Benko et al., 2003), which is 
controlled by availability of ligand (Fig. 1.9) (Escher and Wahli, 2000; Benko et al., 
2003). In the absence of ligand, the nuclear receptor heterodimer complex, when bound 
to the relevant hormone response element, is associated with co-repressor proteins (and 
histone deacetylase), which maintain the chromatin in a compact state, and therefore 
transcription is repressed (Renaud and Moras, 2000). However, ligand binding triggers 
confonnational changes in PPAR and RXR that are accompanied by dissociation of the 
co-repressor complex and recruitment of a co-activator complex with histone 
acetyltransferase (HAT) activity. This results in histone acétylation, local unwrapping of
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chromatin and activation of gene transcription (Fig. 1.9) (Jepsen and Rosenfeld, 2002; 
Escher and Wahli, 2000; Aranda and Pascual, 2001).
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Figure 1.9: Diagrammatic representation of the PFAR:RXR heterodimer bound to a 
PPAR-response element (PPRE). Ligand binding promotes the binding of a co-activator 
complex that initiates acétylation of histone proteins leading to the localised unwrapping of the 
chromatin and transcription by RNA polymerase. HAT: histone acetyl-transferase (Escher and 
Wahli, 2000; Renaud and Moras, 2000).
1.7.3 PPAR ligands
PPARs act as lipid sensors and bind ligands derived from dietary lipids or their 
metabolie products (Barish and Evans, 2004; Berger and Moller, 2002; Xu et al., 2001). 
PPARs can be activated by a wide variety of saturated and unsaturated fatty acids 
(Table 1.5). Long-chain fatty aeids, eicosanoids and inflammatory mediators such as 
leukotrienes and prostaglandins are natural activators of PPARs (Mandard et al., 2004; 
Willson et al., 2000; Willson et al., 2001). In addition to endogenous fatty acids and their 
metabolites, PPARs are also molecular targets of pharmaeeutieal compounds 
(Table 1.5) (Willson et al., 2000; Evans et al., 2004; Willson et al., 2001). For example, 
fibrates are PPARa agonists and widely used to treat hypertriglyceridemia (Willson et al., 
2000; Evans et al., 2004), while PPARy is the only receptor for the thiazollidinedione
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(TZD) class of antidiabetic drugs (Xu et al., 2001). Currently there is no specific 
pharmaceutical ligand for PPARp, although several are in clinical development (Willson 
et al., 2000; Marx et al., 2004). -
The ligand-binding domains of all PPAR isoforms bave sufficiently divergent amino 
acid sequences to allow some ligand specificity (Escher and Wahli, 2000; Xu et al., 
2001). Unlike other nuclear receptors, PPARs contain a large ligand-binding pocket 
allowing them to bind bulky ligands, such as phospholipids and synthetic fibrates, as well 
as the relatively simple fatty acids (Li et al., 2003). Besides the size and shape, the 
hydrophobic/hydrophilic balance of the ligand-binding pocket plays an important role in 
ligand-binding specificity (Li et al., 2003). The capacity of fatty acids, differing in chain 
length and/or degree of unsaturation, as ligands for the three PPAR isoforms has received 
widespread attention (Gilde and van Bilsen, 2003). Studies demonstrate that both 
long-chain saturated, mono- and polyunsaturated fatty acids bind to PPARa and PPARp 
with more or less comparable affinity (Gilde and van Bilsen, 2003). In contrast, PPARy 
has very low affinity for saturated fatty acids and is preferably activated by PUP As over 
monounsaturated fatty acids, although a prostaglandin J2 derivative, 15-deoxy-A^^’^ '^ -PGJ2 
has been widely postulated as the main natural ligand for PPARy receptor (Khan and 
Vanden Heuvel, 2003; Gilde and van Bilsen, 2003; Forman et al., 1995).
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Table 1.5: Natural and synthetic ligands for PPARs.
Ligand
PPA Rs
a P y
a-ilnoienic acid (18:3, ALA) + + +
n-3 PU FA ElcGsapentaenoic acid (20:5, ERA) + + +
Docosahexaenoic acid (22:6, DHA) + + +
Linoleic acid (18:2, LA) + + +
n-6 PU FA y-linolenic acid (18:3, GLA) + + +
Dihomo-y-linolenic acid (20:3, DGLA) + + +
Arachidonic acid (20:4, AA) + + +
n-9 PU FA
Palmitoleic acid (16:1) + + ±
Natural Oleic acid (18:1) + + ±
lig an d s Capric acid (10:0) - - -
S atu ra ted  FA Palmitic acid (16:0) + + -
Stearic acid (18:0) + + -
8-hydroxyeicosapentaneoic (8-HEPE) + - -
8S-hydroxylate epoxyeicosatrienoic (8S-HETE) + - -
E ico san o id s Leukotriene 84 (LTB4) + - -
9-hydroxyoctadenoic (9-HODE) - - +
1 3 -hydroxyoctadenoic (13-HODE) - - +
15-deoxy-A^^’^ ''-prostagIandin J2 (15D-A^ '^^ -^PGJ2) - - +
Clofibrate + - +
H ypolipidem ic Ciprofibrate + - +
d ru g s Bezafibrate + + +
Pirinixic acid (Wy-14643) + - -
S ynthetic
H ypoglycaem ic
d ru g s
Troglitazone (CS045); (TZD) - - +
ligands Rosiglitazone (TZD) - - +
L-796449; non-thiazollidinedione - - +
A nti-inflam m atory
d ru g s
Indomethacin - - +
Fenoprofen - - +
Ibuprofen - - +
+: binding affinity of ligand to PPAR
no affinity has been reported due to these ligands 
±: no consensus in the literature of the effects due to these ligands
Table was compiled from data in reviews (Khan and Vanden Heuvel, 2003; Gilde and van Bilsen, 2003; 
Escher and Wahli, 2000; Desvergne and Wahli, 1999; Willson et al., 2000; Kota et al., 2005; Corton et al., 
2000).
1.7.4 Synthetic ligands of PPARs
The fibrates encompass a class of clinically utilised hypolipidaemic agents that were 
first synthesized in the 1950s and came into clinical use in the 1960s (Thorp and Waring, 
1962). Clofibrate (ethyl y?-chlorophenoxy isobutyrate) was the first of this class of drugs, 
which was followed by the introduction of other fibrates, such as bezafibrate, gemfibrozil, 
ciprofibrate, and fenofibrate (Fig. 1.10) (Bhatnagar, 1998). Gemfibrozil and fenofibrate 
are currently approved for use in the United States, while bezafibrate and ciprofibrate are 
mainly prescribed in Europe (Fazio and Linton, 2004). Fibrates bind mainly to PPARa, 
which is primarily expressed in liver, heart, skeletal muscle, and kidneys and regulate 
expression of the genes involved in lipid metabolism (Bremer, 2001; Chapman, 2003; 
Fruchart et al., 2001; Escher and Wahli, 2000). Many studies have been conducted over 
the past two decades to test the effects of fibrates on the plasma lipid profile and mortality 
from CHD (Fazio and Linton, 2004; Elkeles et al., 1998; Vakkilainen et al., 2003; 
Asztalos and Schaefer, 2003; Biijmohun et al., 2005). The wide spectrum of 
lipid-modulating actions of fibrates is mediated by their capacity to mimic the structure 
and biological functions of fatty acids (Chapman, 2003; Fazio and Linton, 2004).
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Figure 1.10: Chemical structure of fibrates. Fibrates bind to PPARa and mimic the 
structure and biological functions of fatty acids (Chapman, 2003).
In contrast to fibrates that mainly target PPARa, members of the thiazollidinedione 
family (TZD) of antidiabetic compounds are specific PPARy ligands (Ferre, 2004; Zhang 
and Young, 2002). Ciglitazone, pioglitazone and rosiglitazone are presently used in the 
treatment of Type-2 Diabetes and lower hyperglycaemia, hyperinsulinaemia and 
hypertriglyceridemia (Berger and Moller, 2002; Willson et al., 2000; Evans et al., 2004; 
Kota et al., 2005). TZDs act by enhancing the sensitivity of tissues to insulin, especially 
in skeletal muscle and adipocytes, resulting in increased insulin-dependent glucose 
utilisation in these tissues and thereby decreasing plasma glucose levels (Willson et al., 
2001; Guan et al., 2002; Camejo, 2003).
1.7.5 Complementary roles of PPARs in lipid metabolism
PPARs activate genes that regulate several aspects of lipid metabolism involved with 
uptake, intracellular transport and oxidation of fatty acids, lipoprotein assembly and 
metabolism (Guan et al., 2002; Mandard et al., 2004). PPARa is a critical regulator of 
lipid oxidation, i.e. mitochondrial.and peroxisomal p-oxidation and co-oxidation in the 
endoplasmic reticulum, and lipid transport (Guan et al., 2002). Ligand-activation of 
PPARa increases fatty acid uptake and activation into fatty acyl-CoA by inducing 
FAT/CD36 and F ATP gene expression (Duval et al., 2004; Guan et al., 2002). PPARa 
activation also favours the up-regulation of FABPs that serves as a “cytoplasmic 
gateway” for transport of LCFAs to different metabolic pathways and the 
nucleus (Mandard et al., 2004; Guan et al., 2002; Tan et al., 2002).
In lipoprotein metabolic pathways (see Section 1.3.3 for more details), 
ligand-activation of PPARa, e.g. mediated by fibrates, increases the expression and 
activity of LPL, thereby increasing the clearance of the TAG-rich lipoproteins such as 
CM and VLDL (Duval et al., 2004; Fruchart, 2001; Camejo, 2003; Castrillo and 
Tontonoz, 2004; Chapman, 2003) and suppresses transcription of apo C-III, a potent 
inhibitor of LPL (Mandard et al., 2004; Guan et al., 2002; Fazio and Linton, 2004). 
PPARa activation enhances transcription of the major HDL apolipoproteins, apo A-I and 
apo A-II, thereby increasing HDL synthesis and reverse cholesterol transport (Guan et al., 
2002; Mandard et al., 2004; Fruchart, 2001; Fazio and Linton, 2004). Activation of 
PPARa induces transcription of PLTP, a protein modulating the conversion of pre-PHDL
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into mature HDL by transferring phospholipids from VLDL/LDL to HDL (Duval et aL, 
2004; Fazio and Linton, 2004). PPARa activation also up-regulates the expression of 
HDL-receptors, /.e. ABCAl and SR-Bl, in vascular cells and macrophages, thereby 
allowing the removal of intracellular free cholesterol leading to a reduction in 
atherogenesis (Fruchart, 2001; Mandard et al., 2004; Duval et al., 2004; Fruchart et al., 
1999), and induces cholesterol conversion to bile acids by increasing expression of 
LXR (Duval et al., 2004; Mandard et al., 2004). Moreover, ligand-activation of PPARa 
induces a reduction in the number of the atherogenic dense-LDL particles, and increases 
resistance of LDL to oxidation (Guo et al., 2001; Griffin and Fielding, 2001). These 
changes in lipoproteins are related to alterations in their apolipoprotein content, such as 
decreased apo B, apo C-III and apo E levels in TAG-rich lipoproteins and increased 
apo AI and apo All in HDL (Fruchart et al., 1999; Guo et al., 2001; Fruchart, 2001; Fazio 
and Linton, 2004).
PPARp is linked to cell renewal and differentiation (Escher and Wahli, 2000), and 
regulation of lipid metabolism and energy homeostasis (Evans et al., 2004; Dressel et al.,
2003). In skeletal muscle, PPARP up-regulates fatty acid oxidation and energy 
expenditure to a greater extent than PPARa (Evans et al., 2004; Dressel et al., 2003; 
Wang et al., 2003). PPARp also improves the blood lipid profile by increasing HDL-C 
and lowering LDL and TAG levels (Guan et aL, 2002). In addition, PPARp promotes 
reverse cholesterol transport by up-regulating the expression of the ATP-binding 
cassette A1 (ABCAl), thereby increasing the efflux of free cholesterol from peripheral 
cells (Guan et al., 2002; Chen et al., 2003).
PPARy is a “master switch” for the differentiation of adipocytes, resulting in the 
formation of “fat” cells and lipid storage (Evans et al., 2004; Francis et al., 2003). 
Activation of PPARy stimulates the storage of fatty acids in mature adipocytes by acting 
at several steps: (1) activation of LPL to release FA from lipoproteins, (2) activation of 
the cellular FA transporters, and (3) activation of intracellular FA estérification and TAG 
synthesis (Guan et al., 2002; Ferre, 2004; Willson et aL, 2001; Escher and Wahli, 2000). 
Activation of PPARy also lowers hyperglycemia and hyperinsulinemia by stimulating 
glucose uptake into adipocytes and muscle tissue (Ferre, 2004; Marx et al., 2004). In 
addition, PPARy activation further increases insulin sensitivity by down-regulating the 
secretion of adipocyte hormones, such as adiponectin, TNFa and resistin, that inhibit
35
insulin-stimulated glucose transport and utilisation (Guan et aL, 2002; Ferre, 2004). 
Thus, PPARy induces TAG synthesis and storage in adipocytes and influences glucose 
metabolism and insulin sensitivity in muscle and liver tissues (Fig. 1.11) (Willson et al., 
2001; Ferre, 2004). In summary PPARa, PPARp and PPARy co-operate to regulate 
blood lipid profile and glucose homeostasis. PPARa is abundant in the liver, whereas 
skeletal muscle tissue is the major source of PPARp. Ligand-activation of PPARa and 
PPARp increases fatty acid uptake and P-oxidation in liver, muscle, and heart, whereas 
PPARy ligands enhance lipid storage in adipocytes (Fig. 1.11).
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Figure 1.11: Complementary roles of PPAR isoforms in lipid metabolism. Three PPAR 
isoforms regulate lipid and glucose homeostasis in liver, adipose tissue and skeletal muscle. 
Whereas PPARa and PPARP increase fatty acid oxidation, PPARy enhances fat storage in 
adipocytes and tissue insulin sensitivity (Fvans et al., 2004).
1.7.6 PPARs and atherosclerosis
PPARa plays a critical role in the inhibition of atherogenesis at several stages (Chen 
et al., 2003; Neve et al., 2001). PPARa down-regulates the expression of VCAM-1, 
thereby decrease migration of monocytes into the arterial wall (Willson et aL, 2000). 
PPARa also suppresses transcription of inflammatory mediators, such as interleukins and 
tumour necrosis factor-a that are required for progression of the atherosclerotic 
plaque (Chen et aL, 2003; Blanquart et aL, 2003; Cabrero et aL, 2002). Furthermore, 
ligand-activation of PPARa modulates expression of nuclear factor kB (NFkB), a potent
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inflammatory mediator of the vascular wall cells, and inhibits progression of the 
atherosclerosis (Fruchart et aL, 1999).
PPARy reduces cytokine (TNFa, IL-ip, and IL-6) production, an anti-inflammatory 
effect of PPARy that could be beneficial in the inhibition of atherosclerotic 
progression (Tham et aL, 2003; Verges, 2004). In addition, PPARy reduces the 
expression of metalloproteinases that are implicated in plaque destabilization, leading to 
plaque rupture and myocardial infarction (Desvergne and Wahli, 1999; Ricote et aL, 
1999; Verges, 2004). PPARy also plays critical roles in the macrophages/foam 
cells (Blanquart et aL, 2003; Chen et aL, 2003; Plutzky, 2003). Monocytes express 
PPARy when exposed to oxidised-LDL. Subsequently, ligand activation of PPARy 
induces monocyte differentiation and promotes uptake of oxidised-LDL through the 
induction of scavenger receptors, such as FAT/CD36 (Tham et aL, 2003; Plutzky, 2003; 
Guan et aL, 2002; Desvergne and Wahli, 1999; Zhang and Chawla, 2004). In foam cells 
ox-LDL activates PPARy and LXR (Barish and Evans, 2004), leading to an increase in 
the expression of FAT/CD36 and further uptake of ox-LDL itself (Marx et aL, 2004; 
Barish and Evans, 2004; Tham et aL, 2003; Zhang and Chawla, 2004). PPARy and LXR 
activation also enhances transcription of ABCA-1 protein and therefore promotes efflux 
of intracellular cholesterol (Barish and Evans, 2004; Castrillo and Tontonoz, 2004; Puddu 
et aL, 2003; Tham et aL, 2003). Thus, the net function of PPARy-LXR co-operation in 
macrophages is to reduce LDL-C by taking-up LDL/ox-LDL, and promoting cholesterol 
removal by enhancing reverse cholesterol transport, leading to cholesterol disposal in the 
liver (Barish and Evans, 2004).
In contrast to the inhibitory effects of PPARa and PPARy on the progression of 
atherosclerosis (Fruchart et aL, 1999; Tham et aL, 2003; Verges, 2004), PPARp plays a 
role in the pathology of diseases associated with vascular smooth muscle cells (VSMC) 
proliferation and atherosclerosis (Zhang et aL, 2002). PPARP is upregulated in VSMC 
during vascular lesion formation and modulates VSMC proliferation (Puddu et aL, 2003). 
In addition, deletion of PPARp from foam cells increases the availability of inflammatory 
suppressors and reduces atherosclerotic lesion formation. Therefore, PPARp controls the 
inflammatory status of the macrophage, promotes macrophage lipid accumulation and 
likely contributes to the development of atherosclerosis (Lee et aL, 2003a; Puddu et aL,
2003).
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1.8 Hypothesis, aims and objectives
The research project described in this thesis originates from a desire to understand 
the effects of different LCFAs and fibrates on gene expression levels in cardiomyocytes. 
Studies on the physiological role of fatty acids have revealed that they influence lipid 
metabolism by functioning as regulators of gene expression (Jump, 2004; Pegorier et al., 
2004; Clarke, 2000). The regulatory function of LCFAs on gene expression is achieved 
by controlling the abundance and activity of transcription factors (Sampath and Ntambi, 
2004; Khan and Vanden Heuvel, 2003; Clarke, 2001; Jump, 2002a; Guan et al., 2002; 
Mandard et al., 2004; Jump, 2002a). Previous studies have shown that LCFA 
characteristics, such as chain length and degree of unsaturation, differentially affect gene 
expression levels in cardiomyocytes (Biagi et al., 1999; Bordoni et al., 1996; Dyerberg et 
al., 2004; Williams et al., 2004; Cameron-Smith et al., 2003; Belury, 2002; van der Lee et 
al., 2000a; Hickson-Bick et al., 2000; Clavel et al., 2002). In this study, the P19CL6 
cell-line was used as a cardiovascular model system (Habara-Ohkubo, 1996) and it was 
hypothesised that LCFAs differentially affect gene expression levels in this cell-line. 
Thus, the research focused on both the characterisation of the cell-line and investigating 
the effects of different LCFAs (palmitic, oleic, linoleic, and a-linolenic acids) and 
clofibrate on gene expression levels and the aims and objectives of this study were as 
follows:
Aim-1: Characterisation of the P19CL6 cell line at the transcriptional level.
Objectives:
• Comparison of the expression profiles of selected cardiac- (a-MHC and P-MHC) 
and skeletal muscle-specific genes (MyoD and Myogenin) in P19CL6 cells with 
those of the H9C2(2-1) skeletal muscle cell-line, as well as mouse heart and 
skeletal muscle tissue.
Evaluation of optimal culture conditions where the P19CL6 cells display a 
cardiomyocyte phenotype.
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Investigation of the effect of different media and micronutrients on “beating” 
phenotype of the PI 9CL6 cell-line.
Microscopic analysis to define the cellular morphology and phenotype of 
P19CL6 cells.
Comparison of global transcriptome levels in P19CL6 and H9C2(2-1) cells, as 
well as mouse cardiac, skeletal muscle, and embryonic heart tissue, by microarray 
analysis to characterise the P19CL6 cells.
Aim-2: To determine the effects of LCFAs and clofibrate on gene expression levels in 
P19CL6 cells.
Objectives:
• Ascertain the expression, at the mRNA level, of H-FABP, PPARa, PPARp, and 
PPARy in P19CL6 cells cultured in response to LCFAs and clofibrate.
• Compare global transcriptome levels in P19CL6 cells cultured with different 
LCFAs and clofibrate, using cDNA microarrays.
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Chapter 2
Materials and Methods
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Chapter 2:
Materials and Methods
2.1 Materials
Dulbecco’s Modified Eagle Medium (DMEM), DMEM-F12, RPMI-1640, 
a-Minimum Essential Medium (a-MEM), foetal bovine serum (FBS), bovine serum 
albumin (BSA), Trizol reagent, phosphate-buffered saline tablets (PBS), ultra-pure 
20x SSC buffer (sodium chloride-sodium citrate), ultra-pure 10% SDS (sodium dodecyl 
sulphate), Oligo dT(i2-i8) primer. Mouse COT-1 DNA, poly A, Denhardt’s solution, and 
Superscript II Reverse Transcriptase kit were purchased from Invitrogen Corporation 
(Paisley, UK). Sigma-Aldrich Company Ltd. (Poole, UK) supplied lOOx 
penicillin-streptomycin (10,000 Units/ml and 10 mg/ml, respectively), bacteriological 
agar, long-chain fatty acids including palmitic (16:0 saturated FA), oleic (18:ln-9 
monounsaturated FA), linoleic (18:2n-6 PUFA), and a-linolenic (18:3n-3 PUFA) acids, 
clofibrate, fatty acid-ffee bovine serum albumin (BSA), sodium acetate 
(DNfl5e/RNfl5e-free), sodium pyrophosphate, phorbol myristate acetate (PMA), 
chloroform, isopropyl alcohol, and dimethyl sulphoxide (DMSO). SV Total-RNA 
Isolation, SV Gel and PCR Clean-Up, and nested PCR kits, nucleotide mixtures, Taq 
DNA polymerase enzyme, 100 bp DNA ladder, Blue-Orange Loading dye, formamide 
and agarose for gel electrophoresis were purchased from Promega Corporation 
(Southampton, UK) and MWG (Milton Keynes, UK) supplied oligonucleotide primers. 
Ready-To-Go RT-PCR beads, AutoSeq G-50 columns. Microarray CodeLink Activated 
Slides (Amine-Binding Slides), HybriSlip microarray coverslips (24x60 mm), Cy3-dCTP 
and Cy5-dCTP fluorescent dyes were obtained from Amersham Biosciences (Chalfont St. 
Giles, UK) and Coming Life Sciences (Coming B.V. Life Sciences, Schiphol-Rijk, 
Netherlands) supplied ProntoPlus microarray kit. Ambion Ltd. (Huntingdon, UK) 
supplied ultra-pure DEPC-treated nuclease-ffee water, mouse heart and embryonic 
total-RNA, and RNA stabilization solution (RNA/a/er), whereas mouse embryonic heart 
and skeletal muscle total-RNA were purchased from Zyagen (Zyagen, San Diego, USA) 
and Panomics (Panomics Inc., Redwood City, USA), respectively. RNga^y MinElute
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Cleanup kit, RN^^e-free DNase, and MinElute PCR purification kit were obtained from 
Qiagen Ltd. (Crawley, UK). Mixed-bed AG 501-X8 (D) molecular biology grade resin 
was purchased from Bio-Rad (Hemel Hempstead, UK), and Fisher Scientific supplied 
chloroform-resistant Oak Ridge centrifuge tubes (Loughborough, UK). Tissue culture 
flasks, petri dishes and 6-well plates were provided by Nunclon Products (Nunclon, 
Roskilde, Denmark) and 150 cm  ^peel-off flasks were obtained from Helena BioSciences 
Europe Ltd. (Sunderland, UK). Specific batches of foetal bovine serum (FBS) were 
purchased from Bio west Ltd. (Ringmer, UK).
2.2 Methods
2.2.1 Cell culture
The P19CL6 cell-line is a sub-clone of the P19 cell-line (Habara-Ohkubo, 1996), the 
former having been specifically selected on their ability to differentiate into 
cardiomyocytes when cultured in the presence of DMSO (Habara-Ohkubo, 1996; Hosoda 
et al., 2001; Skeijanc, 1999). The literature on the culture and differentiation of PI 9 cells 
into cardiomyocytes describes the utilisation of two processes, namely culturing cells 
under standard conditions where cells are adhered to cell culture plastic (Habara-Ohkubo, 
1996), or non-adherent conditions where cells grow on agar plates to produce cell 
aggregates prior to re-plating under adherent conditions (van der Heyden et al., 2003; 
Morley and Whitfield, 1993; van der Heyden and Defize, 2003; Skeijanc, 1999; 
McBumey, 1993; Smith et al., 1987). In this study both culture conditions and their 
effects on gene expression levels were investigated, as detailed below.
2.2.1.1 Culture of P19CL6 cell under adherent conditions
P19CL6 cells were purchased from Riken Cell Bank (Ibaraki, Japan) (Habara- 
Ohkubo, 1996) in growing flasks and cultured in normal culture media (NCM) containing 
a-MEM supplemented with 10% FBS and 1% penicillin-streptomycin. To split the cells, 
media was aspirated and washed with 5 ml of autoclaved phosphate-buffered saline (PBS; 
10 mM phosphate buffer, 2.7 mM potassium chloride, 137 mM sodium chloride, pH 7.4).
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Cells were then incubated with 2 ml of a 0.25% trypsin-EDTA solution at 37°C until cells 
detached from the flask (5 minutes). Trypsin was neutralised by adding fresh media 
(1:20; trypsin:media) and the cell suspension divided into two 175 cm  ^flasks.
Differentiation of P19CL6 cells into cardiomyocytes was induced with a 
DMSO-containing differentiation media (Habara-Ohkubo, 1996). Cells were plated in 
37 mm diameter wells (6-well culture plates) at a density of 2x10^ cells per well in 5 ml 
of differentiation media (DM; a-MEM/10% FBS/1% penicillin-streptomycin and 
1% DMSO). Cells were maintained in DM for 15 days and the media refreshed every 
second day. Finally, cells were harvested by scraping into 1 ml PBS at the end of the 
incubation period and stored at -80°C until RNA extraction.
To prepare frozen stocks, cells were first treated with trypsin, as described above, 
and then centrifuged for 5 minutes at lOOOxg (2,000 rpm; Sigma-6K10 centrifuge; 
Sigma Ltd., Germany). After aspirating the supernatant, the cell pellet was re-suspended 
in freezing media containing 91% FBS and 9% DMSO at a density of 2x10^ cells/ml. 
Cells were stored under liquid nitrogen (-200°C).
2.2.1.2 Culture of P19CL6 cells under non-adherent conditions
P19CL6 cells were plated in 100 mm diameter bacterial petri dishes (1x10^ cells per 
dish) covered with a thin layer of 0.5% agar (0.5 g agar dissolved in 100 ml nuclease-free 
water and autoclaved) using DMEM-F12 media for 4 days, with or without 1% DMSO, 
as indicated, to form cell aggregates (Skeijanc^ 1999). Cell aggregates were collected by 
centrifugation at lOOOxg (2,000 rpm) for 5 minutes and re-suspending in 15 ml fresh 
media before re-plating into 75 cm  ^culture flasks for 15 days, either in the presence or 
absence of 1% DMSO. Cells were observed daily by phase-contrast microscopy and 
collected at the end of the incubation period by scraping into 1 ml PBS and stored at 
-80°C.
2.2.1.3 Culture of H9C2(2-1) cells under adherent conditions
The H9C2(2-1) cell line was obtained from the European Collection of Cell Cultures 
(ECACC; Salisbury, UK) (Kimes and Brandt, 1976) in a frozen ampoule. The ampoule 
was thawed on ice and the cells transferred to a 25 cm  ^ tissue culture flask containing 
5 ml of a-MEM media/10% FBS/1% penicillin-streptomycin. The culture media was 
refreshed after 8 hours once the cells had adhered to the flask (Kimes and Brandt, 1976). 
To plate new passages the cells were divided into new flasks, as described above for 
P19CL6 cells. Frozen stocks were prepared by re-suspending the cells in freezing media 
(91% FBS and 9% DMSO) at a density of 2-4x10^ cells/ml, as described for P19CL6 
cells, and stored under liquid nitrogen (-200°C).
For experimental purposes the cells were plated in 37 mm diameter wells (6-well 
culture plates) at a density of 2x10^ cells/well in 5 ml of differentiation media (DM; 
a-MEM/10% FBS/1% penicillin-streptomycin and 1 % DMSO) (Kimes and Brandt, 
1976). Cells were maintained in DM and the media refreshed every second day. Finally, 
cells were harvested by scraping into 1 ml PBS at the end of incubation period and stored 
at -80°C until RNA extraction.
2.2.1.4 Culture of THP-1 ceils under adherent conditions
THP-1 cells purchased from American Type Culture Collection (ATCC; 
(LGC Promochem, Teddington, UK) (Tsuchiya et al., 1980; Whatling et al., 2004) have 
suspension growth properties and are able to differentiate into adherent macrophages 
upon exposure to phorbol myristate acetate (PMA). Cells were plated in 25 cm  ^ tissue 
culture flasks in the presence of 5 ml RPMI-1640 media containing 10% FBS and 
1% penicillin-streptomycin. To change the cell culture media the cells were collected by 
centrifugation for 5 min at lOOOxg (2,000 rpm; Sigma-6K10 centrifuge) and re-suspended 
in fresh media. Cells were split into new passages by dividing re-suspended cells at a 
ratio of 1:4 (cell suspension: fresh media).
To differentiate THP-1 cells into macrophages, the cells were centrifuged and the 
cell pellet re-suspended in RPMI-1640 media containing 10% FBS, 
1% penicillin-streptomycin, and 100 nM PMA (100 pM stock solution in DMSO). Cells
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were then cultured with PMA in 6-well plates at a density of 5x10 cells per well for 24, 
48 and 72 hours, as indicated.
To prepare frozen stocks, cells were centrifuged at lOOOxg for 5 min. and the cell 
pellet re-suspended in freezing media (91% FBS and 9% DMSO) to achieve a density of 
2x10^ cells/ml, and stored under liquid nitrogen (-200°C).
2.2.1.5 Determination of P19CL6 cells pulse rate cultured with 
different serum samples
Foetal bovine serum (FBS) samples from four different batches were obtained from 
Biowest Ltd. (Ringmer, UK). P19CL6 cells from different passage numbers were 
incubated with differentiation media (DM; a-MEM/10% FBS/1% DMSO and 
1% penicillin-streptomycin) containing these specific FBS samples for 15 days with 
media refreshed every second day. Cells were observed daily by phase-contrast 
microscopy and changes in cell shape, morphology, and contractile activity (pulses/min) 
recorded. Finally, cells were collected at the end of day 15 by scraping into 1 ml PBS and 
stored at-80°C.
2.2.1.6 Culturing P19CL6 cells with different concentration of 
adrenaline
P19CL6 cells were cultured in differentiation media (6-well plates; 2x10^ cells/well) 
containing 0, 5, 10, 15, and 20 pM adrenaline for 15 days and the media refreshed every 
second day. The cell were examined daily by phase-contrast microscopy to assess the 
“beating” of cardiomyocytes and changes in contractile activity (pulses/min). Cells were 
collected at the end of the incubation period by scraping into 1 ml PBS and stored at 
-80°C.
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2.2.1 7 Determination of P19CL6 cell morphology by microscopic 
analysis under non-adherent culture conditions
Aggregated cells were plated in 6-well plates containing autoclaved coverslips 
coated with polylysine (autoclaved coverslips were immersed in an aqueous solution of 
0.01% polylysine for 30 min. at 37°C; then washed 3x with PBS before use). Coverslips 
were collected on different time points by removing the media and washing with PBS. 
Cells were fixed by immersing in 3% para-formaldehyde (pH 7.2) for 2 hours and 
mounted in 50% glycerol/0.1% azide/PBS on microscope slides (Rudnicki et al., 1990; 
Wilcox, 1993) and were subsequently photographed under 40x magnification using a 
Leica DMIL microscope (Leica GmbH, Wetzlar, Germany) with an attached Colour 
Video Sony 3CCD digital Camera (Sony Corporation, Tokyo, Japan).
2.2.1.8 Determination of P19CL6 cell morphology using nuclei 
staining under adherent culture conditions
Cells were cultured on coverslips under adherent culture conditions. Coverslips were 
collected at different time points and cells were fixed by immersing in 
para-formaldehyde, as described above (Rudnicki et al., 1990; Wilcox, 1993). The 
fixative was removed by washing 3x with PBS. Coverslips were then immersed in 
Hoechst dye (2 pg/ml in PBS) for 5 minutes at room temperature (protected from light) to 
stain nuclei. Finally, coverslips were washed once with PBS and mounted on microscope 
slides in mounting media (50% glycerol/0.1% azide/PBS). Microscopic examination was 
performed at 400x magnification using a Zeiss Axiovert 135 TV fluorescence microscope 
(Carl Zeiss AG, Oberkochen, Germany) setting the excitation and emission filter at 365 
and 420 nm, respectively. Slides were then photographed using a Contax SLR-NX 
camera (Kyocera Yashica Ltd., Reading, UK) and images digitised using a Nikon LS4000 
slide scanner (Nikon UK Ltd., Kingston upon Thames, UK).
46
2.2.1.9 Incubation of P19CL6 cells with different long-chain 
fatty acids
P19CL6 cells were cultured in 150 cm  ^peel-off flasks at a density of 2x10^ cells per 
flask using 30 ml of DMSO-containing media for 14 days to differentiate into 
cardiomyocytes, as indicated. At the end of day-14, media was removed and cells 
washed twice with 15 ml PBS and incubated in 25 ml serum-free media 
(98% a-MEM/1% DMSO/1% penicillin-streptomycin) for 24 hours (day 15). Cells were 
then treated with media either containing bovine serum albumin (BSA), as carrier 
(98% a-MEM/1% penicillin-streptomycin 71% DMSO/0.15 mM BSA), BSA-fatty acid 
(98% a-MEM/1% penicillin-streptomycin /1% DMSO/0.15 mM BSA with 0.4 mM fatty 
acid), or BSA-clofibrate complex (98% a-MEM/1% penicillin-streptomycin 
/1% DMSO/0.15 mM BSA with 0.4 mM clofibrate) for 24 hours (Habara-Ohkubo, 1996; 
Bolon et al., 1997). Finally, media was aspirated off and cells washed with 15 ml PBS. 
Cell lysate was obtained by adding 15 ml of Trizol reagent (1 ml per 10 cm  ^culture area) 
and by passing the cells through a pipette to breakdown genomic DNA, according to the 
manufacturer’s instructions (Life Technologies Ltd., Paisley, UK). The cell lysates were 
collected in nuclease-free centrifuge tubes and stored at -80°C until RNA extraction.
Preparation of BSA/FA and BSA/Fibrate complexes:
Serum-free media was prepared by the addition of DMSO (5 ml) and 
penicillin-streptomycin (5 ml) into 500 ml a-MEM to a final concentration of 
98% a-MEM/1% DMSO/1% penicillin-streptomycin. An appropriate amount of bovine 
serum albumin was dissolved in serum-free media in a beaker to obtain a concentration of 
0.15 mM BSA. It was stirred gently for 2 hours, filter-sterilized and stored at 4°C. In the 
next step, an appropriate amount of fatty acid or clofibrate powder was dissolved in 
100 mM NaOH to prepare a 100 mM stock solution by stirring at 37°C for 
30 minutes (Bolon et al., 1997). Finally, fatty acid (or clofibrate) stock solutions 
(100 mM) were diluted at the ratio of 1:250 with serum-free media containing 0.15 mM 
BSA to achieve a final concentration of 0.4 mM FA (or clofibrate). Media was then 
filter-sterilized and stored at 4°C.
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2.2.2 Total-RNA isolation and purification
Two different RNA isolation methods were used to extract total-RNA from P19CL6, 
H9C2(2-1) and THP-1 cultured cells, mouse heart and skeletal muscle tissues. In the first 
method, the RNA was extracted and purified using a SV Total RNA Isolation kit (mainly 
used in PCR experiments) as illustrated in Fig. 2.1, whereas in the second method, the 
required RNA for microarray experiments was isolated by Trizol reagent and further 
purified, as recommended by the Human Genome Mapping Project (HGMP) protocol.
C u l tu re d  c e l l s  
a n d
T i s s u e  s a m p l e s
Trizol method Total RNAisolation ■ -
SV Total RNA 
Isolation kit
DNase-1 digestion and 
column purification
PCR
experiments
Microarray
experiments
Figure 2.1: Overview of total-RNA isolation methods. Two different RNA isolation methods 
(SV Total RNA Isolation and Trizol) were used for extraction of total-RNA from cultured cells 
or tissue samples. The RNA obtained using the SV Total RNA Isolation kit was used directly in 
PCR experiments, while the RNA obtained using the Trizol method was further purified before 
being labelled with Cy-dye and used in microarray experiments.
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2.2.2.1 Isolation of total-RNA from cell culture samples 
(/) SV Total RNA Isolation method
Frozen cells were thawed on ice and cell lysate prepared by adding lysis buffer 
[4M guanidine isothiocyanate, 0.01 M Tris (pH 7.5), and 0.97% p-Mercaptoethanol] 
according to the manufacturer’s instructions (Promega Corporation, Southampton, UK). 
The lysate mixture was passed through a 20-gauge needle to shear genomic DNA. The 
RNA was precipitated by adding 95% ethanol. Subsequently, the RNA pellet was 
washed by addition of RNA wash solution [60 mM potassium acetate, 10 mM Tris-HCl 
(pH 7.5), and 60% ethanol] and by utilising purification columns provided in the 
SV Total RNA Isolation kit. To erase DNA contaminant, DNA fragments were digested 
upon exposure to DNfl.ye-1 enzyme for 15 minutes at room temperature and the RNA was 
purified by centrifugation for 2 min at 14,000xg (12,300 rpm, Eppendorf microcentrifuge, 
Hamburg, Germany). Total-RNA was then cleaned-up by adding RNA wash solution and 
centrifugation for 2 minutes at 14,000xg (12,300 rpm). Finally, the RNA template was 
eluted into 100 pi nuclease-free water and stored at -80°C.
(//) Trizol method
In the Trizol method, cell lysates were obtained by the direct addition of Trizol 
reagent to the cells (1 ml per 10 cm  ^of cell culture area) and passing the cells trough a 
pipette to breakdown genomic DNA. Then, 0.2 ml of chloroform per 1 ml of Trizol 
reagent was added and samples were incubated for 3 minutes at room temperature. To 
separate the aqueous phase containing total-RNA from phenol-chloroform phase, samples 
were centrifuged at 12,000xg for 15 minutes at 4°C (11,000 rpm using a J2-21 Beckman 
centrifuge and JA-17 Fixed-Angle rotor, USA) using chloroform-resistant nuclease-free 
centrifuge tubes.
The aqueous phase was transferred into an autoclaved chloroform-resistant 
centrifuge tube and 0.5 ml of isopropyl alcohol was added per 1 ml of Trizol. Samples 
were incubated for 10 minutes at room temperature and RNA precipitated by 
centrifugation at 12,000xg for 10 minutes at 4°C (11,000 rpm). The supernatant was 
removed and the RNA pellet washed with >1:1 ratio of 75% ethanokTrizol reagent (v/v).
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Samples were re-centrifliged at 7,500xg (7,000 rpm) for 5 minutes at 4°C and the RNA 
pellet air-dried and dissolved in nuclease-free water and stored at -80°C.
2,22,2 Isolation of total-RNA from mouse tissue samples 
(f) SV Total RNA Isolation method
Whole heart and skeletal muscle tissues (upper leg muscle) were dissected from 
10 week old male GDI wild-type mice (+/+) (a kind gift from Miss Lisa Godfrey, School 
of Biomedical and Molecular Sciences, University of Surrey) and placed in sterile 
microcentrifuge tubes (4°C). Tissue samples were homogenised using an Ultra-Turrax 
T8 homogeniser (IKA Labortechnik, Staufen, Germany) until no visible tissue fragments 
remained, and the cell lysate was prepared by the addition of lysis buffer at the ratio of 
1 ml of lysis buffer per 171 mg tissue mass, according to the manufacturer’s instructions 
(Promega Corporation, Southampton, UK). The RNA was precipitated, purified and 
eluted into nuclease-free water, as indicated previously for cell culture samples.
(ii) Trizol method
In the Trizol method, whole heart and skeletal muscle tissues (upper leg muscle) 
were immersed in sterile tubes containing 2.5 ml of KNAlater, an RNA stabilization 
solution, as indicated in the manufacturer’s instruction (Life Technologies Ltd., Paisley, 
UK). Samples were incubated overnight in KNAlater at 4°C and the reagent was 
removed before storage at -80°C.
To prepare tissue lysate, tissue samples were homogenised in Trizol reagent (1 ml 
per 50-100 mg tissue mass) using an Ultra-Turrax T8 homogeniser until no visible tissue 
fragments remained. Then 0.2 ml of chloroform per 1 ml of Trizol reagent was added and 
samples incubated for 3 minutes at room temperature. Total-RNA was isolated as 
described for cell culture samples. RNA pellet was precipitated at 12,000xg (11,400 rpm) 
for 10 minutes at 4°C using an Eppendorf microcentrifuge. The RNA pellet was washed 
with >1:1 ratio of 75% ethanokTrizol reagent (v/v), dissolved in nuclease-free water, and 
stored at -80°C.
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2.2,23 DNase digestion of total-RNA samples
For microarray experiments the total-RNA samples were treated with DNa^e-I 
enzyme to remove potential genomic DNA contamination. Samples (< 87.5 pi total-RNA 
solution) were incubated with 2.5 units of RNfl^e-free DNa^e-I enzyme for 10 minutes at 
room temperature. Nucleotides and small oligonucleotides were removed by RNA 
purification process using RNeasy MinElute Spin columns, as described below.
2.2.2.4 Purification of total-RNA from nucleotides
To remove nucleotides and small oligonucleotides generated during DNa^e 
digestion, the RNA samples were treated with 350 pi of RLT buffer provided with the 
RNefl^y MinElute kit, and 250 pi of 96% ethanol. The RNA sample was then applied to 
an RNea^y MinElute Spin Column and centrifuged for 15 seconds at 14,000xg  ^
(12,300 rpm) using an Eppendorf microcentrifuge. The RNA, bound to the membrane, 
was washed with 500 pi of RPE buffer provided with the RNea^y MinElute kit, and 
centrifuged (14,000xg, 15 seconds). The washing was repeated by addition of 500 pi of 
80% ethanol to the membrane and centrifugation for 2 min at 14,000xg (12,300 rpm) to 
dry the membrane. The RNA was eluted with 14 pi RNa^e-fi-ee water and collected by 
centrifugation for 1 min at 14,000xg (12,300 rpm) and stored (-80°C).
2.2.2.S Determining the concentration and purity of the RNA
A NanoDrop ND-1000 spectrophotometer (NanoDrop Technologies, Montchanin, 
USA) was used to determine total-RNA concentration by measuring the absorbance of 
sample at 220-350 nm. The spectrophotometer was zeroed using DEPC-treated 
nuclease-ffee water and the RNA sample (1 pi) was scanned at 220 nm to 350 nm, as 
shown in Figure 2.2. The concentration of RNA was determined based on the 
Beer-Lambert equation (c=A.s.b” )^ where b is path length in cm and s is the manipulated 
wavelength-dependent extinction coefficient in ng.cm.pU^ to give the concentration (c) in 
ng/pl. The generally accepted extinction coefficients for nucleic acids are 40 for RNA 
and 50 for double-strand DNA samples. The ratio of absorbance at 260 and 280 nm
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(A260/A280) was used to assess purity of RNA samples with a ratio of 1.8-2.0 generally 
being accepted as pure RNA (Yu et al., 2002; Brown, 2001). The purity of RNA samples 
was further confirmed by the ratio of absorbance at 260 and 230 nm (A260/A230) with a 
ratio of 1.8-2.2 being accepted as high quality, pure RNA (Fig. 2.2).
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Figure 2.2: Example of the output from NanoDrop ND-1000 spectrophotometer for 
determining total RNA concentration. The absorbance of RNA (1 pi) was measured between 
220 nm and 350 nm. The absorbance at 260 nm was converted to a concentration (ng/pl) using 
an Fxtinction Coefficient (F) of 40 for RNA samples. The A260/A280 ratio gives an indication 
of RNA purity, with a ratio of 1.8-2.0 generally accepted as pure RNA (Yu et al., 2002).
2.2.3 Gel electrophoresis
2.2.3.1 Formaldehyde-agarose RNA gel electrophoresis
Formaldehyde-agarose RNA gel electrophoresis was used to eheek total-RNA purity. 
The 1% agarose gel was prepared by melting an appropriate amount of agarose in sterile 
water, and cooling to 60°C. Then, gel running buffer (100 mM MOPS, 40 mM sodium 
acetate, and 5 mM EDTA, pH 8.0) and 37% formaldehyde were added to a final 
coneentration of 20 mM MOPS, 8 mM sodium acetate, 1 mM EDTA, and 
6.6% formaldehyde. The gel was cast under a fume hood and allowed to set for at least 
30 minutes at room temperature.
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Samples were prepared by mixing 4.5 pi total-RNA sample (up to 30 pg RNA) with 
15.5 pi gel-denaturing buffer (12.8 mM MOPS, 5.1 mM sodium acetate, 0.64 mM EDTA, 
8.3% formaldehyde, 64% formamide and ethidium bromide) in a sterile microcentrifuge 
tube and incubated at 65®C for 15 minutes, chilled on ice, and were then centrifuged for 
5 seconds. Finally, 2 pi of gel-loading buffer (50% aqueous glycerol containing 0.5 mM 
EDTA and 0.25% bromophenol blue/xylene cyanol FF, pH 8.0) was added to the samples 
before loading onto the gel.
A pre-run electrophoresis step was applied for 5 minutes at 5 V/cm (measured as the 
distance between the electrodes) before the samples were loaded. The gel was submerged 
in gel running buffer (20 mM MOPS, 8 mM sodium acetate, and 1 mM EDTA, pH 8.0) 
and electrophoresed at 3-4 V/cm. Buffer from each reservoir was collected (after 
2 hours), mixed and returned to the gel apparatus to prevent polarization of the buffer. 
Electrophoresis was stopped when the bromophenol blue had migrated three quarters of 
the length of the gel and the gel was photographed using an ImageMaster YDS UV-light 
camera (Amersham Pharmacia Biotech, San Francisco, USA) with LISCAP-Vl Capture 
Application Software (Amersham Pharmacia Biotech, San Francisco, USA).
2,23,2 DNA agarose gel electrophoresis
Agarose gels (2%) containing ethidium bromide (lxlO”^ %w/v) were used to 
identify PGR products. The gels were prepared by dissolving and heating 2 g of 
analytical grade agarose per 100 ml TBE buffer (90 mM Tris, 90 mM Boric acid, and 
4 mM EDTA, pH 8.0). Samples were prepared by adding 2 pi of Blue-Orange Loading 
dye [0.03% bromophenol blue, 0.03% xylene cyanol FF, 0.4% orange G, 10 mM 
Tris-HCl (pH 7.5), and 50 mM EDTA] to 10 pi of PGR product and loaded onto the gel. 
A 100 bp DNA ladder was loaded on the outer lanes of the gel (5 pi DNA plus 1 pi 
loading dye). The PGR products were separated by electrophoresis at 100 V and the gels 
photographed using an ImageMaster YDS UY-light camera with LISGAP-Yl Capture 
Application Software.
b3
2.2.4 Determination of mRNA levels
To determine gene expression levels, total-RNA was isolated either from cultured 
cells or mouse tissues and the levels of specific mRNAs determined by reverse 
transcriptase polymerase chain reaction (RT-PCR) using relevant gene-specific forward 
and reverse primers. In some experiments, RT-PCR products were re-amplified by 
nested PCR to achieve higher cDNA levels, as indicated (Newton and Graham, 1997; 
McPherson et al., 1995). PCR products were separated by electrophoresis on 2% agarose 
gels containing ethidium bromide (lxlO“^% w/v). Electrophoresis was performed at 
100 V and gels photographed with an ImageMaster YDS UY-light camera and 
LISCAP-Yl Capture Application Software.
2.2.4.1 Designing RT-PCR and nested PCR primers
Primers for both RT-PCR and nested PCR techniques were designed using the 
web-based primer designing software, Primer-3 (http://frodo.wi.mit.edu/cgi-
bin/primer3/primer3_www.cgi), and gene cDNA sequences (NCBI GenBank; 
http://www.ncbi.nlm.nih.gov/). The parameters were set at a product length of 300-900 
base pairs (bp) for RT-PCR and 200-600 bp for nested PCR, a primer length of 20-25 bp, 
and %GC content at 45-60%. The theoretical product sizes were based on the cDNA 
length between the forward and reverse primers, as shown on Fig. 2.3 for MyoD gene. 
The oligonucleotide primers were obtained as lyophilised samples (MWG, Milton 
Keynes, UK) and re-suspended in nuclease-free water, aeeording to the manufacturer’s 
data sheet, to a concentration of 100 pmol/pl and stored at -20°C. Primers used in this 
study are shown in Table 2.1 (RT-PCR primers) and Table 2.2 (nested PCR primers).
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GCT6ATCGCCGCAAGGCCGCCACCATGCGCGAGCGCCGCCGCCTGAGCAAAGTGAATGAG 540
AGTGAATGAG 
Forward primer
GCCTTCGAGACGCTCAAGCGCTGCACGTCCAGCAACCCGAACCAGCGGCTACCCAAGGTG 600
GCCTTCGAGAC
GAGATCCTGCGCAACGCCATCCGCTACATCGAAGGTCTGCAGGCTCTGCTGCGCGACCAG 660
GACGCCGCGCCCCCTGGCGCCGCTGCCTTCTACGCACCTGGACCGCTGCCCCCAGGCCGT 720
GGCAGCGAGCACTACAGTGGCGACTCAGACGCGTCCAGCCCGCGCTCCAACTGCTCTGAT 780
GGCATGATGGATTACAGCGGCCCCCCAAGCGGCCCCCGGCGGCAGAATGGCTACGACACC 840
GCCTACTACAGTGAGGCGGTGCGCGAGTCCAGGCCAGGGAAGAGTGCGGCTGTGTCGAGC 900
CTCGACTGCCTGTCCAGCATAGTGGAGCGCATCTCCACAGACAGCCCCGCTGCGCCTGCG 960
CTGCTTTTGGCAGATGCACCACCAGAGTCGCCTCCGGGTCCGCCAGAGGGGGCATCCCTA 1020
AGCGACACAGAACAGGGAACCCAGACCCCGTCTCCCGACGCCGCCCCTCAGTGTCCTGCA 1080  
ACACAGAACAGGGAACCCAG 
Reverse primer
Figure 2.3: An illustration of the primer-encoding region of the Mouse musculus 
MyoD gene. The published cDNA sequences for Mouse musculus MyoD in the 
NCBI GenBank database was imported into the Primer-3 programme and forward and 
reverse RT-PCR primers designed. In this example, the PCR product is 513 bp (shown 
bold), starting and finishing at nucleotides 531 and 1044, respectively, in the shown 
sequences. The numbers indicated on the right-hand side relate to the nucleotide number 
relative to the start of the gene sequences.
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Table 2.1: Sequences of oligonucleotide primers used for RT-PCR
Oiigo name Sequences %GC Tm°C Productsize
GAPDH-F159^ ATT CAA CGG CAC AGT CAA GGC (21 bp) 52 59.8
556 bp
GAPDH-R760 CAC ATT GGG GGT AGG AAC AC (20 bp) 55 59.4
a-MHC-F5464 ATG GAG GAG ACC ATC AAG GAC (21 bp) 52 59.8
491 bp
a-MHC-R5955 TTG TGT ATT GGC CAC AGC GAG (21 bp) 52 59.8
P-MHC-F1457 CTT CAA CCA CCA CAT GTT CGT G (22 bp) 50 60.3
587 bp
P-MHC-R2043 TCA CCC CTG GAG ACT TTG TCT (21 bp) 52 59.8
MyoD-F372 AGT GAA TGA GGC CTT CGA GAC (21 bp) 52 59.8
513 bp
MyoD-R885 CTG GGT TCC CTG TTC TGT GT (20 bp) 55 59.4
MyoG-F53 AGC TGT ATG AGA CAT CCC CCT (21 bp) 52 59.8
608 bp
MyoG-R661 ACG ATG GAC GTA AGG GAG TG (20 bp) 55 59.4
a-MHC-F5628* GAC GAG GAA TAA CCT CTC CAG CAG (24 bp) 54 64.4
302 bp
a-MHC-R5931* GAG GAA GAG TGA GCG GCG CAT C (22 bp) 64 65.8
P-MHC-F5806* CCC TCA GAC CTG GAG CCT TTG C (22 bp) 64 65.8
205 bp
P-MHC-R6007* GCC AAC ACC AAC CTG TCC AAG TTC (24 bp) 54 64.4
ANF-F206* TGA TAG ATG AAG GCA GGA AGC CGC (24 bp) 54 64.4
203 bp
ANF-R429* AGG ATT GGA GCC CAG AGT GGA CTA (24 bp) 54 64.4
MLC2-F381* CCA CAG CCT CAG GTG ACC GAC (22 bp) 67 65.7
189 bp
MLC2-R569* GAA GGC TGA CTA TGT CCG GGA GAT (24 bp) 54 64.4
CaCh-hF3771* GAA AAG GCA GTT CCC ATG CCG GAA (24 bp) 54 64.4
183 bp
CaCh-hR3953* CGT CCA GCA CAC CTC CTT CAG G (22 bp) 64 65.8
CaCh-mF1232* GGG CGA GGT CAT GGA CGT GG (20 bp) 70 65.5
204 bp
CaCh-mR1436* GGT CTT CTA TTG GCT GGT GAT CCT G (25 bp) 52 64.6
HFABP-F55 GAC TAC ATG AAG TCA CTC GGT GT (23 bp) 48 60.6
326 bp
HFABP-R381 CCG AGT GCT CAC CAC ACT G (19 bp) 63 61.0
PPARa-F367 AAG GGC TTC TTT CGG CGA AC (20 bp) 55 59.4
880 bp
PPARa-R1247 TGG TTG CTC TGC AGG TGG A (19 bp) 58 58.8
PPARP-F784 TTC GCC AAG AAC ATC CCC A (19 bp) 53 56.7
360 bp
PPARP-R1143 TTC TAG AGC CCG CAG AAT GGT (21 bp) 52 59.8
PPARy-F658 AAG CTG TTG GCG GAG ATC TC (20 bp) 55 59.4
856 bp
PPARY-R1514 TAC AAG TCC TTG TAG ATC TCC TG (23 bp) 44 58.9
tNumbers indicate the start site of the forward (F) and reverse (R) primers.
*Primers have been designed based on previously used sequences in the literature (Fassler et al., 1996). 
Tn,: annealing temperature (°C) 
bp: base pair.
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Table 2.2: Sequences of oligonucleotide primers used for nested PCR
O llgo nam e S e q u e n c e s %GC Tm°C P ro d u c ts iz e
GAPDH-F188^ GAC TCC ACT CAC GGC AAA TTC (21 bp) 52 59.8
413 bp
GAPDH-R601 AGT CTT CTG GGT GGC AGT GAT (21 bp) 52 59.8
a-MHC-F5632 AAG AGT GAG CGG CGC ATC AA (21 bp) 55 59.4
302 bp
a-MHC-R5931 CTG CTG GAG AGG TTA TTC CTC (21 bp) 52 59.8
P-MHC-F47 GAG GGC ATT GAG TGG ACA TTC (21 bp) 52 59.8
412 bp
P-MHC-R458 CTT TCT TTG CCT TGC CTT TGC C (21 bp) 50 60.3
MyoD"F590 TAC CCA AGG TGG AGA TCC TG (21 bp) 55 59.4
392 bp
MyoD-R982 GTG GTG CAT CTG CCA AAA GC (21 bp) 55 59.4
MyoG-F32 ACC AGG AGC CCC ACT TCT AT (20 bp) 55 59.4
337 bp
MyoG-R369 GCG CAG GAT CTC CAC TTT AG (20 bp) 55 59.4
HFABP-F97 TCG GTA GCA TGA CCA AGC CTA (21 bp) 52 59.8
242 bp
HFABP-R339 TTT CCC GTC AAC TAG CTC CCT (21 bp) 52 59.8
PPARa-F644 TGA AGA ACT TCA ACA TGA ACA AGG TCA A (28 bp) 36 60.7
350 bp
PPARa-R993 CAG CAT CCC GTC TTT GTT CAT CA (23 bp) 48 60.6
PPARP-F847 TAT GGC GTG CAC GAG GCC (18 bp) 67 60.5
350 bp
PPARP-R1094 TTC ATG AGG CCT GGC CGG T (19 bp) 63 61.0
PPARy-F751 ATA AAG TCC TTC CCG CTG ACC AA (23 bp) 48 60.6
525 bp
PPARy-R1275 GCG GTC TCC ACT GAG AAT AAT GA (23 bp) 48 60.6
tNumbers indicate the start site of the forward (F) and reverse (R) primers. 
Tm: annealing temperature (°C) 
bp: base pair.
2.2 A.2 Reverse Transcription Polymerase Chain Reaction
(RT-PCR)
Gene expression (mRNA) levels were determined by the reverse transcription 
polymerase chain reaction (RT-PCR) (Newton and Graham, 1997). The “Ready-To-Go” 
RT-PCR kit (Amersham Biosciences, Chalfont St. Giles, UK) was used that contains all 
the required constituents for RT-PCR (buffer, nucleotides, enzymes) in a solid bead, with 
the exception of RNA, primers and nuclease-ffee water. Beads were dissolved in 45 pi of
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nuclease-ffee water and then 1 |il of the relevant gene-specific forward and reverse 
primers (100 pmol/pl) were added to the reaction mixture (4°C). Finally, 3 pi of the 
RNA template was added and the PCR samples transferred to a Thermo Hybaid thermal 
cycler (Thermo BioSciences GmbH, Ulm, Germany). The control reaction, supplied with 
the Ready-To-Go kit, was used as a positive control. The one-step protocol for RT-PCR 
was performed according to the scheme summarised in Table 2.3 as recommended in the 
manufacturer’s instructions. The annealing temperature was set at 5°C less than the lower 
Tm calculated by the supplier (MWG, Milton Keynes, UK) for a primer pair, and the 
extension temperature was adjusted to an optimal temperature for Taq DNA 
polymerase (Newton and Graham, 1997; McPherson et al., 1995).
Table 2.3: RT-PCR cycling profile.
First Strand DNA Synthesis
42°C for 30 min Reverse Transcription
1 cycle
95°C for 5 min RNA-DNA Primer Dénaturation
Second Strand DNA Synthesis 
and PCR Amplification
95°C for 1 min Dénaturation
30 cycles*T°C for 1 min Annealing
72°C for 2 min Extension
Final Extension 72°C for 10 min Final Extension 1 cycle
Holding Temperature 25°C -
*T°C is usually 5°C less than the lower annealing temperature (Tm) calculated by the supplier for a 
primer pair
2.2.4.3 Nested PCR
In some samples, no PCR products were visible after an initial RT-PCR 
(Section 2.2.4.2). In these cases it was assumed that the initial mRNA levels, and 
therefore also the amplified PCR product levels, were very low and therefore the PCR 
products were ftirther amplified in a second round of PCR, using “nested”
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primers (Newton and Graham, 1997; McPherson et al., 1995). Nested PCR primers were 
designed to bind to specific gene sequences in the hypothetical RT-PCR product 
(Fig. 2.4). Reagents were added to autoclaved 0.5 ml PCR tubes, as shown in Table 2.4 
and the nested PCR protocol was performed according to the scheme summarised in 
Table 2.5.
m R N A
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Figure 2.4: Diagrammatic representation of RT-PCR product amplification by nested 
PCR. A first set of gene-specific PCR primers (FI and Rl) was used in the RT-PCR 
reaction. In the second amplification, i.e. nested PCR, a separate set of primers (F2 and R2) 
was used to re-amplify the RT-PCR product. F: forward; R: reverse.
Table 2.4: Components in nested PCR tubes.
R e a g e n t V olum e Final c o n c e n tra tio n
DEPC-treated water 
MgCb (25 mM, 25 nmol/^l)
DNA polymerase buffer (lOx) 
dNTPs (10 mM each dNTP)
Primers [(forward and reverse); 100 pmol/pl] 
Taq DNA Polymerase (5 Unit/pl)
DNA template (RT-PCR product)
35.5 1^1
4 III
5 pi
2 pi
0.5 pi 
0.5 pi
2 pi
2 pM 
Ix
0.4 mM each dNTP 
1 pmol/pl 
0.05 u/pl
T ota l v o lu m e 50 pi -
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Table 2.5: Nested PCR cycling profile.
Dénaturation , 95°C for 1 min Dénaturation of double-strand DNA 1 cycle
DNA Strands Synthesis 
and PCR Amplification
95°C for 45 sec Dénaturation
30 cycles*T°C for 45 sec Annealing
72°C for 2 min Elongation
Final Extension 72°Cfor 10 min Final Extension 1 cycle
Holding Temperature 25°C -
*T°C is usually 5°C less than the lower annealing temperature (T^) for a primer pair
2.2.5 Quantitation of PCR products from digitised gel images
In order to get semi-quantitative values of gene expression (mRNA) levels from the 
RT-PCR and nested PCR experiments the photographic image of gels were digitised 
using the Scion Image programme (http://www.scioncorp.com/). In order to obtain 
digital values {i.e. gene expression levels relative to the expression of housekeeping gene) 
a saved image in “TIFF” format was used. First, a lane was marked, as shown for 
GAPDH (Fig. 2.5A). Next, the illumination of the lane was plotted for the marked area
(Fig. 2.5B). The peak area was delineated by drawing tangents to remove the background
;
brightness (Fig. 2.5B, tangent 1). Finally, the “effective pixels” within the peak area were 
taken to represent gene expression level (Fig. 2.5B, tangent 2).
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GAPDH
0
Figure 2.5: An example of the process used to digitise gel images and semi-quantitate PCR 
products using Scion Image software. PCR products were separated on a 2% agarose gel 
containing ethidium bromide and the gel photographed. A saved image in “ lib” format was 
used for image digitisation. First, a lane was marked as shown for GAPDH (A). The 
illumination of the marked area was then plotted (B) and peak area was delineated by drawing 
tangents to remove the background brightness (tangent 1). Finally, the “effective pixels” within 
the peak area were taken to represent gene expression level (tangent 2).
2.2.6 Purification of PCR products from agarose gels
PCR products were separated by agarose gel electrophoresis and visualised, as 
described (Section 2.2.3.2). The PCR products were then excised from the gel and the gel 
slices weighed. The DNA was extracted from the agarose using a Wizard SV Gel and 
PCR Clean-Up kit (Promega Corporation, Southampton, UK). The gel slices were 
dissolved in a membrane-binding solution [4.5 M guanidine isothioeyanate, 0.5 M 
potassium acetate (pH 5.0)] at 65°C and the solution transferred to purification columns 
containing a DNA-binding membrane. The membranes, were washed with a 
membrane-washing solution [10 mM potassium acetate (pH 5.0), 80% ethanol, and 
16.7 pM EDTA (pH 8.0)] and the DNA eluted with nuclease-ffee water. The 
concentration of PCR products was determined by absorbanee spectroscopy using a 
NanoDrop ND-1000 spectrophotometer, as discussed earlier (Section 2.2.2.5), using an 
extinction coefficient (s) of 50 ng.cm.pU’ for double-strand DNA samples. DNA purity 
was assessed by using the absorbance ratio at A260/A280, with a ratio of 1.8-2 regarded 
as aceeptable (Yu et ah, 2002; Brown, 2001).
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2.2.7 DNA sequencing of PCR products and sequence 
comparison
PCR products were sequenced in the Functional Genomic and Microarray Centre 
(School of Biomedical and Molecular Sciences, University of Surrey) using a CEQ 
2000XL DNA Analysis System (Beckman Coulter, Fullerton, USA), and relevant 
gene-specific primers (Fig. 2.6). In order to confirm identity, the DNA sequences of the 
PCR products were compared to the gene sequenees, as obtained from NCBI GeneBank 
Database (http://www.nebi.nlm.nih.gov/), taking into aecount the positions of the PCR 
primers utilised, using the ClustalW sequence analysis programme 
(http://www.ebi.ac.uk/elustalw/). Identity was further eonfirmed by comparison of the 
PCR product sequences to the Mouse musculus Genome database, using the Blast 
algorithm (http://www.nebi.nlm.nih.gov/genome/seq/MmBlast.html/).
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2.2.8 Microarray experiments
P19C16 and H9C2(2-1) cells were cultured in 150 cm  ^peel-off flasks at a density of 
2x10^ cells per flask in the presence of DMSO for 15 days, a time point at which 
spontaneous contraction, i.e. a cardiac-type phenotype, of the P19C16 cells has been 
observed (Habara-Ohkubo, 1996). Total-RNA was isolated from the cultured cells, and 
mouse cardiac and skeletal muscle tissue, by the Trizol method. During the microarray 
experiments cDNA was synthesised, labelled and hybridised on arrays using two different 
methods. In the first method, HGMP protocols (Human Genome Mapping Project; 
http://www.hgmp.mrc.ac.uk/) were followed since microarray slides had been provided 
by the HGMP group, whereas in the second method labelling and hybridisation 
procedures were carried out using a ProntoPlus kit (Coming B.V. Life Sciences, 
Schiphol-Rijk, Netherlands). The ProntoPlus method requires less total-RNA template 
(5 pg) and fluorescent Cy-dye (1 pi) in comparison with the HGMP method (40 pg 
total-RNA and 3 pi dye), and therefore is more economical.
In order to obtain estimates of biologically important parameters, microarray 
experiments were designed as dual-hybridisation optimal interwoven loops, as shown in 
Fig. 2.7, using an online microarray experimental design programme available on the 
MARIE:ExGen Consortium website (http://exgen.ma.umist.ac.uk/) (Simon et al., 2002; 
Dobbin and Simon, 2002; Churchill, 2002; Vinciotti et al., 2005; Wit and McClure, 
2004). The loop experiments were designed based on the number of conditions 
(total-RNA samples) and the number of comparisons (slides). Microarray experiments 
were carried out in a step-by-step procedure, as summarised in Fig. 2.8, including cDNA 
synthesis and labelling by the direct labelling method (Yu et al., 2002), hybridisation of 
labelled-cDNA on arrays, and image acquisition by scanning of arrays using an 
Affymetrix428 scanner (Affymetrix, Santa Clara, USA). BlueFuse (BlueGenome Ltd., 
Great Shelford, UK) software was used for image analysis and the data further analysed 
using Gene Spring-7 (Silicon Genetics, Redwood City, USA) and LLAMA (Live Linear 
Analysis of Micro Array, http://exgen.ma.umist.ac.uk/) software.
The variance between two comparisons in a loop design experiment is dependent on 
the number of paths connecting them (Wit and McClure, 2004; Dobbin and Simon, 2002). 
For example, the comparison of samples 1 and 2 shown in Fig. 2.7A, can be estimated via 
direct (1 to 2) or indirect (1 to 3 and 3 to 2) paths (Wit and McClure, 2004). Therefore,
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the linear modelling approach (LLAMA) was performed to estimate comparisons 
between the samples for each gene via different paths, and to compute path-independent 
values with greater precision (Wit and McClure, 2004; Vinciotti et ah, 2005).
B
C D
Figure 2.7: Representation of dual-hybridisation optimal interwoven loop designs
for (A) three, (B) four, (C) six, and (D) seven conditional microarray experiments.
Experiments were efficiently designed in dual-hybridisation optimal interwoven loops 
using an online microarray experimental design software available on the MARIEiExGen 
Consortium website (http://exgen.ma.umist.ac.uk/) (Simon et al., 2002; Dobbin and 
Simon, 2002; Churchill, 2002; Vinciotti et al., 2005; Wit and McClure, 2004). The Cy3- 
and Cy5-labelled probes were mixed (40 pmol of each) in pairs, according to the 
experimental design, and hybridised on 60x24 mm microarray slides. Arrows represent 
Cy3 to Cy5 direction and show comparisons between the samples throughout the loop. 
Numbers 1-7 indicate total-RNA source depending on experiment.
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Mouse heart and 
skeletal muscle tissues
Total RNA isolation
(Trizol method)
Cell culture 
samples
Image and 
Data analysing
Determining RNA 
concentration
Determining RNA 
concentration
Scanning and 
data capture
DNase digestion and 
RNA purification
cDNA direct labelling 
(Cy3 or Cy5 dye)
Hybridisation of 
labelled cDNA on array
Determining Cy3/Cy5 dye 
incorporation degree
Microarray post-hybridisation 
wash-up
RNA denaturing 
and removing 
unincorporated dye
Figure 2.8: A schematic representation of the steps required for microarray analysis.
Details of each step are provided below.
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2.2.8.1 Microarray procedure (HGMP protocol)
In order to perform microarray experiments based on the HGMP method, all required 
reagents were freshly prepared in an RNase-free environment and experiments were 
performed, as discussed below.
2.2.8.1.1 cDNA synthesis and target labelling
Total-RNA was initially isolated using the Trizol reagent according to the one-step 
procedure, as described in section 2.2.2. The RNA was further purified with the RNeasy 
MinElute kit to remove potential genomic DNA contamination. Finally, purified RNA 
(40 pg total-RNA) was used for cDNA synthesis and labelling with Cy3 or Cy5 
fluorescent dyes according to the “direct incorporation” procedure (Yu et al., 2002).
The synthesis of cDNA and target labelling was achieved as follows: the total-RNA 
sample was placed in a microcentrifuge tube and volume adjusted to 12.9 pi with 
DEPC-treated nuclease-free water. Then, Oligo dT^MN (19 pM) was added (total 
reaction volume 15.4 pi), the solution mixed thoroughly and incubated on a heating block 
at 70°C for 10 min. At the end of the incubation, the tube was chilled immediately on ice 
for 10 min. To initiate cDNA synthesis, the first-strand synthesis buffer [50 mM 
Tris-HCl (pH 8.3), 75 mM KCl, 3 mM M gCy was added followed by addition of DTT 
(10 mM), nucleotide mixture (0.5 mM dATP, dOTP, dTTP, and 0.2 mM dCTP), 
Cy3/Cy5-dCTP dye (0.1 mM), and SuperScript-11 Reverse Transcriptase (14 units/pi), as 
shown in Fig. 2.9. Reagents were mixed (total volume 30 pi), and incubated at 42°C for 
2 hours on a heating block, protected from light. Finally, residual RNA was degraded and 
unincorporated dye was removed before the labelled cDNA was hybridised to the 
microarrays, as discussed below.
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Figure 2.9: Schematic representation of the direct target-labelling procedure. High 
quality RNA samples were used for synthesis and labelling of the cDNA in the presence of 
Oligo dT(i2-i8) primer, buffer, nucleotide mixture, Cy3/Cy5-dCTP, and SuperScript-II 
reverse transcriptase (Yu et ah, 2002).
2.2.8.1.2 RNA dénaturation
Since hybridisation on microarray slide requires pure labelled-cDNA, but not RNA 
(mRNA and rRNA), the latter needed to be removed from the reaction mixture. The 
RNA was denatured by the addition of NaOH (0.17 M) and incubation at 37°C for 
15 minutes followed by the addition of 0.5 M HEPES buffer (N-[2-Hydroxyethyl] 
piperazine-N’-[2-ethanesulfonic acid] sodium salt).
2.2.8.1.3 Removal of unincorporated dye
The fluorescent cDNA probes were purified to maximise the hybridisation and 
minimise non-specific background signal. In order to remove excess unincorporated 
Cy3/Cy5 dye and nucleotide fragments produced during the RNA-denaturing step, a 
MinElute PCR purification column was used (Qiagen Ltd., Crawley, UK). The labelling 
reaction mixture was diluted with 5 volumes of PB buffer provided in the MinElute PCR 
purification kit and applied to the MinElute purification column, allowing labelled-cDNA 
to bind to the membrane. The membrane was washed by the addition of PE buffer, as per 
the manufacturer’s instructions, and the column centrifuged at 14,000xg (12,300 rpm) for 
1 min using an Eppendorf microcentrifuge. Finally, labelled-cDNA was eluted with 20 pi 
Elution buffer by centrifugation for 1 min at 14,000xg (12,300 rpm).
2.2.8.1.4 Determination of Cy3/Cy5 dye concentration and degree of 
incorporation into cDNA
Since an equal amount of Cy3- and Cy5-labelled cDNA should be added to the array, 
it was important to determine the concentration of labelled-cDNA in the samples before 
hybridisation. The Cy3 and Cy5 dyes display maximum absorbance at 550 nm and 
650 nm, respectively, as indicated in the product datasheet (Amersham Biosciences, 
Chalfont St. Giles, UK). ' A NanoDrop ND-1000 spectrophotometer was used to 
determine the Cy3/Cy5 dye concentration by measuring the absorbance of samples 
between 250-750 nm. The spectrophotometer was zeroed using DEPC-treated 
nuclease-fi*ee water and the absorbance of the labelled-cDNA samples (1 pi) between 
250-750 nm determined (Fig. 2.10). The concentration of labelled-cDNA was calculated 
in pmol/pl based on the Beer-Lambert equation c=A/(s.b), using an extinction coefficient 
(s) of 0.15 pmol.cm.pl”  ^ (150,000 M"\cm"^) and 0.25 pmol.cm.pr^ (250,000 M"\cm"') 
for Cy3 and Cy5 dye, respectively. The total cDNA yield (ng) was obtained using a 
modified Beer-Lambert equation (c=A.s.b” )^ where A is absorbance at 260 nm, b is path 
length (cm) and s is a modified wavelength-dependent extinction coefficient (37 
ng.cm.pl"^ for single strand DNA), taking into account the total volume of 
labelled-cDNA sample (pi).
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The data obtained from NanoDrop spectroscopy, was imported into an online 
calculator (http ://www. prontosystems.com/technical_support/calculatore/index.asp) to 
determine the degree of Cy-dye incorporation and calculate the volume (pi) of labelled 
cDNA required for hybridisation on a 60x24 mm microarray slide.
M easure
Re-blank
Blank
Print Screen
Print Report
Start Report
Show Report
I  Measutemenl complete 1 2 /1 9 /2 0 0 4  6 :47  PM
U ser ilraj
Exit
^  0 .1 0  Max A bsorbance
"  0.06
S 0.05
<  0 04
>- 0 03
Sam ple Type Other
Constant 37
Sam ple i PI 9CL6 BSA-Cy5 
ID !
Batch Index 0 
X 260 Im m A bs ; 0.338
Dye 1 Cy3
Dye 1 Abs 0 005
pmol/ul Dye 1 ; 0.4
Dye 2 _______ CyS_______ v j
Dye 2 Abs C o  050 
pmol/ul Dye 2 :i 2.0
220 250 300 350 400 450 500 550 600 650 700 750
3.0.0 B839 Wavelength nm
260/280 I 1.99 
ng/ul ; 121.5
Figure 2.10: Screen features of the NanoDrop ND-1000 spectrophotometer used to 
determine cDNA and Cy3/Cy5-dye concentrations. Samples were scanned between 
220-750 nm and the absorbance for Cy3 and Cy5 dye determined at 550 and 650 nm, 
respectively.
2.2.8.1.5 Hybridisation of labelled-cDNA to microarrays and post-hybridisation 
wash
Hybridisation of the fluorescent cDNA onto microarrays was performed in three 
steps, as discussed below.
(i) Preparing the hybridisation buffer: in the first step, formamide was deionised 
by mixing with AG501-X8 (D) Mixed-Bed resin (5% w/v) and stirring for 2 hours. The 
supernatant was removed using Whatman #1 filter paper, and filter-sterilized (2 pm). 
Hybridisation buffer was prepared according to the HGMP protocol 
(http://www.hgmp.mrc.ac.uk/). The reagents were mixed in a sterile tube to final 
concentrations as follows: deionised formamide (40% v/v), Denhardfs
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solution (0.1 % Ficoll-400, 0.1 % polyvinylpyrrolidone, and 0.1 % BSA), SSC (750 mM 
NaCl and 75 mM sodium citrate), SDS (sodium dodecyl sulphate, 0.1% w/v), sodium 
pyrophosphate (1 mM), and Tris (50 mM, pH 7.4). The buffer was filter-sterilized (2 pm) 
and stored in small aliquots at -20°C.
(ii) Hybridisation of targets on microarrays: in the hybridisation step, purified 
Cy3- and Cy5-labelled cDNA samples (40 pmol each) were mixed in pairs, according to 
the experimental plan, as shown for the P19CL6-embryo-heart comparison loop design 
(Fig. 2.11). The sample volume was reduced until targets were dried, using a Speed-Vac 
Uniscience Gyrovap centrifuge (VA Howe Ltd., Banbury, UK). Pellets were dissolved in 
1 pi nuclease-free water to accelerate the dissolution of targets in hybridisation buffer 
(39 pi). Then poly A oligonucleotide (0.115 pg/pl) and mouse Cot-1 DNA (0.17 pg/pl) 
were added to suppress cross-hybridisation of cDNA to mouse repetitive DNA and tubes 
were incubated at 100°C for 5 minutes on a heating block, protected from light.
Tubes were cooled at room temperature for 10 min (protected from light) and 
hybridisation mixtures were then applied to the centre of arrays that had been placed in 
hybridisation chambers. Coverslips were placed over the arrays, taking care not to 
introduce air bubbles. A humidified atmosphere was provided by applying 30 pi of 
SSC (750 mM NaCl and 75 mM sodium citrate) into the wells on two sides of the 
chambers. Chambers were sealed and incubated at 50°C for 20 hours (protected from 
light) using a pre-warmed water-bath.
(iii) Post-hybridisation wash of microarray slides: for the post-hybridisation 
washing step of microarrays the slides were immersed in SSC/SDS solution [150 mM 
NaCl, 15 mM sodium citrate, and 0.2% (w/v) sodium dodecyl sulphate] for 2 min at room 
temperature to facilitate removal of the coverslips. Slides were then washed sequentially 
(2x5 min each step) using the following wash solutions: (a) SSC solution (150 mM NaCl 
and 15 mM sodium citrate), (b) SSC/SDS solution (15 mM NaCl, 1.5 mM sodium citrate, 
and 0.1% (w/v) sodium dodecyl sulphate), and (c) SSC solution (15 mM NaCl, 1.5 mM 
sodium citrate). Finally, arrays were dried by centrifugation at 70xg (800 rpm) for 5 min 
using an ICE Centra CL3 centrifuge (International Equipment Company, Needham 
Heights, USA) and stored in the dark until scanning.
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Figure 2.11: Representation of (A) design and (B) description of loop comparison for 
P19CL6 ceils, mouse embryo and mouse heart total RNA. The RNA samples from 
P19CL6 cultured cells and mouse embryo and heart were used for cDNA synthesis and 
labelling. The Cy3- and Cy5-labelled probes were mixed (40 pmol of each) in pairs, 
according to the experimental design (Simon et al., 2002; Dobbin and Simon, 2002), and 
hybridised on 60x24 mm mieroarray slides. A dye-swap technique was performed to 
minimise the effect of different Cy3/Cy5 dye intensities. Arrows represent Cy3 to Cy5 
direction and show comparisons between the samples throughout the loop. Samples 1 -3 are 
P19CL6, embryo and mouse heart total RNA.
2.2.S.2 Microarray procedure (ProntoPlus kit)
The ProntoPlus kit (Corning B.V. Life Sciences) provided all required solutions for 
cDNA synthesis, labelling and purification, and hybridisation.
2.2.8.2.1 cDNA synthesis and target labelling
Total-RNA was isolated using the Trizol reagent and used for cDNA synthesis and 
labelling according to the “direct incorporation” procedure (Yu et al., 2002). The 
synthesis of cDNA and target labelling was achieved as follows: The total-RNA sample 
(5 pg total-RNA) was placed in a microcentrifuge tube (on ice) and the volume adjusted 
to 20 pi with nuclease-ffee water after addition of random (0.15 pg/pl) and Oligo dT 
(0.1 pg/pl) primers. This RNA/primer solution was mixed thoroughly and incubated on a 
heating block at 70°C for 10 min. At the end of the incubation, the tube was chilled 
immediately on ice.
While the RNA/primer solution was incubated at 70°C, the labelling mixture was 
prepared separately in microcentrifuge tubes for the Cy3 and Cy5 dyes. ChipShot reverse 
transcriptase 5x reaction buffer (8 pi), MgCh (4.8 pi), dNTP mix (2 pi for Cy3 and 3 pi
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for Cy5 reaction tube), Cy-dye (1 pi into relevant reaction tube) and ChipShot reverse 
transcriptase (3.2 pi), all provided by the manufacturer, were added into tubes and final 
volume was adjusted at 20 pi using nuclease-free water. To initiate cDNA synthesis, the 
entire labelling mixture was added to the RNA/primer solution, mixed, centrifuged briefly 
and incubated at room temperature for 10 min, protected from light. The reaction mixture 
(total volume 40 pi) was then incubated at 42°C for 2 hours on a heating block, protected 
from light. Finally, residual RNA was degraded and unincorporated dye was removed 
before the labelled cDNA was hybridised.
2.2.S.2.2 RNA dénaturation and removal of unincorporated dye
The RNA was denatured by the addition of RNa^g H (1 pi) and RNaje solution 
(0.35 pi) to the cDNA synthesis reaction. Reagents were mixed gently and incubated at 
37°C for 15 min. Labelled cDNA was then purified as follows: binding particles (18 pi), 
sodium acetate (4 pi, pH 5.2) and binding solution (310 pi), all provided by the 
manufacturer, were added to the labelled-cDNA sample, mixed gently for 10 sec and 
incubated at room temperature for 1 min. The entire content of tube was applied to a 
Spin-X column and centrifuged at 10,000xg (11,000 rpm) for 1 min using an Eppendorf 
microcentrifuge. The flowthrough was discarded and the column washed with 500 pi of 
80% ethanol by centrifugation at 10,000xg (11,000 rpm) for 1 min. This wash step was 
repeated three times. Finally, labelled cDNA was eluted from the column using 60 pi of 
elution buffer, provided by the manufacturer, and centrifuged at 10,000xg (11,000 rpm) 
for 1 min after incubation of column at room temperature (1 min). The eluted cDNA was 
stored in a light-proof container at -80°C. Cy-dye incorporation was assessed with a 
NanoDrop ND-1000 spectrophotometer, as discussed above.
2.2.8.2.3 Pre-soak and pre-hybridisation wash
Dust and weakly bound oligonucleotides were removed from the microarray slides 
by washing with Pre-Soak and Pre-Hybridisation solutions, prepared as the 
manufacturer’s instructions. Microarray slides were immersed in pre-warmed (42°C for 
30 min) Pre-Soak Solution and incubated at 42°C for 20 min. Arrays were transferred
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into Wash Solution 2 (5% v/v Universal Wash Reagent A in deionised water) and washed 
twice by incubation at room temperature for 30 sec. Arrays were then transferred into 
pre-heated (42°C for 30 min) Universal Pre-Hybridisation Solution for 15 min. Arrays 
were incubated twice in Wash Solution 3 (1% v/v Universal Wash Reagent A in 
deionised water) at room temperature for 30 sec. Finally, arrays were rinsed with 
nuclease-ffee water at room temperature and dried by centrifugation at 70xg (800 rpm) 
for 2 min using an ICE Centra CL3 centrifuge. Slides were used in hybridisation or 
stored in a dust-free slide holder.
2.2.8.2.4 Hybridisation of labelled-cDNA to microarrays and post-hybridisation 
wash
In the hybridisation step, purified Cy3- and Cy5-labelled cDNA samples (40 pmol 
each) were mixed in pairs, according to the experimental plan, and the reaction volume 
minimised using a Speed-Vac Uniscience Gyrovap centrifuge (VA Howe Ltd., Banbury, 
UK) until targets were nearly dried. Pellets were dissolved in 40 pi of Universal 
Hybridisation Solution (1 pi for each pmol of labelled-cDNA) and tubes were incubated 
at 95°C for 5 minutes on a heating block, protected from light. Condensate was collected 
by centrifugation at 13,500xg (12,000 rpm) for 2 min and applied on the centre of the 
arrays that had been placed in hybridisation chambers, as discussed above for the HGMP 
method. Chambers were sealed and incubated at 42°C for 20 hours (protected from light) 
using a pre-warmed water-bath.
At the end of the incubation period microarray slides were immersed in pre-warmed 
(42°C for 30 min) Wash Solution 1 (10% v/v Universal Wash Reagent A and 0.5% v/v 
Universal Wash Reagent B in deionised water) for 2 min to remove coverslips. Slides 
were then transferred into fresh pre-warmed (42°C for 30 min) Wash Solution 1 for 
5 min. Arrays were incubated in Wash Solution 2 (5% v/v Universal Wash Reagent A in 
deionised water) for 10 min at room temperature and were then incubated with Wash 
Solution 3 (1% v/v Universal Wash Reagent A in deionised water) at room temperature 
for 2 min. The latter wash step was repeated and slides were dried by centrifugation at 
70xg (800 rpm) for 2 min using an ICE Centra CL3 centrifuge and stored in the dark until 
scanning.
2.2.S.3 Microarray scanning and data capture
Dust was removed from hybridised slides using dust-pro spray. Slides were then 
placed in an Afrymetrix 428 scanner (Affymetrix; Santa Clara, USA) that excited the 
Cy3/Cy5-dye labels with a laser and measured the emitted light at 532 and 
635nm (Kawasaki, 2004). The laser power and photomultiplier tube settings (gain) were 
adjusted to achieve good signal-to-noise ratios while avoiding signal saturation. At each 
microarray coordinate, Cy3 or Cy5 fluorescence intensity is directly proportional to the 
amount of labelled-cDNA present. The pixel intensities were converted to a 16-bit 
“TIFF” image format for visualisation and saved for each channel separately, Cy3 and 
Cy5, until further image and data analysis.
2.2.8.4 Image analysis
Images scanned for Cy3 and Cy5 fluorescence were overlaid using BlueFuse 
software (BlueGenome Ltd., Great Shelford, UK) and analysed in two steps: placing of 
the grids, and quantification. Whereas placing the grids is a manual procedure, the 
BlueFuse software is able to quantitate the signals for each spot automatically based on 
the spot coordinates and the grid map. The software utilizes auto-segmentation and edge 
detection to calculate spot intensities and background noise. The overall dimensions of 
the microarrays are approximately 53x18 mm including 48 sub-grids, arranged in 12 rows 
and 4 columns, with 18 rows and 20 columns in each sub-grid (Fig. 2.12). Average spot 
diameter was 160 pm and the average distance from spot-to-spot centre was 220 pm. The 
array consists of 7,524 oligonucleotides, which represent 7,445 sequences, plus 79 
controls. The array description file (Mm_SGC_AV2.gal) obtained from Human Genome 
Mapping Project website (HGMP; http://www.hgmp.mrc.ac.uk/), describes the 
coordinates of each spot on the array. Once scanned images for Cy3 and Cy5 were 
overlaid, coordinates of positive and negative “control spots” were defined and a 
theoretical sub-grid map adjusted on the spots manually.
75
00000000000000000000
+ + + + + + + + + + + + + + + + + + +  
+ + + + + + + + + + + + + + + + +
î î î î î î î î î î î î î î î î î î î î
T h eo re tica l m a p  o f 
s p o ts  c o o rd in a te s
•  M ouse k n o w n  o lig o s
°  N egative a n d  p o s itiv e  
c o n tro l s p o ts ,  b a c te ria l 
p ro b e s , t is s u e -s p e c if ic  
g e n e s ,  an d  la n d in g  lig h ts
MCI
MR1
MCI
MR2
MCI
MRS
MCI
MR4
MC1
MRS
MC1
MR6
MCI
MR7
MC1
MR8
MCI
MR9
MCI
MR10
MCI
MR11
MCI
MR12
MC2
MR1
MC2
MR2
MC2
MRS
MC2
MR4
MC2
MRS
MC2
MR6
MC2
MR7
MC2
MR8
MC2
MR9
MC2
MR10
MC2
MR11
MC2
MR12
MCS
MR1
MCS
MR2
MCS
MRS
MCS
MR4
MCS
MRS
MCS
MR6
MCS
MR7
MCS
MR8
MCS
MR9
MCS
MR10
MCS
MR11
MCS
MR12
MC4
MR1
MC4
MR2
MC4
MRS
MC4
MR4
MC4
MRS
MC4
MR6
MC4
MR7
MC4
MR8
MC4
MR9
MC4
MR10
MC4
MR11
MC4
MR12
Figure 2.12: Layout of Mouse Known Gene SGC Oligo Set Array, version 2 (~7.5k 
oligos). Array includes 48 sub-grids, arranged in 12 rows and 4 columns, with 18 rows and 
20 columns in each sub-grid. There are -7,500 mouse known genes on the microarray 
slide (shown in black). The array map file identifies the spots based on theoretical 
coordinates of positive and negative control spots (shown in grey) and quantifies the pixel 
intensity for all spots. MC and MR of each sub-grid indicate the position of sub-grid on the 
microarray slide.
Once grid adjustment was completed, the pixel intensities for spots was determined. 
The BlueFuse software identified each spot in the overlaid image files fi"om a scanned 
array (Fig. 2.13) and quantified the pixel intensity of the spot and its (local) background. 
This software also identified and excluded regions of the spot that behaved significantly 
differently from the norm (such as specks of dust) and assigned flags to indicate the 
quality of the data. However, images were also checked manually and artefact areas were 
flagged. The spots were assigned confidence values ranging 0-1 automatically, with a 
value of one corresponding to the highest spot quality. Since the array consists of
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duplicate spots for each gene, the measured intensities were therefore fused to obtain an 
average signal for each gene and an Excel-type spreadsheet was generated for each slide 
to use in further analyses. Scatter plots were generated (Fig. 2.14) based on the signal 
ratio of channel-2 to channel-1 (Ch2:Chl; Cy5 and Cy3 signals, respectively).
Figure 2.13: An example of an overlaid image generated after microarray scanning 
and analysis using the BlueFuse Software. Scanned images for Cy3 and Cy5 were 
imported into BlueFuse programme. Background and artefact signals were exeluded and 
signals for each microarray spot quantified based on the spot coordinates.
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Figure 2.14: An example of a scatter plot generated after microarray scanning and analysis 
using the BlueFuse Software. The labelled cDNA from P19CL6 cells and mouse embryo were 
hybridised onto a microarray, which was then scanned. Cy3 and Cy5 signals (Chl and Ch2, 
respectively) were quantified for each microarray spot and spots were given a colour flag, ranging 
from red, orange, blue, light blue, and green representing confidence values from 0-1. Finally, the 
distribution of spots was plotted based on the signal ratio of P19CL6-Cy3 and mouse embryo-Cy5.
2.2.8.S Data analysis
2.2.8.5.1 Normalisation and filtering of microarray data
A number of statistical algorithms have been developed to normalise microarray data 
and to control for experimental variations (Goldsmith and Dhanasekaran, 2004). The 
procedure was optimised by self-against-self hybridisation of P19CL6 cDNA labelled 
with both Cy3 and Cy5, according to the HGMP protocols. In order to analyse 
microarray data, the Excel-type output data generated by BlueFuse software was imported 
into the Gene Spring-7 programme (Silicon Genetics; Redwood City, USA). For the all 
arrays, Cy3 signal (test signal) was compared with Cy5 signal (control signal), therefore, 
the gene expression levels were expressed as the Cy3:Cy5 signal ratio. Microarray data 
were then analysed in several steps. First, the intensity-dependent per spot and per chip 
normalisation, often called non-linear or LOWESS normalisation, was performed on each
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array. Normalisation eliminated dye-related artefacts and corrected artefacts caused by 
non-linear rates of dye incorporation as well as inconsistencies in the relative 
fluorescence intensity between Cy3 and Cy5 dyes. Since such artefacts often result in a 
curve in the graph of raw (test signal) versus control signal, normalisation fits a straight 
line through the data and adjusts the control value for each spot. In addition, a dye-swap 
technique, used in the experimental loop design minimised the differences in Cy3 and 
Cy5 incorporation (Goldsmith and Dhanasekaran, 2004).
After normalisation, the data set was filtered to eliminate the spots with low quality. 
Filtering was performed based on “filter on flags” and “filter on data file” methods, the 
latter was applied in two steps including “filter on uniformity” and “filter on circularity”. 
For all experiments, spot uniformity and circularity were restricted at being greater 
than 0.5 (out of 1.0) in at least 50% of the arrays. Data normalisation and filtering were 
first performed on the self-against-self hybridisation experiment (Fig. 2.15 A) in order to 
optimise the procedures. Normalisation and filtering eliminated the spots with low quality 
and generated a scatter plot representing acceptable data (Fig. 2.15B).
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Figure 2.15: Illustration of the scatter plots for the self-against-self hybridisation of 
P19CL6 cells before (A) and after (B) data normalisation and filtering. RNA template was 
isolated from P19CL6 cells and divided into two aliquots that were labelled with Cy3 and Cy5 
dye, respectively. Targets were mixed and hybridised on a single array. The array was scanned 
and the image analysed. Data was normalised based on the intensity-dependent per spot and per 
chip normalisation method and filtered according to the flag statues, spot uniformity and spot 
circularity. The scatter plots of self-hybridisation experiment were generated (A) before and (B) 
after data normalisation and filtering processes.
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Once normalisation and filtering was completed, a scatter plot was generated to 
demonstrate the relative distribution pattern of gene expression levels, where X- and 
Y-axes represent Cy5 (control) and Cy3 (test) channels, respectively (Fig. 2.16). Spots 
were expressed in different colours, based on Cy3:Cy5 signal ratio. Generally, the red 
spots represent the genes over-expressed in the sample labelled with Cy3, whereas the 
green spots indicate the genes under-expressed in the same sample, i.e. over-expressed in 
the sample that was labelled with Cy5 (Fig. 2.16). However, the majority of the genes, 
with Cy3:Cy5 signal ratio close to 1 (yellow spots), showed no differential expression. In 
order to demonstrate the genes with distinct changes in their expression levels, the cut-off 
point was defined at ±2-fold expression, therefore, the spots of the outer sides of ±2-fold 
gene expression lines were regarded as over- or under-expressed depending on the 
samples tested (Fig. 2.16).
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Figure 2.16: An example of scatter plot generated by GeneSpring-7 software to represent the 
gene expression levels based on Cy3:Cy5 signal ratio for P19CL6 vs H9C2(2-1). Samples 
were labelled with Cy-dyes and hybridised onto a microarray. The array was scanned and data 
normalised and filtered. A scatter plot was generated to demonstrate the relative distribution 
pattern of gene expression levels based on the Cy3:Cy5 signal ratio represented in different 
colours (arrow). Red and green colours represent up- and down-regulation of the genes in the test 
sample (Cy3-labelled), respectively. The cut-off point of significant changes in gene expression 
level was defined at ±2-fold changes.
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2.2.8.S.2 Linear modelling and cluster analysis of microarray data
The dual-hybridisation microarray data was analysed with a per-gene linear model, 
using the Live Linear Analysis of Micro Array programme (LLAMA) available on the 
MARIE:ExGen Consortium website (http://exgen.rna.umist.ac.uk/), to generate 
differential gene expression estimates between contrast pairs , i.e. Cy3:Cy5 ratios, in a 
log2 scale. The data produced by linear modelling was further analysed by a web-based 
Complete Linkage Clustering software (http://rana.lbl.gov/) (Eisen et al., 1998) to 
generate a pair-wise linkage clusters. Analysis formed a hierarchical cluster, which was 
visualised with TreeView software (http://rana.lbl.gov/) (Eisen et al., 1998). Microarray 
data was also used to perform principal component analysis (PCA) and to generate 
correlation matrix in order to estimate correlation of samples using SPSS for Windows 
(SPSS Inc., Chicago, USA).
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Chapter 3:
Characterisation of the P19CL6 cell-line
3.1 Introduction
Fatty acids and fibrates are able to regulate lipid-related genes expression in various 
cells (Mesa et al., 2004; Jump, 2004; Guo et al., 2001; Chapman, 2003). To determine 
the effect of fatty acids and fibrates on gene expression levels in cardiovascular cells the 
P19CL6 cell line, a clonal derivative of P19 mouse embryonal carcinoma cells (Habara- 
Ohkubo, 1996), was used as a cellular model for the cardiovascular system. During the 
course of various incubations of P19CL6 cells in the presence of DMSO, required for the 
differentiation of these cells into beating cardiomyocytes (Habara-Ohkubo, 1996; 
Skeijanc, 1999), it was noted that a “beating” phenotype was observed in some cultures, 
but not others. As one of the initial aims of this thesis was to investigate the effects of 
fatty acids and fibrates in cardiomyocytes it was imperative that the cell-type being used 
was both correctly characterised and cultured under the correct conditions to facilitate 
beating.
There are several potential reasons for not observing the “beating” phenotype, 
namely that; (a) the cells display a “mixed” phenotype, (b) have lost their cardiomyocyte 
properties, (c) cell density is too low or (d) the cell culture media affects the cells. These 
phenomena have been observed in other cell culture systems. For example, the 
H9C2(2-1) cell line was derived from H9C2 embryonic rat heart tissue, and was initially 
described to have skeletal muscle cells properties (Kimes and Brandt, 1976). However, 
subsequent investigations showed that these cells also exhibited a cardiomyocyte-specific 
subtype of calcium channel (Hescheler et al., 1991; van Nieuwenhoven et al., 1998). 
Furthermore, the properties of the Caco-2 enterocyte model system have been shown to 
be passage-dependent (Yu et al., 1997). In terms of the cell culture media it is known that 
adrenaline affects the “beating” of P19CL6 cells (van der Heyden and Defize, 2003; 
McBumey et al., 1982; Faquin et al., 2002; Takahashi et al., 2003) and therefore the 
serum used to make the culture media could affect cell characteristics.
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In view of this finding, the aim of these studies was to characterise the P19CL6 cells in 
more depth, with the specific objectives and rationales as follows:
Objective 1: To measure the gene expression profiles of cardiac- and skeletal-muscle 
specific proteins, comparing PI9CL6 and H9C2(2-1) cells, mouse heart and skeletal 
muscle tissues.
Contractile muscle cells consist of thick and thin filament proteins, which are 
responsible for the striated appearance of cardiac and skeletal muscle myotubes (Gulick et 
al., 1991). Myosin heavy chain (MHO) is a member of a multigene family and a major 
protein in the thick muscle filaments (Robbins et al., 1986; Metzger et al., 1995). The 
distribution of MHC isoforms in different tissues is cell type-specific (Gulick et al., 
1991), with cardiac isoforms (a-MHC and p-MHC) predominantly expressed in the 
heart (Gulick et al., 1991; Metzger et al., 1995). Likewise, myosin light chain-2 (MLC2), 
atrial natriuretic factor (ANF), and cardiac isoform of voltage-dependent a-calcium 
channel (CaCh-h) are known as cardiac-specific genes (Fassler et al., 1996). On the other 
hand, the skeletal muscle-specific isoform of the a-calcium channel (CaCh-m) and the 
genes encoding myogenic regulatory factors MyoD and Myogenin, are expressed only in 
skeletal muscle cells and are required for skeletal muscle formation and 
myogenesis (Sabourin and Rudnicki, 2000; Buckingham, 2001; Fassler et al., 1996). 
Thus, in this study the mRNA expression levels of cardiac- (a-MHC, P-MHC, MLC2, 
ANF, and CaCh-h) and skeletal muscle-specific genes (MyoD, Myogenin and CaCh-m) 
was used to characterise the P19CL6 cells, comparing them to H9C2(2-1) cells, and also 
mouse heart and skeletal muscle tissue.
Objective 2: Determine whether the “beating” characteristic of P19CL6 cells is 
dependent on passage number.
The morphogenic appearance, growth rate, gene expression profile, and endocrine 
function of some cells e.g. Caco-2 enterocyte, SaOS-2 osteoblast-like, and FRTL-5 
thyroid cells is known to be passage-dependent (Green et al., 2001; Arkell and Jackson, 
2003; Gao et al., 2002; Yu et al., 1997). Since P19CL6 cells are relatively poorly 
characterised, it was important to investigate the effect of passage number on the 
“beating” characteristic of PI 9CL6 cells.
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Objective 3: Ascertain the effect of foetal bovine serum (FBS) and adrenaline on the 
“beating” characteristic of PI 9CL6 cells.
Foetal bovine serum contains a variety of nutrients required for cell growth and 
development, and differences in the composition or concentration of these nutrients may 
affect cellular differentiation and gene expression profiles (van der Heyden and Defize, 
2003; Skeijanc, 1999; Takahashi et ak, 2003; Nag et al., 1985; Wilton and Skeijanc, 
1999). In addition, vitamins and hormonal content of culture media such as ascorbic acid, 
adrenaline, oxytocin, and thyroid hormones (T3), have been reported to act as potent 
inducers of cell differentiation and beating in cardiomyocytes (Habara-Ohkubo, 1996; 
van der Heyden and Defize, 2003; Paquin et al., 2002; Takahashi et al., 2003; Rodriguez 
et al., 1994; Pennec et al., 2002; Wobus et al., 1994). Therefore, the effect of different 
FBS samples was investigated to determine whether different batches affected the growth 
characteristics, e.g. “beating” phenomenon of P19CL6 cells. In addition, the effect of 
adrenaline on the “beating” phenotype of PI 9CL6 cells was investigated in more detail.
Objective 4: To use microscopic cell biology techniques to characterise the P19CL6 
cells.
P19-derived cardiomyocytes are mono-nucleated cells (Skeijanc, 1999), while 
skeletal muscle cells propagate as mono-nucleated myoblasts and, with time, begin to 
form multi-nucleated tubular structures (Kimes and Brandt, 1976; Skeijanc, 1999). 
Microscopic analysis, including nuclear staining, was used to differentiate between the 
potentially cardiac-like or skeletal muscle-like phenotype of P19CL6 cells.
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3.2 Comparison of gene expression profiles of cardiac- and 
skeletal muscle-specific genes in P19CL6 and H9C2(2-1) 
cell-Iines
3.2.1 Rationale
A review of the literature on cell culture conditions for P19CL6 and P I9 cells 
showed that essentially two conditions were used in the culture of these cells (Habara- 
Ohkubo, 1996; Morley and Whitfield, 1993; van der Heyden et ak, 2003; van der Heyden 
and Defize, 2003; Skeijanc, 1999). The efficiency and rate at which P19 embryonic cells 
can be induced to differentiate into beating cardiomyocytes has been shown to vary 
according to the differentiation protocol (Anisimov et ak, 2002). The original paper 
describing the isolation of PI9CL6 cells and characterising them as cardiomyocytes used 
adherent culture conditions (Habara-Ohkubo, 1996). However, a substantial number of 
papers, especially those related to investigation with P19 cells (van der Heyden et ak, 
2003; van der Heyden and Defize, 2003; Skeijanc, 1999; McBumey, 1993) used 
non-adherent conditions {i.e. growth on agar plates to produce cell aggregates) before 
re-plating under adherent conditions (Smith et ak, 1987; van der Heyden et ak, 2003; 
Skeijanc, 1999). In this investigation, both adherent and non-adherent culture conditions 
were studied to establish their effects on gene expression levels.
3.2.2 Results
Separation of RT-PCR products by agarose gel electrophoresis showed that GAPDH, 
a house-keeping gene (Ullmannova and Haskovec, 2003), was detected in both P19CL6 
and H9C2(2-1) cells cultured under adherent conditions, thus confirming the presence of 
mRNA in the samples tested (Fig. 3.1). Under adherent conditions, P19CL6 cells 
expressed the cardiac-specific gene a-MHC, but not p-MHC, whereas H9C2(2-1) cells 
did not express either MyoD or Myogenin, which are specific to skeletal muscle cells, 
under the same conditions (Fig. 3.1). Similar results were produced when the experiment 
was repeated (data not shown).
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Likewise, the detection of nested PCR products showed expression of GAPDH in 
both P19CL6 and H9C2(2-1) cells, although, multiple PCR products for GAPDH were 
detected (Fig. 3.2), indicating poor specificity of the GAPDH primers. Therefore new 
primers were designed for detecting GAPDH expression levels in further experiments. 
Under adherent conditions, P19CL6 cells expressed the cardiac-specific genes a-MHC
GAPDH a-M H C p-MHC MyoD M y o g en in
500 bp 
400  bp
300 bp ' f  "' ' t200bp
Figure 3.1: Expression of a-MHC, P-MHC, MyoD and Myogenin in (A) P19CL6 and 
(B) H9C2(2-1) cells, cultured under adherent conditions on exposure to 1% DMSO, as 
detected by RT-PCR. Cells were cultured under adherent conditions for 15 days in the 
presence of 1% DMSO. Total RNA was isolated and mRNA levels determined by RT-PCR 
using gene-specific primers (Table 2.1). Theoretical sizes of gene-specific PCR products 
were: GAPDH: 362 bp; a-MHC: 302 bp; p-MHC: 513 bp; MyoD: 392 bp; Myogenin: 
337 bp, as shown by arrows.
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Figure 3.2: Expression of a-MHC, P-MHC, MyoD and Myogenin in (A) P19CL6 and 
(B) H9C2(2-1) cells, cultured under adherent conditions on exposure to 1% DMSO, as 
detected by nested PCR. Cells were cultured under adherent conditions for 15 days in the 
presence of 1% DMSO. Total RNA was isolated and mRNA levels determined by RT-PCR 
followed by nested PCR using gene-specific primers (Table 2.2). Theoretical sizes of 
gene-specific PCR products were: GAPDH: 275 bp; a-MHC: 302 bp; P-MHC: 410 bp; 
MyoD: 392 bp; Myogenin: 337 bp, as shown by arrows.
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and p-MHC, as well as the skeletal muscle-specific markers MyoD and Myogenin, 
whereas H9C2(2-1) cells expressed only MyoD and Myogenin under the same conditions 
(Fig. 3.2).
In the P19CL6 cells cultured for 15 days under non-adherent conditions, expression 
of cardiac-specific a-MHC and p-MHC as well as skeletal muscle-specific genes (MyoD 
and Myogenin) was observed under all conditions, independent of the presence or 
absence of DMSO (Fig. 3.3). A time-dependent gene expression profile of P19CL6 cells 
cultured under non-adherent conditions showed expression of GAPDH occurred at all 
time points throughout the incubation period, confirming the presence of mRNA in the 
samples (Fig. 3.4). Under these conditions, P19CL6 cells expressed cardiac-specific 
genes (a-MHC and P-MHC) and skeletal muscle markers (MyoD, and Myogenin) at all 
time points.
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Figure 3.3: Expression of a-MHC, P-MHC, MyoD and Myogenin in P19CL6 cells 
cultured under non-adherent conditions, as determined by nested PCR. P19CL6 cells 
were cultured on petri dishes in the presence of either differentiation (with DMSO) or normal 
culture media, i.e. DM and NCM, respectively. After four days, the aggregated cells were 
transferred into standard tissue culture flasks and incubated for 15 days with either DM or 
NCM. RNA was isolated from the cells at the end of the 15 days incubation period and 
mRNA levels determined by RT-PCR followed by nested PCR, using gene-specific primers 
(Table 2.2). Theoretical sizes of gene-specific PCR products were; GAPDH: 413 bp; 
a-MHC: 302 bp; P-MHC: 410 bp; MyoD: 392 bp; Myogenin: 337 bp, as shown by arrows.
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A semi-quantitative estimation of gene expression levels, relative to GAPDH 
expression, showed that the expression of a-MHC, P-MHC, MyoD and Myogenin 
increased up to day-9 and then decreased (Fig. 3.5). The lowest relative gene expression 
levels were observed on day-3, whereas the highest values were displayed on day-9. In 
addition, relative expression of a-MHC and p-MHC was higher than MyoD and 
Myogenin at all time points. Moreover, unlike differences in the expression levels of 
a-MHC and p-MHC, the skeletal-specific genes (MyoD and Myogenin) were expressed 
at similar levels between day 7 and day 15 (Fig. 3.5).
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Figure 3.4: Expression of a-MHC, p-MHC, MyoD, and Myogenin in P19CL6 cells 
cultured under non-adherent conditions, as determined by nested PCR. P19CL6 cells 
were cultured on petri dishes in the presence of 1% DMSO. After four days, the aggregated 
cells were transferred into standard tissue culture flasks and incubated for 15 days with 
differentiation media (DM). Cells were collected by scraping into 1 ml phosphate buffered 
saline (PBS) on time points of day 3, 7, 9, 12, and 15. RNA was isolated from the cells and 
mRNA levels determined by RT-PCR followed by nested PCR, using gene-specific primers 
(Table 2.2). Theoretical sizes of gene-specific PCR products were: GAPDH: 413 bp; a-MHC: 
302 bp; P-MHC: 410 bp; MyoD: 392 bp; Myogenin: 337 bp, as shown by arrows.
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Figure 3.5: Time course effect of incubation period on the expression of a-MHC, 
P-MHC, MyoD, and Myogenin in P19CL6 cells cultured under non-adherent 
conditions, as determined by nested PCR. P19CL6 cells were cultured on petri dishes in 
the presence of 1 % DMSO. After four days, the aggregated cells were transferred into 
standard tissue culture flasks and incubated for 15 days with differentiation media (DM). 
Cells were collected by scraping into 1 ml phosphate buffered saline (PBS) on time points of 
day 3, 7, 9, 12, and 15. Total RNA was isolated from the cells and mRNA levels deterrnined 
by RT-PCR followed by nested PCR, using gene-specific primers (Table 2.2). PCR products 
were separated on 2% agarose gel and the gel photographed. The image was digitised using 
Scion Image programme to obtain a semi-quantitative estimation of gene expression levels,
relative to GAPDH expression. Figure shows data from a single experiment. HI a-MHC;
S  P-MHC; C  MyoD; D  Myogenin
3.3 Determining gene expression profiles of a-MHC, P-MHC, 
MyoD and Myogenin in mouse heart and skeletal muscle 
tissues
3.3.1 Rationale
Previous work has shown that the expression of mouse cardiac myosin heavy chain 
isoforms (a-MHC and P-MHC) is restricted to contracting cardiac myocytes (Metzger et 
al., 1995; Morkin, 2000; Skeijanc, 1999), whereas regulation of skeletal muscle 
differentiation centers mainly on a family of transcription factors including MyoD and 
Myogenin (Edmondson and Olson, 1989; Yun and Wold, 1996; Buckingham, 2001; 
Black et al., 1995). Since a-MHC, p-MHC, MyoD and Myogenin mRNA was detected 
in P19CL6 cells, it was important to check the stringency of primers in mouse heart and 
skeletal muscle tissues.
3.3.2 Results
The expression of cardiac-specific genes, a-MHC and P-MHC, was detected in 
mouse heart tissue by RT-PCR (Fig. 3.6). In contrast, the skeletal muscle tissue did not 
express skeletal muscle-specific genes, MyoD and Myogenin, under the PCR conditions 
used (Fig. 3.6). Similar results were produced when the experiment was repeated (data 
not shown). These results could be explained by very low levels of mRNA for these 
genes, and therefore nested PCR was used to further amplify these signals. The detection 
of nested PCR products confirmed the expression of a-MHC and p-MHC in the heart 
tissue, while, under these conditions the expression of both MyoD and Myogenin was 
also apparent (Fig. 3.7). Similarly, skeletal muscle tissue displayed expression of MyoD 
and Myogenin (skeletal muscle-specific genes) as well as a-MHC and p-MHC 
(cardiac-specific genes).
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Figure 3.6: Detection of a-MHC, P-MHC, MyoD and Myogenin in mouse heart and 
skeletal muscle tissue, as determined by RT-PCR. Heart and skeletal muscle tissues were 
dissected from 10 weeks old GDI wild type (+/+) male mice. Total RNA was extracted and 
gene expression levels determined by RT-PCR using gene-specific primers (Table 2.1). 
RT-PCR products were separated on 2% agarose gel containing ethidium bromide and gel 
photographed. Theoretical sizes of gene-specific PCR products were: GAPDH: 556 bp; 
a-MHC: 491 bp; p-MHC: 587 bp; MyoD: 513 bp; Myogenin: 608 bp, as shown by arrows.
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Figure 3.7: Expression of a-MHC, P-MHC, MyoD and Myogenin in mouse heart and 
skeletal muscle tissue, as determined by nested PCR. Heart and skeletal muscle tissues were 
dissected from 10 weeks old GDI wild type (+/+) male mice. Total RNA was extracted and 
gene expression levels determined by RT-PCR followed by nested PCR using gene-specific 
primers (Table 2.2). PCR products were separated on 2% agarose gel containing ethidium 
bromide and gel photographed. Theoretical sizes of gene-specific PCR products were: 
GAPDH: 413 bp; a-MHC: 302 bp; p-MHC: 410 bp; MyoD: 392 bp; Myogenin: 337 bp, as 
shown by arrows.
3.4 Determining gene expression profiles of ANF, MLC2, 
CaCh-h, and CaCh-m in P19CL6 cells, mouse heart and 
skeletal muscle tissues
3.4.1 Rationale
Since the outcome from the investigation of a-MHC, P-MHC, MyoD, and Myogenin 
genes was inconclusive, the expression of other genes was examined. These were atrial 
natriuretic factor (ANF) and myosin light chain-2 polypeptide (MLC2) as well as cardiac 
(CaCh-h) and skeletal muscle (CaCh-m) isofonus of voltage-dependent L-type calcium 
channel (Fassler et ak, 1996).
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3.4.2 Results
RT-PCR analysis confirmed that mouse heart tissue expressed the cardiac-specific 
genes including a-MHC, p-MHC, ANF, MLC2, and CaCh-h (Fig. 3.8). Under these 
conditions, the expression of a-MHC and P-MHC was not detected in skeletal muscle 
tissue and several faint bands were observed in a-MHC and p-MHC lanes that were 
different from the theoretical target sizes of the respective genes (Fig. 3.8), although 
expression of these genes was previously confirmed in skeletal muscle tissue by nested 
PCR (Fig. 3.7). Unlike a-MHC and P-MHC, the expression of ANF, MLC2, and CaCh-h 
was observed in the skeletal muscle tissue under conditions examined (Fig. 3.8).
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Figure 3.8: Expression of a-MHC, p-MHC, ANF, MLC2 and CaCh-h in mouse heart, 
skeletal muscle tissue and P19CL6 cells, as detected by RT-PCR. Heart and skeletal 
muscle tissues were dissected from 10 weeks old CDl wild type (+/+) male mice and 
total-RNA was extracted from tissues as well as cultured P19CL6 cells, as indicated in 
Materials and Methods. Gene expression levels were determined by RT-PCR, using 
gene-specific primers (Table 2.1). PCR products were separated on 2% agarose gel 
containing ethidium bromide and gel photographed. Theoretical sizes of gene-specific PCR 
products were: GAPDH: 556 bp; a-MHC: 302 bp; P-MHC: 205 bp; ANF: 203 bp; MLC2: 
189 bp; and CaCh-h: 183 bp, as shown by arrows.
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In keeping with mouse heart and skeletal muscle tissues, P19CL6 cells expressed the 
CaCh-h gene, but again, the expression of a-MHC and p-MHC and other cardiac-specific 
genes (ANF and MLC2) was undetectable in the P19CL6 cells by RT-PCR (Fig. 3.8), 
although expression of a-MHC and p-MHC was previously confirmed in P19CL6 cells 
by nested PCR (Fig. 3.2, Fig. 3.3 and Fig. 3.4). Similar results were observed when the 
experiment was repeated (data not shown), confirming the expression of all 
cardiac-specific genes in the heart tissue, ANF, MLC2, and CaCh-h in skeletal muscle, 
and CaCh-h in P19CL6 cells. Examination of the cardiac and skeletal muscle isoforms of 
L-type calcium channel showed that mouse heart and P19CL6 cells expressed only the 
cardiac isoform (CaCh-h), whereas skeletal muscle tissue expressed both cardiac and 
skeletal muscle isoforms (Fig. 3.8 and Fig. 3.9).
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Figure 3.9: Expression of cardiac and skeletal muscle isoforms of voltage-dependent 
calcium channel (CaCh-h and CaCh-m, respectively) in mouse tissues and P19CL6 cells, 
as detected by RT-PCR. Heart and skeletal muscle tissues were dissected from 10 weeks 
old CDl wild type male mice (+/+) and RNA was isolated from tissues as well as cultured 
P19CL6 cells. Gene expression was determined by RT-PCR and PCR products separated on 
2% agarose gels containing ethidium bromide. The primers used are described in Table 2.1 
and theoretical sizes of gene-specific PCR products were: GAPDH: 556 bp; CaCh-h: 183 bp; 
and CaCh-m: 204 bp, as shown by arrows.
3.5 DNA sequencing of PCR products and sequence 
comparison
3.5.1 Rationale
RT-PCR and nested PCR analysis showed that certain cardiac-specific and skeletal 
muscle-specific genes, e.g. a-MHC, p-MHC, MyoD, and Myogenin, were expressed in 
P19CL6 cells. Since this finding had not previously been reported the validity of the 
results was checked by confirming the sequence identity of the PCR products.
3.5.2 Results
PCR product sequences were compared to the known gene sequences published in 
NCBI GenBank database, as shown for MyoD (Fig. 3.10), to determine the identity of 
PCR products in relation to known sequences. Identity was fiirther confirmed by 
comparison of the PCR product sequences to the Mouse musculus Genome database and
MyoD TCTGCAGGCTCTGCTGCGCGACCAGGACGCCGCGCCCCCTGGCGCCGCTGCCTTCTACGC 536
S am ple — TGCAGGCTCTGCTGCGCGACCAGGACGCCGCGCCCCCTGGCGCCGCTGCCTTCTACGC 91
**********************************************************
MyoD ACCTGGACCGCTGCCCCCAGGCCGTGGCAGCGAGCACTACAGTGGCGACTCAGACGCGTC 596
S am ple ACCTGGACCGCTGCCCCCAGGCCGTGGCAGCGAGCACTACAGTGGCGACTCAGACGCGTC 151
* * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * *
MyoD CAGCCCGCGCTCCAACTGCTCTGATGGCATGATGGATTACAGCGGCCCCCCAAGCGGCCC 655
S am ple CAGCCCGCGCTCCAACTGCTCTGATGGCATGATGGATTACAGCGGCCCCCCAAGCGGCCC 211
* * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * *
MyoD CCGGCGGCAGAATGGCTACGACACCGCCTACTACAGTGAGGCGGTGCGCGAGTCCAGGCC 714
Sam ple CCGGCGGCAGAATGGCTACGACACCGCCTACTACAGTGAGGCGGTGCGCGAGTCCAGGCC 271
* * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * *
MyoD AGGGAAGAGTGCGGCTGTGTCGAGCCTCGACTGCCTGTCCAGCATAGTGGAGCGCATCTC 774
S am ple AGGGAAGAGTGCGGCTGTGTCGAGCCTCGACTGCCTGTCCAGCATAGTGGAGCGCATCTC 331
* * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * *
MyoD - CACAGACAGCCCCGCTGCGCCTGCGCTGCTTTTGGCAGATGCACCACCAGAGTCGCCT 834
S am ple CACAGACAGCCCCGCTGCGCCTGCGCTGCTTTTGGCAGATGCACCACCA-----------------  382
* * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * *
Figure 3.10; An illustration of a sequence alignment for a PCR product and the targeted 
gene sequences. The DNA sequence of the nested PCR product was compared to the MyoD 
sequence, as obtained from NCBI, taking into account the positions of the PCR primers 
utilised, using the ClustalW sequence alignment software. The figure shows that the 382 bp 
PCR product (sample) is 100% identical to the Mouse musculus MyoD mRNA in the region 
starting and finishing at nucleotides 477 bp and 834 bp, respectively, based on the positions of 
the PCR primers utilised. The numbers indicated on the right-hand side relate to the nucleotide 
number relative to the start of the gene.
95
ranged from 93% to 100% (Table 3.1). This was considered to be acceptable in terms of 
identity between the published sequences and those obtained from the PCR experiments. 
Therefore, the PCR products were clearly related to the target genes used in the design of 
primers.
Table 3.1: Identity of PCR product sequences to those of target genes.
S o u r c e P 1 9 C L 6  c e i is
G e n e GAPDH a-MHC p-MHC MyoD Myogenin
Id e n ti ty 99% 99% 98% 100% 98%
S o u r c e H 9C 2(2-1) c e l ls
G e n e GAPDH a-MHC P-MHC MyoD Myogenin
Id e n ti ty 93% ND 96% 96%
S o u r c e M o u s e  H e a r t  T i s s u e
G e n e GAPDH a-MHC P-MHC MyoD Myogenin
. Id e n ti ty 99% 99% 99% 98% 98%
S o u r c e M o u s e  S k e le ta l  M u s c le  T i s s u e
G e n e GAPDH a-MHC P-MHC MyoD Myogenin
id e n ti ty 99% 99% 98% 98% 98%
ND: No primer products detected by agarose gel electrophoresis.
3.6 Investigating the effect of FBS, passage number and 
adrenaline on the ‘^ beating” phenotype of P19CL6 cells
3.6.1 Rationale
The effect of culture media on heart cell growth and proliferation has been reported 
previously (Nag et al., 1985; Habara-Ohkubo, 1996; van der Heyden and Defize, 2003; 
Paquin et al., 2002). There was therefore evidence to suggest that FBS could influence 
cellular differentiation and gene expression in P19CL6 cells. In addition, the growth rate, 
gene expression, and function of some cells is passage-dependent (Green et al., 2001; 
Arkell and Jackson, 2003; Gao et al., 2002; Yu et al., 1997) and therefore passage number
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could affect the phenotype of the P19CL6 cells. Furthermore, vitamins and hormones 
may induee cell differentiation in cardiomyocytes and in particular, the effect of 
adrenaline on P19CL6 cells has been established (Habara-Ohkubo, 1996; Nag et al., 
1985; Pennec et al., 2002). Therefore, the effect of FBS, passage number and adrenaline 
on the “beating” characteristic of PI 9CL6 eells was investigated.
3.6.2 Results
Beating was observed mainly in localised areas with a high eell density (“islets”) 
independent of FBS type but only in passages 12-16 (Table 3.2). Beating was first 
observed on day-12, and pulse rates (beats/min) were measured on day-15. Pulse rates 
ranging from 17-41 beats per minute were recorded (Table 3.2). Statistical analysis 
showed that the “beating” phenotype was independent of the FBS used and was likely to 
be dependent on passage number (Table 3.2 and Fig. 3.11).
Table 3.2: Comparison of pulse rate observed in P19CL6 cells cultured with different FBS 
samples.
Media
type
Pulse Rate (Mean ± SD)
P12 P13 P14 P15 P16 P17-22
DM1 30.6+6.6 (n=3) 33 (n=1) 26, 29 (n=2) 27+5.3 (n=3) 23+2.6 (n=3) ND
DM2 29,41 (n=2) 30.3+1.5 (n=3) 26±5.1 (n=4) 24 (n=1) 23, 21 (n=2) ND
DM3 30, 32 (n=2) 28.3±4 (n=3) 37, 23 (n=2) 23±2.6 (n=3) 1 8 ,18(n=2) ND
DM4 33.7+3.5 (n=4) 27, 29 (n=2) 23 (n=1) 25.3+4 (n=3) 23.315.6 (n=3) ND
FBS from four different batches (DM1-DM4) was used to prepare differentiation media. Pulse rate was recorded as 
beats per min. Data are shown as Mean ± Standard Deviation. PI2: passage number; ND: not detected; n: number 
of localised beating areas in the wells.
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Figure 3.11: Determination of the effect of different FBS batches on the “beating” 
characteristic in P19CL6 cells cultured under adherent conditions. P19CL6 cells from 
different passage numbers (12-16) were cultured in the presence of 1% DMSO under 
adherent conditions using different FBS samples DM1-DM4 referring to media made up 
with four different FBS samples. Pulse rate (beats/min) was recorded on day-15 of 
incubation. Two-Way between-groups ANOVA analysis showed no significant difference 
between the FBS samples used.
Beating was observed only in passages 12-16 (Table 3.2). The lowest pulse rate 
(17 beats per min) was observed in passage 16, while passage 12 displayed the highest 
pulse rate (41 beats per min) and beating was never observed in passage 17 or above. 
Statistical analysis confirmed that the passage number of the P19CL6 cells had a 
significant effect on the “beating” phenotype (Fig. 3.12). Regression analysis showed an 
inverse correlation of pulse rate with passage number and a significant reduction of pulse 
rate with increasing passage number in P19CL6 cells (P<0.001) (Fig. 3.12). In addition, a 
Two-Way ANOVA revealed significant differences (P<0.01) between the passages 
examined. However, there was no significant effect of FBS on passage number, i.e. there 
was no significant effect of FBS on pulse rate in P19CL6 cells from different passage 
numbers.
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Figure 3.12: Determination of the effect of passage number on “beating” characteristic in 
P19CL6 cells cultured under adherent conditions. The data shown in Table 3.2 has been 
plotted. A linear regression analysis of correlation between pulse rate and passage number 
showed a significant effect of passages number on pulse rate (y= -2.58x +63.3, R^=0.486, 
P<0.001). Two-Way ANOVA between-groups analysis confirmed significance difference 
between the different passage numbers of P19CL6 cells (P<0.01). a, b, and c represent 
passages with significant difference in the pulse rate of P19CL6 cells.
Beating was observed in P19CL6 cells cultured under adherent conditions with 
adrenaline concentrations ranging from 0-20 pM and pulse rates (pulses/min) were 
measured on day-15 (Table 3.3). Synchronous beating was observed on day 15 in a large 
culture area in the cells cultured with 20 pM adrenaline. Statistical analysis showed that 
pulse rate in P19CL6 cells correlated with the adrenaline concentration, and increased 
significantly (P<0.001) with increasing concentration (Fig. 3.13). In addition, One-Way 
ANOVA between-group analysis confirmed significant differences in the pulse rate of 
P19CL6 cells cultured with different adrenaline concentrations (Fig. 3.13).
Table 3.3: Effect of adrenaline on the beating phenotype of P19CL6 cells
P u ls e  R a te  (M ean  ±  SD)
0 pM 5 pM 10 pM 15 pM 20  p M t
23+ 7  (a7=9) 2 6+ 5 .9  (a7=9) 31+8 (A7=10) 40 + 8 .7  (a7=8) 44+4.6 (n=6)
P19CL6 cells from passage 12 were plated in 6-well plates in three biologieal repeats. Pulse rate was 
recorded as beats/min and data are shown as Mean ± Standard Deviation, n: number of localised beating 
areas in the wells; f: synchronous beating (cells from a large culture area were beating together).
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Figure 3.13: Determining the effect of different concentrations of adrenaline on 
“beating” in P19CL6 cells cultured under adherent conditions. P19CL6 cells 
(passage 12) were cultured with 0, 5, 10, 15, and 20 pM adrenaline under adherent 
conditions. Pulse rate (beats/min) was recorded on day-15 of incubation. Linear regression 
analysis showed a correlation of pulse rate with adrenaline concentration (y=l.lx+21.8, 
R^=0.541, P<0.001). One-Way ANOVA analysis confirmed a significant effect of 
adrenaline on pulse rate in P19CL6 cells (P<0.001). a, b, and c represent groups (adrenaline 
concentrations) with significant difference in the pulse rate of P19CL6 cells.
3.7 Microscopic examination of P19CL6 cells under adherent 
culture conditions for nuclei staining
3.7.1 Rationale
Cardiac and skeletal muscle cells display characteristic cell morphologies which can 
be assessed by light and/or fluorescence microscopy (Skerjanc, 1999; Rudnicki et ak, 
1990; Wilcox, 1993). P19-derived cardiomyocytes display a mononuclear morphology, 
whereas P19-derived skeletal muscle cells fuse to form multinucleated myotubes with 
time in culture (Skeijanc, 1999; van der Heyden et ak, 2003). As the outcome of previous 
PCR-based experiments to measure gene expression levels were equivocal in defining 
P19CL6 cells as cardiomyocytes, it was thought that microscopy may help to resolve their 
identity.
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3.7.2 Results
P19CL6 cells, cultured on coverslips under both adherent and non-adherent 
conditions, showed a mononuclear cell morphology with no cell fusion throughout 
15 days of incubation as observed by phase-contrast microscopy (Fig. 3.14) (Kimes and 
Brandt, 1976; Skerjanc, 1999). The mononuclear nature of the P19CL6 cells was 
confirmed by fluorescence microscopy, using a nuclear stain (Fig. 3.15).
0
0
Figure 3.14: Phase-contrast microscopy of P19CL6 and H9C2(2-1) ceils. PI9CL6 cells were 
cultured on petri dishes in the presence of 1% DMSO. After four days, the aggregated cells were 
cultured on coverslips, which were collected on different time points. Cells were fixed using 
para-formaldehyde and light micrographs were taken using 4Qx magnification (A) on day 6, and (B) 
day 15 of the incubation period. Single cells are shown in enlarged boxes to show cardiomyocyte 
morphology. H9C2(2-1) cells were cultured in 37 mm diameter culture plates for 15 days under 
adherent conditions. Phase contrast micrographs were taken using 4Qx magnification (C) on day-6 
before cell fusion and (D) day-15, when cells displayed multinucleated myotubes.
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Conversely, under phase-contrast microscopy, H9C2(2-1) cells cultured under 
adherent conditions propagated as myoblasts and, with time, began to form tubular 
structures (Fig. 3.14). However, the H9C2(2-1) cells cultured on coverslips did not form 
fused tubular structures and therefore the expected multinucleated morphology of these 
cells, a characteristic of skeletal muscle cells, could not be confirmed by fluorescence 
microscopy.
Figure 3.15: Nuclear staining of P19CL6 cells cultured under adherent conditions. P19CL6 
cells were cultured on eoverslips under adherent conditions in the presence of %1 DMSO. 
Coverslips were collected on different time points and fixed using para-formaldehyde. 
Coverslips were then immersed in Hoechst dye to stain nuclei. Coverslips were washed once 
with PBS and mounted on slides. Mieroscopic examination was performed at 400x 
magnification using a Zeiss Axiovert 135 TV fluorescent microscope (Carl Zeiss AG, 
Oberkochen, Germany) setting the excitation and emission filters at 365 nm and 420 nm, 
respectively. Slides were photographed using a Contax SLR-NX camera (Kyocera Yashica Ltd., 
Reading, UK). All P19CL6 cells showed a mononuclear morphology, as shown on (A) day-6 
and (B ) day-15 of the incubation.
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3.8 Discussion
The P19CL6 cell line, a derivative of P19 embryonal carcinoma cells, is widely used 
as an in vitro model of cardiovascular cells (Young et al., 2004; van der Heyden and 
Defize, 2003; van der Heyden et al., 2003; Peng et al., 2002; Anisimov et al., 2002; 
Paquin et al., 2002; Ridgeway et al., 2000; Monzen et al., 2001) that can differentiate into 
beating cardiomyocytes on exposure to DMSO (Habara-Ohkubo, 1996). During the 
course of various incubations of P19CL6 cells it was noted that the '"beating" phenotype 
was inconsistent between cultures. As one of the principal aims of this thesis was to 
investigate the effects of fatty acids and fibrates in cardiomyocytes, it was imperative that 
the cell-type being used was both correctly characterised and cultured under the correct 
conditions. Thus, the aim of this chapter was to characterise the P19CL6 cells in greater 
depth.
A review of the literature, focusing on P19CL6 and P19 cell culture conditions, 
showed that two separate methods are commonly used (Habara-Ohkubo, 1996; Morley 
and Whitfield, 1993; van der Heyden et al., 2003; van der Heyden and Defize, 2003; 
Skeijanc, 1999). The original paper that described the isolation of P19CL6 cells and 
characterised them as cardiomyocytes used adherent culture conditions (Habara-Ohkubo, 
1996). However, a substantial number of papers, especially those relating to P19 
cells (van der Heyden et al., 2003; van der Heyden and Defize, 2003; Skeijanc, 1999; 
McBumey, 1993), used non-adherent cell culture conditions {Le. growth on agar plates 
prior to re-plating under adherent conditions) (Smith et al., 1987; van der Heyden et al., 
2003; Skeijanc, 1999). In order to understand and define conditions under which the 
P19CL6 cells display a cardiomyocyte phenotype, different culture conditions were 
investigated. The expression of cardiac- and skeletal muscle-specific genes was 
investigated under both adherent and non-adherent culture conditions in order to define 
specific conditions for the culture of P19CL6 cardiomyocytes. Initially, the H9C2(2-1) 
skeletal muscle cell-line was used as a positive control for skeletal muscle 
phenotype (Kimes and Brandt, 1976), and later, mouse heart and skeletal muscle tissue 
were also examined.
Under adherent cell culture conditions, the detection of RT-PCR products showed 
that P19CL6 cells expressed the cardiac-specific a-MHC gene (but not p-MHC), whereas 
H9C2(2-1) cells did not expressed the skeletal muscle-specific MyoD and Myogenin
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genes (Fig. 3.1). Since the H9C2(2-1) cell-line has been previously characterised as a 
skeletal muscle cell-line (Kimes and Brandt, 1976) and therefore would be expected to 
express the skeletal muscle-specific genes, MyoD and Myogenin, it was likely that the 
mRNA levels were too low to be detected by RT-PCR, and therefore a second round of 
PCR amplification (nested PGR) was performed. The detection of nested PCR products 
showed that P19CL6 cells expressed a-MHC and P-MHC as well as MyoD and 
Myogenin, whereas H9C2(2-1) cells displayed expression of only MyoD and Myogenin 
under the same conditions (Fig. 3.2). Expression of the cardiac-specific a-MHC and 
p-MHC mRNA in the P19CL6 cells was expected as these cells have been previously 
characterised as cardiomyocytes (Habara-Ohkubo, 1996). Similarly, the expression of 
MyoD and Myogenin in H9C2(2-1) cells was also expected and this, to some extent, 
confirms the skeletal muscle phenotype of these cells (Kimes and Brandt, 1976; 
Edmondson and Olson, 1989; Sabourin and Rudnicki, 2000; Yun and Wold, 1996; 
Fujisawa-Sehara et al., 1990). However, in addition to the expression of a-MHC and 
p-MHC, expression of MyoD and Myogenin was also detected in P19CL6 cells 
(Fig. 3.2), which initially suggested that these cells may have a heterogeneous phenotype.
As the P19CL6 cells cultured under adherent conditions did not display the cardiac 
gene expression pattern that was expected, it was thought that aggregation might be 
required for the differentiation of P19CL6 cells into cardiomyocytes. Aggregation of P19 
cells is apparently required for their differentiation into cardiac, skeletal muscle, or neural 
cells (Armour et al., 1999; McBumey, 1993; Skeijanc, 1999; Skeijanc et al., 1994; Smith 
et al., 1987; van der Heyden and Defize, 2003; van der Heyden et al., 2003), and these 
cells do not differentiate efficiently if cultured on adherent solid glass or plastic 
surfaces (McBumey, 1993; Smith et al., 1987). Under non-adherent culture conditions, 
consistent expression of cardiac- (a-MHC and P-MHC) and skeletal muscle-specific 
genes (MyoD and Myogenin) was observed under different culture conditions after 15 
days in the presence or absence of DMSO (Fig. 3.3). Since a mixed phenotype was 
observed under all conditions, the time-dependent experiment of these genes was 
investigated. The purpose of this experiment was to determine whether the P19CL6 cells 
express only a-MHC and P-MHC, and not MyoD and Myogenin, at the same time point 
during 15 days of incubation.
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P19CL6 cells consistently expressed a-MHC and p-MHC as well as MyoD and 
Myogenin throughout the incubation period, increasing up to day-9 and then decreasing. 
Moreover, on day-3 and day-9 the lowest and the highest relative expression levels were 
observed with all genes. In addition, the relative expression of a-MHC and P-MHC was 
higher than that of MyoD and Myogenin at all time points. Though these data could not 
be statistically validated (n=l), they indicate that the P19CL6 cells do not express only 
the cardiac-specific genes, i.e. a-MHC and P-MHC, at any time point of the incubation.
The effect of different culture conditions (adherent and non-adherent), incubation 
period (time-course) and presence or absence of DMSO showed that the P19CL6 cells 
may display a mixed phenotype. Therefore, other characteristics were investigated in 
order to validate the cardiac phenotype of the P19CL6 cells. The micronutrient levels in 
serum used to make the cell culture media could affect cell growth and 
differentiation (van der Heyden and Defize, 2003; Skeijanc, 1999; Takahashi et al., 2003; 
Nag et al., 1985; Wilton and Skeijanc, 1999), therefore the effect of FBS on “beating" 
characteristic of P19CL6 cells was examined. There was no significant difference in 
pulse rates with media prepared with four different FBS samples (Table 3.2 and 
Fig. 3.11). It is therefore reasonable to conclude that FBS itself does not directly affect 
the “beating" characteristics of P19CL6 cells. However, passage number of the P19CL6 
cells had a significant effect on the beating phenotype with an inverse correlation between 
passage number and pulse rate for passages 12 to 16 (Table 3.2 and Fig. 3.12). Above 
passage 16 no beating was observed in any cultures, suggesting that the P19CL6 cells 
lose their “beating" characteristic with increasing passage number and therefore the 
P19CL6 cells with the lower passage number are more likely to display a cardiac 
phenotype. However, Two-Way ANOVA showed no significant effect of FBS on 
passage number, i.e. there was no significant effect of FBS on pulse rate in P19CL6 cells 
fi-om different passage numbers.
Vitamins and hormones act as potent inducers of cell differentiation and beating in 
cardiomyocytes (Habara-Ohkubo, 1996; van der Heyden and Defize, 2003; Skeijanc, 
1999; Wobus et al., 1994; Takahashi et al., 2003; Nag et al., 1985; Rodriguez et al., 1994; 
Pennec et al., 2002). In particular, adrenaline has been shown to affect beating of the 
P19CL6 cells (Habara-Ohkubo, 1996; Pennec et al., 2002; Wobus et al., 1994), and 
therefore the effect of adrenaline on the “beating" phenotype of PI9CL6 cells cultured
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under adherent conditions was investigated. Beating was observed in the P19CL6 cells 
cultured with different concentrations of adrenaline, even in the absence of adrenaline, 
suggesting that P19CL6 cells may display “beating” characteristic of cardiomyocytes, 
since contraction in cardiomyocytes is triggered by changes in intracellular Ca^ "^  
concentration and does not require adrenaline (Katz and Lorell, 2000; Katz, 2001). In 
addition, a significant positive correlation between pulse rate and adrenaline 
concentrations was observed (Table 3.3 and Fig. 3.13) that can be explained by an 
increase in Ca^  ^conductance on exposure to adrenaline (Pennec et al., 2002).
The detection of cardiac- and skeletal muscle-specific genes in the P19CL6 cells 
together with the loss of the “beating” characteristics with increasing passage number 
suggests a cell-type with a mixed cardiac and skeletal muscle phenotype. However, 
drawing this conclusion requires validation of the data in two ways: (i) using the positive 
and/or negative controls, and (ii) confirming the identity of PCR product DNA sequences 
to known gene sequences. In order to compare the P19CL6 cells phenotype with positive 
and/or negative control samples, mouse heart and skeletal muscle tissues were used as 
representatives of the cardiac and skeletal muscle phenotypes.
Consistent expression of a-MHC, p-MHC, MyoD and Myogenin was detected in 
heart as well as skeletal muscle tissue (Fig. 3.7). This result was not expected, as heart 
tissue should express only a-MHC and P-MHC (Gulick et al., 1991; Metzger et al., 
1995), whereas skeletal muscle only expresses MyoD, and Myogenin (Sabourin and 
Rudnicki, 2000; Buckingham, 2001). Therefore, initially the expression of other 
cardiac-specific genes, such as atrial natriuretic factor (ANF) and myosin light chain-2 
polypeptide (MLC2) was used to characterise the cardiac and skeletal muscle phenotypes, 
with cardiac (CaCh-h) and skeletal muscle (CaCh-m) isoforms of voltage-dependent 
L-type calcium channel being included later in the study (Fassler et al., 1996). The 
expression of ANF and MLC2 was detected in heart as well as skeletal muscle tissue but 
not in P19C16 cells (Fig. 3.8). In addition, mouse heart tissue and P19CL6 cells 
consistently expressed only the CaCh-h (cardiac isoform), whereas skeletal muscle tissue 
showed expression of both CaCh-h and CaCh-m isoforms under the same conditions 
(Fig. 3.8 and Fig. 3.9). These results suggested that the expression of ANF, MLC2 and 
CaCh-h is not exclusive to cardiomyocytes and can be detected in skeletal muscle tissue. 
This conclusion is in line with our previous observations from a-MHC, p-MHC, MyoD
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and Myogenin gene expression that indicate both the cardiomyocytes and skeletal muscle 
myotubes may express cardiac- (a-MHC and P-MHC) and skeletal muscle-specific genes 
MyoD and Myogenin.
In order to confirm that PCR products were correct, they were extracted and 
sequenced. Comparison of GAPDH, a-MHC, P-MHC, MyoD, and Myogenin PCR 
product sequences to known gene sequences displayed 93%-100% identity, confirming 
that the DNA sequences of the PCR products were identical to those of the expected 
genes (Table 3.1). In other words, expression of supposedly cardiac- and skeletal 
muscle-specific genes was confirmed in both the heart and skeletal muscle tissues. This 
result may have implications for other work and needs to be rigorously investigated and 
confirmed, but this was not within the scope of this study. A bioinformatics approach 
utilising the Human Genome Bio-Information database (GeneCards, 
http://bioinfo.weizmann.ac.il/cards/index.shtml/) was used to explain the observed results. 
This database shows the expression pattern of a given gene in twelve different human 
tissues, based on microarray experiments (Shmueli et al., 2003; Yanai et al., 2004), and 
confirms that both heart and skeletal muscle tissue express a-MHC, p-MHC, MyoD and 
Myogenin (Fig. 3.16 and Fig. 3.17). The a-MHC and P-MHC mRNA expression level is 
detectable only in cardiomyocytes if a laboratory procedure such as RT-PCR is used, and 
therefore these genes are considered as cardiac-specific genes in the literature (Gulick et 
al., 1991; Metzger et al., 1995; Morkin, 2000). A similar explanation could also apply for 
MyoD and Myogenin as skeletal muscle-specific genes (Sabourin and Rudnicki, 2000; 
Buckingham, 2001; Fassler et al., 1996). However, more sensitive techniques, such as 
microarrays, showed that both heart and skeletal muscle tissue express a-MHC, P-MHC, 
MyoD and Myogenin {Human Genome Bio-Information database) (Fig. 3.16 and 
Fig. 3.17). Since the nested PCR technique used in this study was more sensitive than the 
technique used in the literature, i.e. RT-PCR, it is therefore reasonable to observe 
expression of MyoD and Myogenin in the heart tissue (and P19CL6 cells) or to detect 
a-MHC and p-MHC in the skeletal muscle cells (Fig. 3.3 and Fig. 3.7).
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Figure 3.16: Tissue-specific gene expression patterns obtained from the GeneCards 
database information for the expression of (A) a-MHC and (B) P-MHC in different 
human tissues. The expression of a given gene in twelve different human tissues is shown 
based on duplicate microarray analysis. BMR: born marrow; SPL: spleen; TMS: thymus; 
BRN: brain; SPC: spinal cord; HRT: heart; MSL: skeletal muscle; LVR: liver; PNC: 
pancreas; PST: prostate; KDN: kidney; LNG: lung.
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Figure 3.17: Tissue-specific gene expression patterns obtained from the GeneCards 
database information for the expression of (A) MyoD and (B) Myogenin in different 
human tissues. The expression of a given gene in twelve different human tissues is shown 
based on duplieate microarray analysis. BMR: born marrow; SPL: spleen; TMS: thymus; 
BRN: brain; SPC: spinal cord; HRT: heart; MSL: skeletal muscle; LVR: liver; PNC: 
pancreas; PST: prostate; KDN: kidney; LNG: lung.
Since the PCR-based experiments to investigate tissue-specific gene expression 
profiles in P19CL6 cells were inconclusive and did not clearly confirm the cardiac or 
skeletal muscle phenotype of P19CL6 cell-line, it was thought that the examination of cell 
morphology by light and fluorescence microscopy may provide some answers in this 
respect. A mononuclear cell morphology with no cell fusion throughout the incubation 
period was observed by phase-contrast microscopy in P19CL6 cells (Fig. 3.14) that was 
later confirmed by fluorescence microscopy, using a nuclear stain (Fig. 3.15). In contrast, 
H9C2(2-1) myoblasts cultured under adherent conditions, fused with time and formed 
tubular multinucleated structures, the characteristic morphology of skeletal muscle cells
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(Fig. 3.14) (Skeijanc, 1999; van der Heyden et al., 2003). These microscopy observations 
showed that the P19CL6 cells display a mononuclear morphology, as described for 
P19-derived cardiomyocytes (Skeijanc, 1999; Rudnicki et al., 1990; Wilcox, 1993), and 
therefore confirmed, to some extent, a cardiac phenotype of P19CL6 cells.
In conclusion, the techniques used here have not provided a “specific” answer in 
terms of whether P19CL6 cells show a cardiac, skeletal muscle or mixed phenotypes, and 
with respect to the tissue-specific gene expression profiles and microscopy observations 
of P19CL6 cells, it cannot be concluded that the P19CL6 cell-line is a pure cardiac 
cell-line. Therefore, as a next step, it was thought to compare global transcriptome levels 
in P19CL6 and H9C2(2-1) cells, as well as mouse cardiac and skeletal muscle tissues 
using microarray analysis to characterise the P19CL6 cells in greater depth.
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Chapter 4:
Characterisation of the P19CL6 cell-line by microarray 
analysis
4.1 Introduction
The P19CL6 cell-line, a sub-clone of P19 mouse embryonal carcinoma 
cells (Habara-Ohkubo, 1996), has been proposed to spontaneously contract after several 
days in culture with DMSO and display a pure cardiac muscle phenotype (Habara- 
Ohkubo, 1996; Hiroi et al., 2001; Hosoda et al., 2001; Young et al., 2004), but in the 
present study, spontaneous contraction was not consistently observed. Thus, the cardiac 
phenotype of P19CL6 cells was further investigated by determination of the expression 
level of cardiac- (a-MHC and p-MHC) and skeletal muscle-specific genes MyoD and 
Myogenin by PCR-based experiments, but the consistent expression of both cardiac- and 
skeletal muscle-specific genes was detected in the P19CL6 cells (Fig. 3.2; Fig. 3.3; 
Fig. 3.4). In addition, a significant reduction in pulse rate was observed in P19CL6 cells 
with increasing passage number, suggesting that the P19CL6 cells lose their “beating” 
characteristic with increasing passage number (Fig. 3.12 and Table 3.2). Collectively, 
these observations did not clearly define whether the P19CL6 cells show a cardiac, 
skeletal muscle or heterogeneous phenotype. Moreover, the literature on the 
differentiation of P19 mouse embryonal cells into cardiomyocytes showed that the 
P19-derived cardiomyocytes are embryonic in nature (Skeijanc et al., 1998; van der 
Heyden and Defize, 2003; Rudnicki et al., 1990; Skeijanc, 1999), and therefore, P19CL6 
cell-line could potentially display an embryonic phenotype as well. The aim of this 
chapter was to use cDNA microarray analysis as a tool to facilitate the further 
characterisation of the P19CL6 cells by investigation of global transcriptome levels with 
specific objectives and rationales as follows:
Objective 1: To establish whether the P19CL6 cell-line display global transcriptome 
levels similar to those of the H9C2(2-1) cell-line or mouse heart and skeletal muscle 
tissue.
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cDNA microarray can potentially be used to measure the expression level of 
thousands of genes and provides a global analysis of gene expression at the level of 
transcription (Goldsmith and Dhanasekaran, 2004; Simon et al., 2002). Phenotypic 
differences among cells of different types are determined by changes in the global 
expression profiles or “transcriptome” (Napoli et al., 2003; Goldsmith and Dhanasekaran, 
2004; Simon et al., 2002; Henriksen and Kotelevtsev, 2002), which provide evidence for 
the characterisation of different cell types (Goldsmith and Dhanasekaran, 2004; Clarke et 
al., 2004; Kawasaki, 2004). Therefore, a microarray analysis was performed to compare 
the global transcriptome in the P19CL6 cell-line with those of the H9C2(2-1) cells, 
characterised previously as skeletal muscle cells (Kimes and Brandt, 1976), and mouse 
cardiac and skeletal muscle tissues.
Objective 2: To compare gene expression profiles in the P19CL6 cell-line with those of 
mouse embryonic and adult heart tissues.
There is a wealth of evidence to confirm that embryonic and adult cardiomyocytes 
display different metabolic pathways (Lehman and Kelly, 2002; Makinde et al., 1998; 
Stanley et al., 2005; Lavrentyev et al., 2004), e.g. embryonic heart relies on glucose as a 
major source of energy whereas adult heart predominantly oxidise fatty acids (Lehman 
and Kelly, 2002; Makinde et al., 1998; Stanley et al., 2005; Lavrentyev et al., 2004) 
embryonic and adult heart therefore display different transcriptome profiles. Since the 
P19-derived cardiomyocytes are embryonic in nature (Skeijanc et al., 1998; van der 
Heyden and Defize, 2003; Rudnicki et al., 1990; Skeijanc, 1999), it was of interest to 
establish whether P19CL6 cells display a transcriptome similar to that of mouse 
embryonic or adult heart tissue.
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4.2 Validation of microarray procedures
4.2.1 Rationale
To optimise microarray normalisation and filtering procedures, a self-hybridisation 
experiment was performed by hybridisation of RNA isolated from P19CL6 cells labelled 
separately with Cy3 and Cy5 to a microarray slide. Normalisation and filtering were first 
performed on the self-hybridisation experiment, as indicated in Materials and Methods, 
and was subsequently applied to the other microarray hybridisations (Yu et al., 2002). 
This process standardised the microarray data and enabled comparison of relative gene 
expression levels (Wit and McClure, 2004; Fang et al., 2003).
4.2.2 Results
Total-RNA isolated fi-om P19CL6 cells was divided into two aliquots, labelled 
separately with Cy3 and Cy5 and hybridised on a microarray slide. Images were captured 
and the data analysed. Normalisation and sequential filtering was then performed on the 
self-hybridisation array to eliminate spots of low quality. Normalisation also removed the 
background noise, systemic bias, and artefact signals, as described in Materials and 
Methods. Scatter plots were generated to compare gene expression patterns before and 
after the normalisation and filtering process (Fig. 4.1). Scatter plots showed a compact 
distribution with nearly all spots between the lines representing ±2-fold changes in gene 
expression level (Fig. 4.1). A linear regression analysis was performed and showed a 
significant correlation of Cy3 and Cy5 signals (slope=0.96, R^=0.98, P<0.001) indicating 
optimisation of normalisation and filtering processes.
14
Self hybridisation 
of P19CL6 
B e fo re  n o rm a lis a t io n  & filte rin g  . . v
“ P19CL6-Cy5
Self hybridisation 
of P19CL6 
A fte r n o rm a lis a t io n  & f ilte rin g
100 MO P10CL6-dy5 «
P I i n  f, << P I 1 C . ", :t 'iM'ftii
Figure 4.1: Scatter plots for the self-hybridisation of P19CL6 cell-line (A) before, and (B) 
after data normalisation and filtering process. Two RNA aliquots of P19CL6 were labelled 
with Cy3 and Cy5 dye, mixed and hybridised on a microarray. Data was nomialised and filtered 
and the scatter plots were generated to demonstrate the gene expression profiles of (A) before, 
and (B) after normalisation and filtering. Scatter plots showed the distribution of spots 
according to the gene expression levels with lines representing ±2-fold changes in gene 
expression levels.
115
4.3 Comparison of global transcriptome levels in the P19CL6 
and H9C2(2-1) cell-lines, as well as mouse cardiac and 
skeletal muscle tissues using microarray analysis
4.3.1 Rationale
Since the results of the PCR-based experiments (Chapter-3) were inconclusive in 
terms of confirming a cardiac, skeletal muscle or heterogeneous phenotype of the 
P19CL6 cell-line, microarray analysis was used for further characterisation of P19CL6 
cells by investigation of global transcriptome levels in P19CL6 and H9C2(2-1) cells, as 
well as mouse cardiac and skeletal muscle tissues.
4.3.2 Results
In order to reduce the number of arrays required to compare global transcriptome 
levels in the P19CL6 cell-line with those of the H9C2(2-1) cell-line and mouse cardiac 
and skeletal muscle tissues, a loop experiment was designed (Fig. 4.2). Microarray data 
was normalised and filtered, as described in Materials and Methods (Section 2.2.8.5). 
The end-point of noimalisatipn and filtering was 2162 spots that were considered to be 
acceptable. Comparison of transcriptome levels in the P19CL6 cell-line with those of the 
H9C2(2-1) skeletal muscle cells showed 327 genes over-expressed in P19CL6 cells 
whereas 382 genes were down-regulated >2-fold (Fig. 4.3A). However, these two cell 
lines displayed similar expression levels for 1453 genes. Comparison of global 
transcriptome levels in H9C2(2-1) cells with mouse skeletal muscle tissue showed à 
relatively compact distribution (Fig. 4.3B). Although the majority of genes (1886 genes) 
were detected between ±2-fold changes in gene expression levels, 100 genes were 
up-regulated in H9C2(2-1) cells, whereas 176 genes were down-regulated, i.e. 
over-expressed in muscle tissue.
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Figure 4.2; Experimental loop design to compare global transcriptome levels in 
P19CL6 and H9C2(2-1) cells, as well as mouse cardiac and skeletal muscle tissues.
(A) loop design showing the four samples (nodes) to be compared. The sample at the start 
of the arrow was labelled with Cy3 and the “target” sample with Cy5. Samples numbered 
1 to 4 are the P19CL6 and H9C2(2-1) cell-lines, mouse skeletal muscle and heart tissue, 
respectively. (B) samples and Cy-dye labelling used on different microarray slides, based 
on the loop design. S1-S4: slide numbers.
The data obtained from the hybridisation of mouse skeletal muscle and heart tissues 
indicated that the expression levels of relatively a few genes changed >2-fold in these 
tissues. Skeletal muscle tissue displayed up-regulation of 105 genes, whereas 98 genes 
were over-expressed in the heart (Fig. 4.3C). Data also showed 1959 genes with 
relatively close Cy3:Cy5 signal ratio lined between ±2-fold changes in gene expression 
lines. Hybridisation of mouse heart tissue versus the P19CL6 cell-line on the other hand, 
showed a wide distribution of gene expression levels with 332 genes over-expressed in 
the heart tissue and 320 genes in the P19CL6 cell-line (Fig. 4.3D).
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After normalisation of microarray data, linear modelling was performed 
(MARIEiExGen; http://exgen.ma.umist.ac.uk/) in order to convert data fi-om the loop 
experiment into a linear model (Wit and McClure, 2004; Dalgaard, 2002; Smyth, 2004). 
The data produced by linear modelling was imported into a web-based clustering 
programme (http://rana.lbl.gov/) (Eisen et al., 1998) to generate a pair-wise linkage 
cluster. Analysis formed a hierarchical cluster based on the phylogenetic algorithm, 
which was visualised with TreeView software (http://rana.lbl.gov/) (Eisen et al., 1998). 
Complete-linkage cluster analysis showed that the H9C2(2-1) cell-line and heart tissue 
were closely related (Fig. 4.4A). In addition, the H9C2(2-1) cell-line was more closely 
related to the heart than skeletal muscle tissue (Fig. 4.4A). Cluster analysis also showed 
that the H9C2(2-1) cell-line and heart tissue were more closely related than the P19CL6 
cell-line and heart tissue (Fig. 4.4B). Furthermore, mouse heart and skeletal muscle 
tissues were more closely related to each other than to the P19C16 cell-line (Fig. 4.4C).
Similar results were obtained using principal components analysis (PCA), 
confirming that the H9C2(2-1) cell-line is more closely related to the mouse heart tissue 
than the P19CL6 cell-line (Fig. 4.5). As indicated in Table 4.1, the correlation coefficient 
between H9C2(2-1) and heart (0.73) was greater than that between P19CL6 and heart 
(0.41). Collectively, the degree of correlation obtained for the P19CL6 and H9C2(2-1) 
cell-lines, and mouse tissues (Table 4.2), indicated a greater correlation between the 
H9C2(2-1) cell-line and heart tissue as compared to the P19CL6 cell-line.
119
/ i
1
o
CD (O ■C CVJ
1 o _ l _J t r CO CO O
Ü o œ CD CD
O) CD i X  X
w qI qI
; ^  
■ Sfl
Q) CD CO CO _J _J
Ü ■c Ü Ü Ü  oW CO Ü CO CD0)
X K CL CL
0) CM
CO G)
CD (O
Figure 4.4: Hierarchical cluster analysis of mRNA expression levels in microarrays 
comparing the P19CL6 and H9C2(2-1) cell-lines, as well as mouse heart and skeletal 
muscle tissue. The comparisons were clustered according to the degree of pair-wise similarity. 
The colour gradient represents green for down-regulation and red for up-regulation. Each gene 
is represented by a single row and comparisons are represented by columns. (A), (B) and (C) 
demonstrate cluster analysis results for different sets of comparisons. Blue, red and yellow 
circles show the close relationship between comparisons, as discussed in the text. H9C2: 
H9C2(2-1) cell-line.
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Figure 4.5: Principal component analysis (PCA) of global transcriptome levels in 
P19CL6 and H9C2(2-1) cells, and mouse heart and skeletal muscle tissue. Circles 
indicate a close relationship between samples, as discussed in the text. PCI and PC2 
represent 70% and 21% of total variance, respectively.
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Table 4.2: Correlation matrix comparing mRNA expression levels in the 
P19CL6 and H9C2(2-1) cell-lines and mouse heart and skeletal muscle tissue.
Sample Mouse Heart Mouse Skeletal Muscle
P19CL6 cell-line 0.405 0.133
H9C2(2-1) cell-line 0.728 0.258
The data obtained from linear modelling was used to perform principal component analysis. The data
is a summary of information indicated in Table 4.1.
4.4 Microarray analysis of global transcriptome levels in the 
P19CL6 cell-line, mouse embryo and heart tissue
4.4.1 Rationale
The investigation of global transcriptome levels in P19CL6 cells showed that the 
P19CL6 cell-line did not display a close correlation with the adult heart tissue (Section 
4.3). However, as P19-derived cardiomyocytes have been characterised as embryonic 
cells (Skeijanc et al., 1998; van der Heyden and Defize, 2003; Rudnicki et al., 1990; 
Skeijanc, 1999), it was of interest to establish whether the P19CL6 cell-line, a sub-clone 
of PI 9 cells (Habara-Ohkubo, 1996), was similar to mouse embryo tissue, as compared to 
adult heart tissue.
4.4.2 Results
A loop experiment was performed to compare global transcriptome levels in the 
P19CL6 cell-line, mouse embryo and heart tissues. Total-RNA isolated from the samples 
was labelled according to the experimental plan (Fig. 4.6) and hybridised to microarrays. 
Microarray data was normalised and filtered, as discussed in Materials and Methods 
(Section 2.2.8.5). The end-point of normalisation and filtering was 4121 spots that were 
considered as acceptable. Scatter plots were generated to demonstrate the distribution of 
gene expression levels based on the Cy3:Cy5 signal ratio (Fig. 4.7).
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Figure 4.6: Experimental loop design to compare global transcriptome levels in P19CL6, 
as well as mouse embryo and heart tissues. (A) loop design showing the three samples 
(nodes) to be eompared. The sample at the start of the arrow was labelled with Cy3 and the 
“target” sample with Cy5. Samples numbered 1 to 3 are the P19CL6 cell-line, mouse embryo 
and heart tissue, respectively. (B) samples and Cy-dye labelling used on different mieroarray 
slides, based on the loop design. SI-S3: slide numbers.
Comparison of global transcriptome in the P19CL6 cell-line with mouse embryo 
showed that the majority of genes (3263 genes) were not differentially expressed. While 
351 genes were found to be over-expressed (>2-fold) in the P19CL6 cell-line, 507 genes 
were down-regulated, i.e. over-expressed in embryo (Fig. 4.7A). Comparison of global 
transcriptome levels in mouse embryo with heart confirmed that 335 genes were 
up-regulated in the embryo whereas heart over-expressed 386 genes (Fig. 4.7B). 
However, the expression levels of the remaining 3400 genes were not significantly 
different in these tissues. A wide distribution of gene expression levels was observed in 
the comparison of mouse heart with the P19CL6 cell-line, with over-expression of 642 
genes in the heart and 690 genes in the P19CL6 cell-line (Fig. 4.7C).
The data from this loop experiment was converted to a linear model using LLAMA 
linear modelling programme (Wit and McClure, 2004; Dalgaard, 2002; Smyth, 2004). 
Complete-linkage cluster analysis was then performed to demonstrate the degree of 
pair-wise similarity in gene expression levels between the samples (Eisen et al., 1998). 
Cluster analysis confirmed that the correlation between mouse embryo and heart was 
greater than that between the P19CL6 cell-line and heart (Fig. 4.8). The relationship 
observed between the embryo and heart was also closer than the relationship between 
embryo and the P19CL6 cell-line. In addition, the P19CL6 cell-line was more closely 
related to the embryo than heart tissue (Fig. 4.8). Similar results were obtained using
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PCA, confirming that mouse embryo and heart tissues are more closely related than the 
P19CL6 cell-line and heart (Fig. 4.9). As summarised in Table 4.3, the correlation 
coefficient between the P19CL6 cell-line and embryo (0.67) was greater than that 
between the P19CL6 cell-line and heart (0.05).
Embry
Heart vs P19CL6
Figure 4.7: Scatter plots of samples: (A) 
P19CL6 cell-line vs mouse embryo, (B) mouse 
embryo vs heart tissue, and (C) heart tissue vs 
P19CL6 cell-line. Green lines indicate equivalent 
expressions (middle line) and 2 fold up- or 
down-regulation. A colour gradient shows red 
spots indicating genes that are up-regulated in the 
Cy3-labelled samples (Y-axis) while green spots 
represent genes that are over-expressed in the 
Cy5-labelled sample (X-axis).
P19CL6-Cy5
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Figure 4.8: Hierarchical cluster analysis of mRNA expression levels in microarrays 
comparing the P19CL6 cell-line and mouse embryo and heart tissue. The comparisons 
were clustered according to the degree of pair-wise similarity. The colour gradient represents 
green for down-regulation and red for up-regulation. Each gene is represented by a single row 
and comparisons are represented by columns.
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Figure 4.9: Principal component analysis (PCA) of global transcriptome levels in the 
P19CL6 cell-line, mouse embryo and heart tissue. Circle shows the close correlation 
between samples, as discussed in the text. Principal components 1 and 2 represent 66% 
and 34% of total variance, respectively.
Table 4.3: Correlation matrix obtained by principal component analysis 
(PCA) of mRNA expression levels in the P19CL6 cell-line and mouse embryo 
and heart tissue.
C o m p ariso n s
C orrela tion  range
Heart vs P19CL6 Embryo vs Heart Embryo vs P19CL6
Heart vs P19CL6 1.000 0.666
Embryo vs Heart 0.666 1.000 0.046
Embryo vs P19CL6 0.046 1.000
P19CL6 vs Heart 1 000 0.666
Heart vs Embryo 0.666 1.000 0,046
P19CL6 vs Embryo 0.046 1.000
The data obtained from linear modelling was used to perform principal component analysis. 
Principal components 1 and 2 represent 66% and 34% of total variance, respectively.
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4.5 Microarray analysis of global transeriptome levels in the 
P19CL6 and H9C2(2-1) celHines, mouse skeletal muscle 
and mouse embryonic and adult heart tissue
4.5.1 Rationale
Previous experiments (Sections 4.3 and 4.4) showed that the P19CL6 cell-line is not 
closely related to the mouse adult heart or skeletal muscle tissue. The correlation 
between the heart and embryo tissues was also closer than that of the heart and the 
P19CL6 cell-line. However, a comparison of global transeriptome levels in the P19CL6 
cell-line with those of embryonic heart has not previously been made. Therefore, an 
experiment was designed to compare global transeriptome levels in the P19CL6 cell-line 
with those of mouse embryonic heart. The H9C2(2-1) cell-line as well as mouse adult 
heart and skeletal muscle tissues were also included in the experiment to validate the 
previous results.
4.5.2 Results
An interwoven loop experiment (Fig. 4.10) was performed in order to compare 
global transeriptome levels in the P19CL6 and H9C2(2-1) cell-lines, and skeletal muscle, 
embryonic heart and adult heart tissue (Simon et al., 2002; Dobbin and Simon, 2002). 
Total-RNA from P19CL6 (two different biological samples) and the other samples were 
hybridised to microarray slides (Table 4.4 and Fig. 4.10). In addition, a reference RNA 
sample was prepared by mixing equivalent amounts of all total-RNA samples (Simon et 
al., 2002; Dobbin and Simon, 2002). Microarray data was normalised and filtered, and 
scatter plots generated (Fig. 4.11; Fig. 4.12; Fig. 4.13).
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Figure 4.10: Representation of dual-hybridisation optimal interwoven loop design for 
microarray experiment. Loop design showing the seven samples (nodes) to be compared. 
The sample at the start of the arrow was labelled with Cy3 and the “target” sample with Cy5. 
Nodes 1-7 indicate total-RNA sources as follows: 1: P19CL6 (1); 2: skeletal muscle; 
3: embryonic heart; 4: P19CL6 (2); 5: Reference total-RNA; 6: H9C2(2-1); 7: adult heart. 
Reference RNA sample was prepared by mixing equivalent amounts of. all total-RNA 
samples (Simon et al., 2002; Dobbin and Simon, 2002).
Table 4.4: Samples and Cy-dye labelling used on different 
microarray slides, based on the loop design.
Array No. Cy3 CyS
1 P19CL6 cell-line (2) Adult heart
2 Reference total-RNA^ Adult heart
3 Embryonic heart H9C2(2-1) cell-line
4 Embryonic heart Reference total-RNA
5 P19CL6 cell-line (1) Skeletal muscle
6 Reference total-RNA P19CL6 cell-line (2)
7 Reference total-RNA Skeletal muscle
8 Skeletal muscle Adult heart
9 Adult heart H9C2(2-1) cell-line
10 P19CL6 cell-line (1) Reference total-RNA
11 P19CL6 cell-line (1) Embryonic heart
12 Skeletal muscle Embryonic heart
13 Adult heart P19CL6 cell-line (1)
14 P19CL6 cell-line (2) H9C2(2-1) cell-line
15 H9C2(2-1) cell-line P19CL6 cell-line (1)
16 P19CL6 cell-line (2) Skeletal muscle
17 P19CL6 cell-line (2) Embryonic heart
18 H9C2(2-1) cell-line Reference total-RNA
ÎThe reference sample was prepared by mixing equivalent amounts of all total-RNA 
samples. The P19CL6 cell-lines 1 and 2 represent two different biological samples.
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Since the LLAMA linear modelling programme was unable to analyse all microarray 
data, two theoretical loops (1 and 2) were designed for the experimental interwoven loop 
(Fig. 4.14) and these theoretieal loops were then analysed using LLAMA (Wit and 
McClure, 2004; Dalgaard, 2002; Smyth, 2004). In addition, since both the PGA and 
complete-linkage cluster analysis showed similar results for the previous experiments 
(Sections 4.3 and 4.4), only PGA was performed on loops 1 and 2. The correlation 
coefficients were then determined between the samples in different clusters of 
comparisons, as shown with coloured lines in the PGA-derived data (Fig. 4.15). A more 
detailed inspection of the PGA showed that the correlation of the P19GL6 eell-line with 
embryonic heart tissue was consistently higher than that of the P19GL6 cell-line with 
adult heart (Fig. 4.15 and Table 4.5). A comparison of the H9G2(2-1) cell-line with the 
P19GL6 cell-line showed that the H9G2(2-1) eell-line eonsistently displayed a greater 
correlation to the heart than the P19GL6 cell-line (Table 4.5 and Table 4.6). Moreover, 
both cell-lines showed a high degree of eorrelation with mouse embryonic heart tissue 
(Table 4.5 and Table 4.6). Furthermore, the correlation of embryonic and adult heart 
tissues was also greater than that of P19GL6 eells and heart, as indieated in Table 4.5.
1
Figure 4.14: Representation of theoretical loops 1 and 2 derived from optimal interwoven 
loop design for microarray experiment. Loop designs showing the seven samples (nodes) to 
be compared. The sample at the start of the arrow was labelled with Cy3 and the “target” 
sample with Cy5. Nodes 1-7 indicate total-RNA sources as follows: 1: P19GL6 (1); 2: skeletal 
muscle; 3: embryonic heart; 4: P19CL6 (2); 5: Reference total-RNA; 6: H9C2(2-1); 7: adult 
heart. P19CL6 (1) and (2) represent two different biological samples. Reference RNA sample 
was prepared by mixing equivalent amounts of all total-RNA samples (Simon et al., 2002; 
Dobbin and Simon, 2002).
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Figure 4.15: Principal components analysis (PCA) of global transeriptome levels in the 
P19CL6 and H9C2(2-1) cell-lines, mouse skeletal muscle and embryonic and adult heart 
tissue obtained from theoretical loops 1 and 2. The PGA-derived data (A) and (B) correspond 
to the loop 1 and 2, respectively. Goloured circles represent different clusters of comparisons to 
be determined. Ad-heart: adult heart; Em-heart: embryonic heart
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Table 4.6: Correlation 
the mouse embryonic 
component analysis.
matrixes of P19CL6 and H9C2(2-1) cell-lines to 
and adult heart tissues obtained for principal
C o m p ariso n s M ouse em bryon ic  h ea rt M ouse ad u lt h ea rt
P19CL6 cell-line 0.732 0.248
H9C2(2-1) cell-line 0.720 0.444
Ad-heart: mouse adult heart; Em-heart: mouse embryonic heart. The data is a summary of 
information indicated in Table 4.5.
4.6 Discussion
The present study shows that the P19CL6 cell-line does not display a pure cardiac 
phenotype, according to the global transeriptome profiles, as analysed here with cDNA 
microarrays. Collectively, the results indicate that although the P19CL6 cell-line 
displayed some characteristics of cardiomyocytes and, to some extent, showed a 
correlation with mouse adult heart tissue, global transeriptome profiles of the P19CL6 
cell-line were more closely related to the mouse embryonic heart tissue. In contrast, the 
H9C2(2-1) cell-line was more closely related to the adult heart tissue than the P19CL6 
cell-line. Therefore, based on these observations it seems that the H9C2(2-1) cell-line is 
more suitable cardiomyocyte model system than the P19CL6 cell-line.
Analysis of data fi'om different experiments indicated that the mouse adult heart and 
skeletal muscle tissues are closely related (Fig. 4.3C and Fig. 4.4C) while the P19CL6 
cell-line did not show a high degree of correlation with adult heart tissue (Fig. 4.3D). In 
addition, the correlation between the heart and skeletal muscle was greater than that 
between heart and the P19CL6 cell-line (Fig. 4.4C and Table 4.1). The correlation 
between the heart and skeletal muscle was also greater than that the P19CL6 cell-line and 
skeletal muscle tissue (Fig. 4.4C and Table 4.1). Therefore, the global transeriptome 
profiles observed in the P19CL6 cell-line were not indicative of a pure cardiac or skeletal 
muscle phenotype. Furthermore, the P19CL6 cell-line were more closely related to the 
mouse embryo tissue than heart tissue (Fig. 4.8 and Table 4.3). The global transeriptome 
in the P19CL6 cell-line also showed a greater correlation with mouse embryonic heart 
(Table 4.5 and Table 4.6). In addition, the correlation coefficient between the P19CL6
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cell-line and embryonic heart (0.73) was greater than that between P19CL6 and adult 
heart (0.25). Therefore, based on the data obtained here the P19CL6 cell-line displays a 
phenotype closer to an embryonic heart rather than adult heart. This conclusion is in line 
with other studies indicating that the P19-derived cardiomyocytes are embryonic in 
nature (Skeijanc et al., 1998; van der Heyden and Defize, 2003; Rudnicki et al., 1990; 
Skeqanc, 1999). Therefore, the P19CL6 cell-line is not a pure adult heart model system, 
as it has been claimed (Habara-Ohkubo, 1996), and more likely displays an embryonic 
heart phenotype.
Analysis of microarray data showed that the H9C2(2-1) cell-line was closely related 
to the mouse skeletal muscle tissue (Fig. 4.3B). The mouse adult heart and skeletal 
muscle tissues were also closely related (Fig. 4.3C and Fig. 4.4C). Therefore, it can be 
concluded that the H9C2(2-1) cell-line is closely related to the mouse heart tissue 
(Fig. 4.3 and Fig. 4.4B). The correlation between the H9C2(2-1) cell-line and heart tissue 
was also greater than that between the H9C2(2-1) cell-line and skeletal muscle tissue 
(Fig. 4.4A; Fig. 4.5; Table 4.2). These observations were supported by other studies 
confirming that although the H9C2(2-1) cell-line was initially described to have skeletal 
muscle cell properties (Kimes and Brandt, 1976) subsequent investigations showed that 
these cells also display cardiomyocyte properties such as expression of the 
cardiomyocyte-specific subtype of calcium channel (Hescheler et al., 1991; van 
Nieuwenhoven et al., 1998). Consequently, the H9C2(2-1) cell-line is now being widely 
used as a cardiomyocyte model system (Mestril et al., 1994; Nyayapati et al., 1996; van 
der Putten et al., 2002; Kanaya et al., 2005; van Nieuwenhoven et al., 1998; Minakawa et 
al., 2003). Moreover, the H9C2(2-1) cell-line showed a correlation with embryonic heart 
tissue (Table 4.5 and Table 4.6). As indicated in the previous studies, the H9C2(2-1) 
cell-line is a rat embryonic cardiac-derived cell-line (Mestril et al., 1994; Kimes and 
Brandt, 1976; van der Putten et al., 2002; Brostrom et al., 2000) and this may explain the 
embryonic properties of this cell-line.
The inspection of global transeriptome levels revealed a close correlation between 
the skeletal muscle tissue and the H9C2(2-1) cell-line (Fig. 4.3B). Skeletal muscle tissue 
was also closely related to heart tissue (Fig. 4.3C), which led us to draw the conclusion 
that the H9C2(2-1) cell-line and adult heart tissue, were closely related. In contrast, the 
P19CL6 cell-line did not display a close gene expression pattern to the heart tissue 
(Fig. 4.3D). These observations suggest that the H9C2(2-1) cell-line is a better
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cardiomyocyte model system than the P19CL6 cell-line. Similar results were also 
obtained by analysis of data from different experiments indicating that although both the 
P19CL6 and H9C2(2-1) cell-lines were more closely correlated to heart tissue than 
skeletal muscle, the H9C2(2-1) cell-line and adult heart tissue were more closely related 
than the P19CL6 cell-line and heart tissue (Fig. 4.4B; Fig. 4.5; Table 4.1; Table 4.5). 
Therefore, it is reasonable to conclude that the H9C2(2-1) cell-line is a better cardiac 
model system than the P19CL6 cell-line. This observation is in the agreement with 
previous studies that used the H9C2(2-1) cell-line as a cardiomyocyte model 
system (Mestril et al., 1994; Nyayapati et al., 1996; van der Putten et al., 2002; Kanaya et 
al., 2005; van Nieuwenhoven et al., 1998; Minakawa et al., 2003), even though the 
H9C2(2-1) cell-line was initially described as skeletal muscle cell-line (Kimes and 
Brandt, 1976).
In conclusion, these data indicate that the P19CL6 cell-line is more closely related to 
the embryonic heart than the adult heart tissue. However, the H9C2(2-1) cell-line 
consistently displayed a greater correlation to the heart than of the P19CL6 cell-line. 
Therefore, based on the global transeriptome profiles it can be concluded that the 
H9C2(2-1) cell-line is a better cardiomyocyte model system than the P19CL6 cell-line.
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Chapter 5:
Investigation of the effect of long-chain fatty acids and 
fibrates on gene transcription in P19CL6 cell-line
5.1 Introduction
Fatty acids have various roles in physiology that impact on lipid, carbohydrate and 
protein metabolism as well as growth and differentiation, namely; (i) functioning as a 
source of energy, (ii) serving as structural components, and (iii) functioning as a regulator 
of gene expression (Jump, 2004; Pegorier et al., 2004; Clarke, 2000). The regulatory 
function of long-chain fatty acids (LCFAs) on gene expression is achieved by controlling 
the abundance and activity of transcription factors such as SREBP, PPARa, PPARp, 
PPARy, HNF4-a, and LXR (Sampath and Ntambi, 2004; Khan and Vanden Heuvel, 
2003; Clarke, 2001; Jump, 2002a; Guan et al., 2002; Mandard et al., 2004). Previous 
studies have shown that the characteristics of LCFA, e.g. chain length and degree of 
unsaturation, differentially affect gene expression levels in cardiomyocytes (Biàgi et al., 
1999; Bordoni et al., 1996; Dyerberg et al., 2004; Williams et al., 2004; Cameron-Smith 
et al., 2003; Belury, 2002; van der Lee et al., 2000a; Hickson-Bick et al., 2000; Clavel et 
al., 2002). In particular, n-3 and n-6 PUF A supplementation has been implicated in the 
induction of FA uptake, transport and p-oxidation (Cameron-Smith et al., 2003; Clavel et 
al., 2002; Ntambi and Bene, 2001; Jump, 2004; Clarke, 2000), thereby modulating blood 
lipid profiles and preventing the progression of atherosclerosis (Fruchart, 2001; Ferre, 
2004; Guan et al., 2002; Thies et al., 2003; Mandard et al., 2004).
Several cell culture and animal model systems have been used to study the effects of 
LCFAs and fibrates on cardiomyocytes at the gene expression level (Biagi et al., 1999; 
Gilde et al., 2003; Stavinoha et al., 2004; Dyerberg et al., 2004; Cameron-Smith et al., 
2003; Clavel et al., 2002; Marti et al., 2002; Gamier et al., 1993; Kong and Rabkin, 
2004). These ligands are known to alter gene expression levels. However, the extent of 
alteration and up- or down-regulation of gene expression is dependent on the gene itself, 
incubation/intervention period, cell type and fatty acid properties (van der Lee et al..
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2000a; Cook et al., 2001; Marti et al., 2002; Gamier et al., 1993; Gilde et al., 2003; De 
Vries et al., 1997; van Bilsen et al., 1997; Stavinoha et al., 2004; Chang et al., 2001).
Therefore, based on the effects of LCFAs and fibrates on the other cardiomyocyte 
model systems it was hypothesised that the mRNA levels of lipid metabolism-related 
genes such as H-FABP, PPARa, PPARp, and PPARy would be affected by these ligands 
in mouse P19CL6 cells. In addition, since the effects of fatty acids differ based on their 
chain length and degree of unsaturation (Ntambi and Bene, 2001; Jump, 2004) it was 
hypothesised that LCFAs would differentially affect the expression levels of these 
proteins. Furthermore, the effects of LCFAs and fibrates on global transeriptome levels 
was investigated in order to obtain a broader picture of the effects of these compounds on 
gene expression levels in the P19CL6 cell-line. Therefore, the aim of this chapter was to 
investigate the effects of LCFAs including palmitic (saturated FA), oleic 
(monounsaturated FA), linoleic (n-6 PUFA), and a-linolenic (n-3 PUFA) acids and 
clofibrate on gene expression levels in the P19CL6 cell-line with the specific objectives 
as follows:
Objective 1: Determine the effect of LCFAs and clofibrate on the expression of H-FABP, 
PPARa, PPARp, and PPARy in the P19CL6 cell-line, using PCR-based analysis.
Objective 2: Investigation of the effect of LCFAs and clofibrate on global transeriptome 
levels in P19CL6 cells, using microarray analysis.
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5.2 Determination of LCFAs and clofibrate effects on the 
expression of H-FABP, PPARa, PPARP, and PPARy in 
P19CL6 cells
5.2.1 Rationale
LCFAs and fibrates are known to affect the expression of a panel of lipid 
metabolism-related genes (van der Lee et ah, 2000a; van der Lee et ah, 2000b; Brandt et 
ah, 1998; Stavinoha et ah, 2004; Young et aL, 2001; Gilde et ah, 2003; Ouali et ah, 2000). 
In particular, we were interested in the effect of these ligands on the expression of 
PPARa, PPARP, PPARy and H-FABP in the P 19CL6 cell-line.
5.2.2 Results
P19CL6 cells were cultured with DMSO, total-RNA isolated and the mRNA 
expression levels of H-FABP, PPARa, PPARp, and PPARy determined. The detection of 
RT-PCR products showed expression of GAPDH, a housekeeping gene (Ullmannova and 
Haskovec, 2003), in P19CL6 cells cultured under adherent conditions, thus confirming 
the presence of mRNA in the sample (Fig. 5.1). The expression of H-FABP and PPARp 
was also detected in P19CL6 cells, whereas expression of PPARa and PPARy was not 
observed under the conditions used (Fig. 5.1). Similar results were obtained when the 
experiment was repeated (data not shown).
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Figure 5.1: Expression of H-FABP, PPARa, PPARp and PPARy in P19CL6 cells cultured 
under adherent conditions on exposure to 1% DMSO, as detected by RT-PCR. P19CL6 
cells were cultured with 1% DMSO for 15 days, total-RNA isolated and mRNA levels 
determined by RT-PCR using gene-specific primers (Table 2.1). RT-PCR products were 
separated on 2% agarose gel containing ethidium bromide and the gel photographed. 
Theoretical sizes of gene-specific PCR products were GAPDH: 362 bp; H-FABP: 242 bp; 
PPARa: 880 bp; PPARP: 360 bp; PPARy: 856 bp.
Since there is no published data on the expression of PPARs in the P19CL6 cell-line, 
the THP-1 human monocyte-like cell-line was used as a positive control to optimise 
primer specificity and PCR conditions. THP-1 cells differentiate into macrophages and 
express PPARs upon exposure to phorbol myristate acetate (PMA) (Fu et aL, 2002; Neve 
et al., 2001; Kohro et al., 2004). Phase-contrast microscopy of THP-1 monocytes 
cultured for 24, 48, and 72 hours with 100 nM PMA showed an adherent monolayer, 
which was interpreted to indicate differentiation into macrophages-like cells. Analysis of 
gene expression levels in THP-1 cells cultured with 100 nM PMA showed expression of 
GAPDH at all the time points throughout the incubation period (Fig. 5.2), whereas 
PPARa and PPARy were not detected at any time point (Fig. 5.2). However, after a 
second round of PCR with nested primers, the expression of PPARa and PPARy in 
differentiated THP-1 cells was detected (Fig. 5.3), confinning the requirement for nested 
PCR (second amplification) to detect expression of these genes. Likewise, the detection 
of nested PCR products confinued the expression of H-FABP, PPARa, PPARp and 
PPARy in P19CL6 cells (Fig. 5.4).
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Figure 5.2: Expression of PPARa and PPARy in THP-1 cells, as detected by RT-PCR.
THP-1 cells were cultured with 100 nM PMA for 24, 48, and 72 hours, RNA isolated and 
gene expression levels determined by RT-PCR using gene-specific primers (Table 2.1). 
RT-PCR products were separated on 2% agarose gel containing ethidium bromide and the 
gel photographed. Theoretical sizes of gene-specific PCR products were GAPDH: 362 bp; 
PPARa: 880 bp; PPARy: 856 bp
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Figure 5.3: Expression of PPARa and PPARy in THP-1 cells, as detected by RT-PCR 
and nested PCR. THP-1 cells were cultured with 100 nM PMA for 48 hour, RNA isolated 
and gene expression levels determined by RT-PCR followed by nested PCR using 
gene-specific primers (Table 2.2). PCR products from both RT-PCR and nested PCR steps 
were separated on 2% agarose gel containing ethidium bromide and the gel photographed. 
Theoretical sizes of gene-specific PCR products were GAPDH: 362 bp; PPARa: 880 bp; 
PPARy: 856 bp (for RT-PCR) and GAPDH: 362 bp; PPARa: 350 bp; PPARy: 525 bp (for 
nested PCR).
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Figure 5.4: Expression of H-FABP, PPARa, PPARp, and PPARy in P19CL6 cells 
cultured under adherent conditions on exposure to 1% DMSO, as detected by nested 
PCR. P19CL6 cells were cultured with 1% DMSO for 15 days, RNA isolated and gene 
expression levels determined by RT-PCR followed by nested PCR using gene-specific 
primers (Table 2.2). PCR products were separated on 2% agarose gel containing ethidium 
bromide and the gel photographed. Theoretical sizes of gene-specific PCR products were 
GAPDH: 280 bp; H-FABP: 242 bp; PPARa: 350 bp; PPARP: 247 bp; PPARy: 525 bp.
In order to determine the effects of LCFAs and fibrate on gene expression levels, 
P19CL6 eells were cultured with 0.4 mM LCFAs or clofibrate, as discussed in the 
Materials and Methods. The mRNA expression of H-FABP, PPARa, PPARP and PPARy 
in P19CL6 cells was detected by RT-PCR followed by nested PCR techniques. 
Semi-quantitative gene expression levels, relative to GAPDH expression, were then 
calculated (Table 5.1). A One-Way ANOVA analysis was conducted to explore the 
impact of LCFAs or clofibrate on gene expression. The expression of H-FABP and 
PPARp did not display significant changes with LCFAs or clofibrate (Table 5.1). 
However, LCFAs had a significant effect (P<0.05) on the expression of PPARa and 
PPARy in P19CL6 eells (Table 5.1). In addition, levels of PPARa and PPARy mRNA 
were significantly increased with all the LCFAs, but not clofibrate (Table 5.1). As this 
data is at best semi-quantitative it should viewed as preliminary, although the results may 
be indicative of the underlying biological response.
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Table 5.1: Comparison of relative H-FABP, PPARa, PPARp, and PPARy gene expression 
levels in P19CL6 cells cultured with different LCFAs or clofibrate.
Gene
Gene Expression Relative to GAPDH (Mean ± SD)
BSA PA OA LA ALA Clo
H-FABP 1.22±0.11 1.15+0.18 1.27+0.12 1.22+0.27 1.27+0.23 1.23+0.16
PPARa 1.27+0.14 1.70+0.40® 1.89±0.19^ i.ooto.io"^ 2.04+0.24"^ 1.49+0.15
PPARP 0.97+0.37 1.09+0.16 1.16±0.23 1.37+0.33 1.35±0.17 1.11+0.17
PPARy 1.21+0.23 1.78±0.21® 1.96+0.22*^ 2.14+0.26"^ 1.80+0.26® 1.24+0.20
P19CL6 cells were cu 
Gene expression levels 
nested PCR. PCRprodi 
the gel photographed. S 
GAPDH. One-Way Ab 
expression. Data is si 
expression levels relati 
a-linolenic acid; BSA: 1 
PA: palmitic acid.
tured with LCFAs or clofibrate (0.4 mM) under adherent conditions, 
were measured in three biological repeats using RT-PCR followed by 
lets were separated on 2% agarose gels containing ethidium bromide and 
emi-quantitative estimation of gene expression was calculated relative to 
vlOVA analysis was conducted to explore the impact of LCFAs on gene 
lown as Mean ± Standard Deviation. Significant differences in gene 
ve to BSA treatment were shown as ^P<0.05, and  ^P<0.001. ALA: 
lovine serum albumin; Clo: clofibrate; LA: linoleic acid; 0 A: oleic acid:
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5.3 Determination of LCFA and clofibrate effects on global 
transeriptome levels in P19CL6 cells, using microarray 
analysis
5.3.1 Rationale
In the previous section, it was shown that PPARa and PPARy mRNA levels were 
increased by LCFAs in the P19CL6 cell-line. Therefore, in order to get a wider 
prospective on the effects of LCFAs and clofibrate in P19CL6 cells microarray analysis 
was used to investigate global transeriptome profiles in P19CL6 cells cultured with these 
ligands.
5.3.2 Results
P19CL6 cells were cultured with 1% DMSO for 14 days and serum-free media for 
day 15. Cells were then treated with LCFAs or clofibrate (0.4 mM) for 24 hours and 
total-RNA isolated. A loop experiment was designed (Fig. 5.5) to investigate the effects 
of LCFAs and clofibrate on global transeriptome levels in the P19CL6 cell-line (Simon et 
al., 2002; Dobbin and Simon, 2002). cDNA was synthesised, labelled according to the 
experimental plan (Fig. 5.5) and hybridised to microarrays. After scanning the 
microarrays, the data was normalised and filtered, as described in the Materials and 
Methods (Section 2.2.S.5). The end-point of normalisation and filtering was 2213 spots 
that were considered as acceptable. Scatter plots were generated, which showed that the 
majority of genes were not differentially expressed (Fig. 5.6). The data from this loop 
experiment was converted into a linear model using the LLAMA linear modelling 
programme (MARIEiExGen; http://exgen.ma.umist.ac.uk/) (Wit and McClure, 2004; 
Dalgaard, 2002; Smyth, 2004). The data produced by linear modelling was imported into 
Gene Cluster (http://rana.lbl.gov/) (Eisen et al., 1998) and the obtained hierarchical 
cluster visualised with TreeView (http://rana.lbl.gov/) (Eisen et al., 1998).
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Figure 5.5: Experimental loop design to compare global transeriptome levels in P19CL6 cells 
cultured with LCFAs or clofibrate. (A) loop design showing the six samples (nodes) to be 
compared. The sample at the start of the arrow was labelled with Cy3 and the “target” sample 
with Cy5. (B) samples and Cy-dye labelling used on different microarray slides, based on the 
loop design. S1-S6: slide numbers. ALA: a-linolenic acid; BSA: bovine serum albumin; Clo: 
clofibrate; LA: linoleic acid; OA: oleic acid; PA: palmitic acid.
Complete-linkage hierarchical cluster analysis of microarray data showed that 
expression levels in cells treated with LA or ALA were similar (Fig. 5.7) and closely 
related to the general effect observed with clofibrate-treated cells (Fig. 5.7). A similar 
pattern was also shown with PCA confirming that LA, ALA and clofibrate were closely 
related to each other (Fig. 5.8) but differed from that of PA and OA (Fig. 5.7 and 
Fig. 5.8).
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Figure 5.7: Hierarchical cluster analysis of mRNA expression levels in microarrays comparing 
the P19CL6 cells cultured with LCFAs and clofibrate. The comparisons were clustered 
according to the degree of pair-wise similarity. The colour gradient represents green for 
down-regulation and red for up-regulation. Each gene is represented by a single row and 
comparisons are demonstrated by columns. ALA: a-linolenic acid; BSA: bovine serum albumin; 
Clo: clofibrate; LA: linoleic acid; OA: oleic acid; PA: palmitic acid.
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Figure 5.8: Principal components analysis (PCA) of global transeriptome levels in P19CL6 
cultured with LCFAs or clofibrate. The red circle shows close relation between the samples. PCI 
and PC2 represent 66% and 19% of total variance, respectively. ALA: a-linolenic acid; BSA: 
bovine serum albumin; Clo: clofibrate; LA: linoleic acid; OA: oleic acid; PA: palmitic acid.
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5.4 Discussion
In order to determine the effect of LCFAs and clofibrate on gene expression levels in 
P19CL6 cells the mRNA expression levels of lipid metabolism-related genes, /.e. 
H-FABP, PPARa, PPARp and PPARy, was initially investigated by PCR analysis in a 
focused study, while global transeriptome levels were subsequently studied by microarray 
analysis.
A semi-quantitative estimation of gene expression levels, using RT-PCR, in P19CL6 
cells cultured with LCFAs or clofibrate (0.4 mM) showed no significant difference in the 
relative expression levels of H-FABP (Table 5.1). Previous studies have shown that 
LCFAs or fibrates up-regulate H-FABP in cardiomyocytes (Chang et al., 2001; van der 
Lee et aL, 2000a; van Bilsen et al., 1997; Gamier et aL, 1993; Clavel et al., 2002). 
However, other studies showed no changes in H-FABP mRNA after a high-fat 
diet (Veerkamp and van Moerkerk, 1993; Gamier et al., 1993; Coe and Bemlohr, 1998). 
Similar contradictory observations have also been reported on the expression of H-FABP 
in skeletal muscle cells, indicating no significant response in cellular H-FABP content to 
high-fat diet for one week (Roepstorff et aL, 2004; Veerkamp and van Moerkerk, 1993), 
whereas long-term (4 weeks) supplementation significantly increased expression of 
H-FABP mRNA (Roepstorff et al., 2004). Therefore, the non-response of H-FABP 
expression levels, as observed here, can probably be explained by the relatively short 
exposure time (24 hours). This leads to the conclusion that H-FABP gene expression 
responds slowly to LCFAs and clofibrate, and incubations for longer than 24 hours would 
probably be required before any effects of these ligands on H-FABP mRNA expression 
would be observed.
P19CL6 cells cultured with LCFAs or clofibrate also showed no significant changes 
in the relative expression level of PPARp, whereas the expression of PPARa and PPARy 
was significantly increased in the presence of LCFAs, regardless of the chain length and 
degree of unsaturation (Table 5.1). Therefore, the observations made in this study are in 
agreement with previous work which showed that dietary fat and fibrates increased 
PPARa and PPARy expression levels in different tissues (Vidal-Puig et aL, 1996; Bonilla 
et aL, 2000; Akbiyik et aL, 2004a; Groubet et aL, 2003; Moral et aL, 2004; Chambrier et 
aL, 2002; Cabrero et aL, 2003; Madsen et aL, 2005). Unlike the significant increase 
observed in PPARa and PPARy expression levels, incubation of P19CL6 cells with
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LCFAs or clofibrate did not affect the expression of PPARp (Table 5.1). This 
observation is consistent with previous reports showing that the ingestion of dietary fat 
has no effect on PPARp expression levels, as shown in rat colon mucosa and human 
endothelial cells (Delage et al., 2005; Ye et al., 2002).
In this study, PI9CL6 cells cultured with clofibrate showed no statistically 
significant change in the expression levels of the PPAR isoforms (Table 5.1), although 
the induction of PPARa mRNA by clofibrate has been shown in other model 
systems (Akbiyik et al., 2004a; Ibabe et al., 2005; Guan et al., 2003; Akbiyik et al., 
2004b; Amsaguine-Safir et al., 2003). The non-response of PPARa gene expression 
level, as observed here, can probably be explained by the short exposure time (24 hours) 
as long-term incubations have been mainly used in other studies (Amsaguine-Safir et al., 
2003; Akbiyik et al., 2004a; Guan et al., 2003).
In addition to the effect of LCFAs and clofibrate on H-FABP, PPARa, PPARP and 
PPARy expression level, the effects of these ligands on global transeriptome levels in the 
P19CL6 cell-line was also investigated by cDNA microarray analysis. LA, ALA and 
clofibrate showed similar effects, as shown by cluster analysis (Fig. 5.7) and PCA 
(Fig. 5.8), whereas PA and OA appeared to have a different effect (Fig. 5.7 and Fig. 5.8). 
These observations are in agreement with previous studies showing that dietary SFA and 
PUFA have different effects on gene expression (Weatherill et al., 2005; Lee et al., 2004; 
Siculella et al., 2004; Giudetti et al., 2003a; Giudetti et al., 2003b; Garcia-Pelayo et al., 
2004; Zhao et al., 2004; Weigert et al., 2004), which could be explained by differences in 
the affinity of SFA and PUFA to activate nuclear receptors (Zhao et al., 2004; Gilde and 
van Bilsen, 2003; Khan and Vanden Heuvel, 2003; Forman et al., 1995; Diniz et al., 
2004). The effect of clofibrate on global transeriptome profiles was also more closely 
related to LA and ALA than PA or OA (Fig. 5.7 and Fig. 5.8). Therefore, the effect of 
PUFAs appeared to be similar to that of clofibrate, but differed from that of SFA or 
MUFA (monounsaturated fatty acid).
In conclusion, both RT-PCR and microarray experiments showed that culturing of 
P19CL6 cells with LCFAs or clofibrate affected gene expression. PCR experiments 
confirmed that LCFAs affect the abundance of PPARa and PPARy, but not PPARp or 
H-FABP, under the conditions used. Microarray experiments showed that the effects of
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LA, ALA and clofibrate were similar but differed from those of PA and OA. In addition, 
the effect of clofibrate appeared to be similar to those of PUFAs.
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Chapter 6
Conclusion
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Chapter 6:
6.1 Conclusion
The P19CL6 cell-line, a sub-clone of PI 9 murine embryonal carcinoma cells, is used 
widely as an in vitro model of cardiovascular cells (Young et ah, 2004; van der Heyden 
and Defize, 2003; van der Heyden et ah, 2003; Peng et ah, 2002; Anisimov et ah, 2002; 
Paquin et ah, 2002; Ridgeway et ah, 2000; Monzen et ah, 2001). P19CL6 cells are 
reported to differentiate into spontaneously contracting cardiomyocytes on exposure to 
DMSO and have been proposed to display a pure cardiac muscle phenotype (Habara- 
Ohkubo, 1996; Hiroi et ah, 2001; Hosoda et ah, 2001; Young et ah, 2004). In this study 
P19CL6 cells displayed some characteristics of cardiomyocytes that included the 
expression of cardiac-specific markers, an increase in pulse rate with adrenaline and the 
display of mononuclear cardiomyocyte morphology. However, spontaneous contraction, 
a characteristic of the P19CL6 cell-line (Habara-Ohkubo, 1996), was inconsistent 
between the cultures and the pulse rate decreased significantly with increasing passage 
number, with no “beating” being recorded after passage 16. In addition, the expression of 
markers characteristics of cardiac- (a-MHC, p-MHC and CaCh-h) and skeletal muscle 
(MyoD and Myogenin) cells was observed in the P19CL6 cells, which led us to conclude 
that these cells have a heterogeneous phenotype. A comparison of the P19CL6 cell-line 
was therefore made to the H9C2(2-1) cell-line, characterised as skeletal muscle 
cell-line (Kimes and Brandt, 1976), and mouse cardiac and skeletal muscle tissues. 
Unlike the detection of both cardiac- and skeletal muscle-specific genes in P19CL6 cells, 
the expression of only MyoD and Myogenin, which are markers of skeletal muscle cells, 
was detected in H9C2(2-1) cells. In addition, H9C2(2-1) cells fused with time and 
formed tubular multinucleated structures, a morphology characteristic of skeletal muscle 
cells (Skeijanc, 1999; van der Heyden et al., 2003).
Since this study was initiated to investigate the effects of LCFAs and fibrates on 
cardiac tissue, it was important to use a well-characterised model system. In this study, 
cDNA microarrays were used to characterise the P19CL6 cell-line in more depth. 
Analysis of data indicated that the global transcriptome profiles observed in the P19CL6 
cell-line were not indicative of a pure adult cardiac or skeletal muscle phenotype and 
more closely related to mouse embryonic heart tissue. Therefore, the data obtained here
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showed that the P19CL6 cell-line displays a phenotype closer to embryonic heart than 
adult heart. This conclusion is in accordance with other studies which indicate that the 
P19-derived cardiomyocytes are embryonic in nature (Skeijanc et al., 1998; van der 
Heyden and Defize, 2003; Rudnicki et al., 1990; Skeijanc, 1999) and is in contrast to the 
claim that the P19CL6 cell-line is an adult heart model system (Habara-Ohkubo, 1996). 
In contrast, the H9C2(2-I) cell-line showed a closer correlation with mouse adult heart 
tissue than skeletal muscle tissue or the P19CL6 cell-line. These observations lead to the 
conclusion that the H9C2(2-1) cell-line is a more suitable cardiomyocyte model system 
than the P19CL6 cell-line, and are in agreement with the utilization of the H9C2(2-1) 
cell-line as a cardiomyocyte model system (Mestril et al., 1994; Nyayapati et al., 1996; 
van der Putten et al., 2002; Kanaya et al., 2005; van Nieuwenhoven et al., 1998; 
Minakawa et al., 2003).
Since one of the aims of this study was to determine the effects of LCFAs and 
fibrates on gene expression levels in P19CL6 cells, the mRNA expression levels of lipid 
metabolism-related genes, i.e. H-FABP, PPARa, PPARp and PPARy, was initially 
investigated by PGR analysis in a focused study. Global transcriptome levels were 
subsequently studied by cDNA microarray analysis.
P19CL6 cells cultured with LCFAs or clofibrate showed no significant changes in 
H-FABP and PPARp expression, whereas the expression of PPARa and PPARy was 
significantly increased in the presence of LCFAs, regardless of the chain length and 
degree of unsaturation. The non-response of H-FABP expression levels, as observed 
here, can be explained by the relatively short exposure time (24 hours) since longer 
incubations with LCFAs or fibrates have been linked to increased H-FABP 
expression (Chang et al., 2001; Gamier et al., 1993; Clavel et al., 2002; Veerkamp and 
van Moerkerk, 1993; Coe and Bemlohr, 1998; Cameron-Smith et al., 2003; Roepstorff et 
al., 2004). The observation that the expression of PPARa and PPARy increased in the 
presence of LCFAs is in agreement with previous studies which showed that the 
administration of dietary fat increases PPARa and PPARy expression levels in different 
tissues (Vidal-Puig et al., 1996; Bonilla et al., 2000; Akbiyik et al., 2004a; Groubet et al., 
2003; Moral et al., 2004; Chambrier et al., 2002). However, LCFAs did not affect the 
expression of PPARp in P19CL6 cells, which may suggest that incubations longer than 
24 hours are necessary for the induction of PPARp expression by these ligands.
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In this study, clofibrate showed no statistically significant changes in the expression 
levels of the PPAR isoforms, although the induction of PPARa mRNA by clofibrate has 
been shown in other model systems (Akbiyik et ah, 2004a; Ibabe et ah, 2005; Guan et al., 
2003; Akbiyik et al., 2004b; Amsaguine-Safir et al., 2003). Since longer incubation times 
have been mainly used in previous studies, incubations in excess of 24 hours would 
probably be required before any effects of clofibrate on PPARa mRNA expression would 
be observed in PI9CL6 cells.
Investigation of the effects of LCFAs and clofibrate on global transcriptome levels in 
the P19CL6 cell-line showed that LA, ALA and clofibrate display similar effects, which 
differ from those of PA and OA. Similar observations have been previously reported 
showing that SFA and PUFA have different effects on gene expression (Weatherill et al., 
2005; Lee et al., 2004; Siculella et al., 2004; Giudetti et al., 2003a; Giudetti et al., 2003b; 
Garcia-Pelayo et al., 2004; Zhao et al., 2004; Weigert et al., 2004), which could be 
explained by differences in the ability of SFA and PUFA to activate nuclear receptors 
(Zhao et al., 2004; Glide and van Bilsen, 2003; Khan and Vanden Heuvel, 2003; Forman 
et al., 1995; Diniz et al., 2004). In addition, the effect of clofibrate on global 
transcriptome profiles was more closely related to LA and ALA than PA or OA. 
Therefore, the effect of PUFAs appeared to be similar to that of clofibrate, but differed 
from that of SFA or MUFA.
In conclusion, the H9C2(2-1) cell-line is probably a better cardiomyocyte model 
system than the P19CL6 cell-line. In addition, LA, ALA and clofibrate have a similar 
effect, which differ from those of PA and OA, on gene expression levels in P19CL6 cells. 
These observations are in agreement with the effect of these ligands on other cell-lines, 
tissues, animals and human, and reflect the differential outcomes of SFA, MUFA and 
PUFA on metabolic processes related to CHD.
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6.2 Recommendations for future work:
The works that have been carried out for this thesis has increased our knowledge of 
the P19CL6 cell-line and yielded some interesting results, but has also raised issues that 
need to be addressed:
• The pulse rate in P19CL6 cells decreased significantly with increasing passage 
number until no “beating” was eventually recorded. Investigation of the potential 
changes occurring by increasing passage number at the transcriptional level would 
probably reveal the mechanisms underlying losing the “beating” phenotype in 
P19CL6 cells.
• PC A and cluster analysis showed that the effects of PUFA on global transcriptome 
levels in P19CL6 cells differ from those of SFA and MUFA. Dietary SFAs are 
considered as atherogenic fat, whereas PUFAs are cardioprotective (Ascherio, 
2002; Mori and Beilin, 2001; Wijendran and Hayes, 2004; Dyerberg et al., 2004; 
Calder, 2004a; Mesa et al., 2004; Calder, 2004b). Therefore, further experiments 
are required to identify differentially regulated genes that relate to the novel 
functions and metabolism of SFA, MUFA and PUFA in better cardiomyocyte 
model systems or animals.
• Publications of the results obtained in this study.
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